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ABSTRACT 
Described herein is the chemoenzymatic synthesis of several different types of unnatural 
analogues of Amaryllidaceae constituents. Development and refinement of existing and 
design and execution of new approaches towards the synthesis of C-1 analogues of 
pancratistatin and A-ring heterocyclic analogues of narciclasine are discussed. Evaluation 
of the new analogues as cancer growth inhibitory agents is also described. 
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1. Introduction 
Since the discovery and isolation of narciclasine (1) in 1968 by Ceriotti1 and 
pancratistatin (2), Figure 1, by Pettit2 in 1984 the scientific community has been drawn 
towards these molecules because of their potent antineoplastic activity. The highly 
selective cytotoxicity towards malignant cells ensured the interest of the community in 
developing potential drugs based on their molecular pattern of Amaryllidaceae 
constituents. However, their preclinical development is significantly hampered by the 
relatively low abundance of 1 and 2 in natural sources as well as their poor water 
solubility. 
 
Figure 1. Structure of narciclasine and pancratistatin. 
Synthetic organic chemistry is an indispensable tool which can address both of 
these issues by developing efficient ways to synthesize of the different analogues of 1 and 
2 which may also help to establish the biological mechanism of action of these 
fascinating molecules. The main goal of this thesis will be to devise new ways and refine 
existing approaches towards synthesis of C-1 analogues of pancratistatin such as 5 a-c 
and A-ring heterocyclic analogues of narciclasine of type 6 and 7, Figure 2. Biological 
2 
evaluation of these synthetic compounds will be performed in order to provide us with 
new insight towards mechanism of action and help to refine minimal pharmacophore 
requirements. 
 
Figure 2. General strategy for synthesis of analogues of pancratistatin and narciclasine. 
The unifying theme of all these approaches will be the use of a highly versatile chiral 
building block – cis-cyclohexadiene diol 4. The utilisation of such a chiral building block 
for the synthesis of complex organic targets has been a common theme in the Hudlický 
group for many years. This compound is obtained by biooxidation of bromobenzene 3 by 
the whole cell fermentation with strain of E. Coli JM109 (pDTG601A). Diol 4 will be 
used in the synthesis of unnatural derivatives 5 a-c, 6, 7. When completed these 
compounds will be evaluated by screening against cancer cell lines.  
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2. Historical 
2.1. Amaryllidaceae alkaloids 
2.1.1. Discovery and biosynthesis 
Amaryllidaceae is a large family of flowering perennial plants. There have been used for 
a long time in folk medicine for treatment of various ailments because of the high 
amounts of various bioactive alkaloids. In the ancient Greek and Roman medicine the 
plants of the Narcissus genus and their essences were used for the treatment of tumours 
and cancer–like diseases.3  
In 1877 the first alkaloid from this family was isolated from N. pseudonarcicuss and 
named lycorine (8), Figure 3.4 It is one of the most abundant alkaloids in the family and 
possesses some antitumoral activity. More than 100 members of this family of alkaloids 
were subsequently isolated and despite their shared isoquinoline structures they belong to 
structurally different groups. Here our attention will be focused on the group of these 
alkaloids which share the isocarbostyril structural motif, namely (9). 
 
Figure 3. Structure of lycorine and isocarbostyril.  
4 
Compounds with the highest anticancer activity were isolated and characterised in the 
late 20th century. All of these congeners are highly oxygenated compounds and share the 
same structural isocarbostyril pattern (9). The first of this class of naturals products, 
narciclasine (1), was isolated in 1968,1 closely followed by isolation of 7-
deoxynarcilasine or lycoricidine, (10).5 Two decades later pancratistatin (2) was isolated 
by Pettit et al. in 1984,2 and 7-deoxypancratistatin (11) was isolated by Ghosal in 1989.6 
trans-Dihydronarciclasine (12) was produced first semi-synthetically in 19757 from 
narciclasine and only in 1990 was isolated from a natural source by Pettit.8 The latest of 
the active compounds was 7-deoxy-trans-dihydronarciclasine (13) isolated in 1993 by the 
same group,9 Figure 4. 
 
Figure 4. Three major isocarbostyril congeners of Amaryllidaceae family and their 
respective 7-deoxy versions. 
While the exact biosynthetic pathway towards these compounds is unknown, it is 
reasonable to assume that they all share common biosynthetic origin. Two major starting 
materials for biogenesis of all alkaloids of Amaryllidaceae family are phenylalanine (14) 
and tyrosine (17). They undergo transformation into protocatechuic aldehyde (15) and 
tyramine (18) respectively. Coupling of those two compounds followed by reduction and 
5 
methylation leads to the central intermediate in the biosynthesis - O-methylnorbelladine 
(19), Figure 5.10 
 
Figure 5. Biosynthetic pathway to a common intermediate O-methylnorbelladine (19). 
The general pathway to phenanthridine type alkaloids proceeds via oxidative cyclization 
of 19. Different types of regioselective oxidative cyclization lead to a wide variety of 
products. The main question is whether a para-para or para-ortho regioselective 
coupling is involved in the particular case of narciclasine (1). Studies of the biosynthetic 
pathway were performed with labeled compounds to show that narciclasine is most likely 
produced via a para-para phenol oxidative process.10 Oxidation of O-methylnorbelladine 
(19) followed by Michael addition yields noroxomaritidine (20). Oxidation of this 
intermediate is thought to produce narciclasine in series of oxidation steps,10 Figure 6. 
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Figure 6. Transformation of O-methylnorbelladine to narciclasine.  
The exact biosynthetic route has not yet been established for other congeners of 
narciclasine such as 2, 10-13. But as all of these compounds share a similar structure, it is 
reasonable to assume that they all share the same biosynthetic pathway. 
 
2.1.2. Selected total syntheses. 
2.1.2.1. Total syntheses of narciclasine. 
The goal of this section is not to present all existing syntheses of narciclasine and 
pancratistatin-type molecules, which have been the topic of a number of reviews.4, 10-22 
First racemic and first enantioselective synthesis will be presented in detail. A few other 
selected syntheses, especially those published after 2008, will be shown in an abbreviated 
form.  
Despite being the earliest of all isocarbostyril congeners discovered and displaying the 
most potent anticancer properties, narciclasine (1) has received the least attention from a 
synthetic standpoint. Indeed, only four total syntheses of this compound are known to 
date. The first synthesis of narciclasine (1) was reported by Rigby and Matteo23 in 1997. 
Their synthetic strategy involved the transformation of the commercially available methyl 
7 
ester of the cyclohexene carboxylate acid 21 to epoxyalcohol 22, which was converted to 
a chiral isocyananate 23 by lipase resolution, Scheme 1. Reaction of the lithium 
derivative of 25 with this isocyanate led to amide 26, which upon photocyclization 
conditions furnished the full framework of 1, Scheme 1. A similar strategy was utilised 
by this group three years later in the synthesis of pancratistatin.24  
 
Scheme 1. Rigby`s first enantioselective synthesis of narciclasine. 
8 
In the second reported synthesis of 1 Hudlický25, 26 used chiral cyclohexadiene diol 29 as 
a C-ring fragment for synthesis of narciclasine. This diene was submitted to a hetero-
Diels-Alder reaction to provide the key bicyclic intermediate 30. Suzuki coupling of this 
compound with arylboronic acid 31 and reduction led to enone 32, which, after 
installation of the correct stereochemistry in position 2 and cyclization was followed by 
deprotection, furnishing narciclasine (1) in twelve steps.  
 
Figure 7. Hudlický`s synthesis of narciclasine. 
The third synthesis of narciclasine was reported by Keck et al.27 In 1999 their group 
published a general approach towards both natural narciclasine and ent-lycoricidine. The 
pivotal point of their synthesis is an intramolecular 6-exo radical cyclization between a 
radical generated from alkyne and oxime 35, Figure 8. Chirality in this synthesis was 
achieved by using a chiral pool starting material, namely D-gulonolactone 33, as a 
precursor to alkyne 34. 
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Figure 8. Keck`s synthesis of narciclasine. 
The most recent synthesis of 1 was reported in 2002 by Elango and Yan.28 Their 
approach to the construction of narciclasine was similar to that previously reported by 
Hudlický for the synthesis of 10-epi-7-deoxypancratistatin26, 29 and consists of 
intramolecular opening of epoxide 41 to form phenanthridine 42, Scheme 2.The starting 
material used in their synthesis was the achiral cyclohexadiene diol 39 produced by the 
whole-cell oxidation of benzene. In order to transform it to the chiral conduramine 40 an 
enantioselective hetero-Diels-Alder reaction with chiral nitroso compound 37 was 
performed. In a few steps, that included bromohydrine formation and alkylation, the key 
epoxide 41 was prepared. Intramolecular Lewis acid-catalyzed epoxide opening led to the 
tricyclic product 42, which upon benzylic oxidation and elimination provided protected 
narciclasine 42. Finally, deprotection gave enantiomerically pure narciclasine (1) in ten 
steps. 
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Scheme 2. Yan`s synthesis of narciclasine. 
2.1.2.2. Total syntheses of lycoricidine. 
Lycoricidine (10) has attracted much more attention as a synthetic target and constitutes 
the earliest example of an isocarbostyril Amaryllidaceae alkaloid made by synthesis. The 
first racemic synthesis was performed by Ohta and Kimoto.30 Incidentally, on the way to 
this compound they had also prepared the protected version (49) of another related 
natural product, then as yet undiscovered 7-deoxypancratistatin (11).  
The synthesis began with the allylic alcohol 44, a precursor for a diene whose Diels-
Alder reaction with ethyl acrylate provided, after hydrolysis, acid 45, Scheme 3. After 
Curtius rearrangement and electrophilic cyclization tetracycle 46 was further 
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functionalised to establish the four hydroxyl stereocenters of 7-deoxypancratistatin. 
Finally, elimination of the unprotected C-1 alcohol moiety in 49 led to lycoricidine (10). 
 
Scheme 3. First racemic synthesis of lycoricidine. 
The first enantioselective synthesis of (+)-lycoricidine was performed by Paulsen and 
Stubbe.31 Enantioselectivity was achieved by utilising a chiral pool starting material, 
namely a derivative of glucose, aldehyde 50, Scheme 4. This aldehyde was transformed 
into nitroolefin 51 and reacted with the lithium derivative of piperonylic ester 52 to 
produce advanced intermediate 53. Upon acidic deprotection it was cyclized to 
cyclohexane 54, whereupon reduction and recyclization led to 7-deoxypancratistatin (11). 
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This natural product was submitted to selective reprotection followed by elimination to 
produce lycoricidine (10). 
 
Scheme 4. First enantioselective synthesis of lycoricidine. 
Other syntheses of lycoricidine were reported by Chida in 1991,32, 33 Hudlický in 1992,34, 
35 by Martin in 1993,36 by Keck in 1996,27, 37 and Yan in 2002.38 
The latest synthesis of lycoricidine was performed by Yadav in 2009.39In this chiral pool 
approach D-(+)-mannose was transformed to ω-iodo glycoside 57 in five steps, as shown 
in Scheme 5. Iodoether 57 was opened with allyl bromide in presence of zinc and the 
product of this transformation was cyclized with Grubbs 1st generation catalyst to furnish 
the cyclohexenol acetate 59. This product was subjected to two different sets of 
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aziridination conditions in order to produce the key aziridine 59. Coupling of 6-
iodopiperonylic acid 56 with compound 59 led to N-acylated aziridine 60. Deprotection 
and oxidation was followed by silica gel-catalyzed rearrangement of the aziridine moiety 
to allyl amide product 61. The tertiary amide 62 was subjected to an intramolecular Heck 
cyclization. This cyclization has been featured in many approaches of lycoricidine, 
namely those by Ogawa,32 Hudlický,34 Martin,36 and Weinreb.40 Isocarbostyril 63 was 
deprotected with formic acid to provide lycoricidine (10). 
 
Scheme 5. Yadav`s synthesis of lycoricidine. 
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2.1.2.3. Pancratistatin total syntheses. 
Pancratistatin (2) has attracted much more attention from the synthetic community than 
other members of the Amaryllidaceae family. The first total synthesis of 2 was reported 
by Danishefsky and Lee41 in 1989 only five years after its isolation. The synthesis began 
with pyrogallol 64 as the precursor for the A-ring of 2, Scheme 6. Further 
functionalization provided amide 65 with all carbons required for the skeleton of 
pancratistatin. Iodolactonization of cyclohexene ring was performed followed by key 
installation of the nitrogen atom via Overmann rearrangement of compound 68, lactone 
69 was produced. This compound was submitted to dihydroxylation, followed by 
rearrangement of lactone to amide, and finally, upon the removal of protecting groups, 
pancratistatin (2) was attained. 
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Scheme 6. Danishefsky`s synthesis of pancratistatin. 
The first enantioselective synthesis was reported by Hudlický42, 43 in 1995. Chirality in 
this synthesis was provided by the microbial metabolite cis-diol 4, Scheme 7. It was 
transformed into vinyl aziridine 70, which was subjected to nucleophilic opening with the 
cuprate derived from ortho-lithiation of amide 71. This sequence provided compound 72, 
containing all carbons of (2). Cyclization of 72 upon detosylation should have provided 
short access to the phenanthridone skeleton of the final target, but because of 
atropoisomerism the cyclization of amide did not take place and no desired 
phenanthridone was obtained. Therefore the expected short access to the major skeleton 
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was somewhat hampered by lengthy functionalization steps in order to provide the 
desired phenanthridone. The endgame was achieved by heating epoxide 74 in water, 
providing pancratistatin in 13 steps. 
 
Scheme 7. Hudlický`s enantioselective synthesis of pancratistatin. 
This report was closely followed by that of Trost who reported another synthesis of (2) in 
the same year.44 The next formal synthesis was performed by Haseltine in 1997,45and 
Magnus and Sebhat completed their total synthesis in 1998.46, 47 Rigby utilized his 
previously used narciclasine strategy for the synthesis of pancratistatin in 2000.24 A relay 
synthesis of pancratistatin from narciclasine was published in 2001 by Pettit48 and will be 
discussed in detail in section 2.1.3.4. This approach was followed by Kim`s synthesis in 
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2002.49, 50 In 2006 Li51 completed one of the shortest synthesis of pancratistatin. All of 
these early syntheses of (2) up to 2008 have been covered in an excellent review13 by 
Kornienko and Manpadi along with the estimation of economic viability of each route.  
In 2009 Madsen applied a chiral pool strategy for the synthesis of pancratistatin (2).52 The 
chief strategy rests on the reaction of methyl ω-iodoglycoside 82 with allyl bromide 78 in 
the presence of zinc, followed by ring-closing metathesis,  
Figure 9. Allyl bromide 78 was produced from piperonal 75 in 10 steps. Lactone 80 was 
obtained from 79 by ring-closing metathesis. At this point, a formal total synthesis of 
pancratistatin was achieved by intercepting the intermediate reported by Danishefsky.41 
Nevertheless, the endgame of the synthesis was improved in comparison with the original 
sequence by utilisation of milder conditions.  
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Figure 9. Madsen`s synthesis of pancratistatin. 
The most recent enantioselective synthesis of pancratistatin was published by Alonso.53 
The main strategy of Alonso`s approach lies in the organocatalytic condensation of β-
aryl-α-nitro-α,β-enals such as 85 with protected dihydroxyacetone 83 in the presence of 
pyrrolidine catalysts, Figure 10. Enal 85 was obtained from 5-methoxypiperonal 84 in 
two steps. Formal [3+3] annulation reaction of 85 with protected dihydroxyketone 83 
provided the key intermediate 86 with five contiguous chiral centres identical to those of 
final target. The optical purity of 86 was improved up to 99:1 er by a single 
recrystallization and 86 was then subjected to subsequent reduction, reprotection and 
Bischler-Napieralski cyclization to provide phenanthridone 89. Deprotection of 89 
furnished (2), accessed in nine one-pot operations. This strategy was proven to be 
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versatile and was applied to the synthesis of 7-deoxypancratistatin and a few analogues 
that will be discussed in the Section 2.1.3.3. 
 
Figure 10. Alonso`s synthesis of pancratistatin. 
The most recent racemic synthesis of pancratistatin has been performed by Cho et al.54 
This synthesis followed they previously described strategy, which was already utilized 
once for the synthesis of pancratistatin (2) in 2011.55 It employed a Diels-Alder reaction 
between 3,5-dibromo-2-pyrone (92) and styrene 91, Scheme 8. Since those two syntheses 
are strategically similar, only the latest one will be discussed. The synthesis began with 
trans-borylation of alkyne 90, thus affording alkene 91, which underwent the required 
[4+2] cycloaddition with 92. Oxidation of boron yielded bicyclic product 93 which was 
reduced and ring-opened to provide diol 94, selective protection and dihydroxylation of 
which provided the skeleton of 1-epi-pancratistatin 95. Inversion of the C-1 center 
provided tetraol 96, which was submitted to a sequence previously developed by this 
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group, that included Curtius rearrangement and Bischler-Napieralski cyclization to yield 
pancratistatin (2), Scheme 8. 
 
Scheme 8. Cho`s synthesis of pancratistatin. 
2.1.2.4. Total syntheses of 7-deoxypancratistatin. 
Since the first enantioselective total synthesis of 11 was performed even before its 
isolation from a natural source in 1989, as part of the synthesis of lycoricidine, Scheme 4, 
it will not be reproduced in this section. A list of syntheses performed after its isolation 
consists of enantioselective synthesis by Hudlický in 1995,56 which was realised through 
a strategy similar to that for pancratistatin, described by this group previously.42 This 
synthesis was closely followed by a radical approach by Keck in 1995.57 One year later 
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Chida58 utilised a chiral pool approach, followed by Plumet in 2000,59 who made use of 
the nucleophilic opening of vinylsulfones. A combination of ring closing metathesis and 
allyl coupling was utilised by Madsen in 2006,60 and Padwa reported a racemic synthesis 
in 200761 making use of an intramolecular Diels-Alder reaction.  
The latest formal total synthesis of racemic 7-deoxy pancratistatin (11) was performed by 
DeShong and Shukla62 in 2012. Crucial connectivity in 100 was established by coupling 
of a -allyl complex formed from protected conduramine 97 with siloxane 98, Scheme 9. 
Preparation of the C-ring fragment ensued from the protected diol 39, previously used in 
the synthesis of narciclasine (1) by Yan.28 A hetero-Diels-Alder reaction was performed 
on 39, followed by reduction and protection to provide the key intermediate 97 which 
was then submitted to Hiyama coupling with silane 98 in the presence of palladium 
catalyst 99, which yielded product 100 with moderate yield. Further cylization and 
oxidation, described previously by Hudlický,56 led to epoxide 101, an intermediate in the 
aforementioned synthesis.  
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Scheme 9. DeShong`s formal synthesis of 7-deoxypancratistatin. 
2.1.3. Synthesis of analogues of Amaryllidaceae alkaloids 
Promising anticancer activity and the as-yet unresolved mechanism of the biological 
action of isocarbostyril congeners of Amaryllidaceae family has attracted the interest of 
the synthetic organic and biological community alike. One of the major obstacles on the 
way to a marketable drug is the poor aqueous solubility of isocarbostyril compounds. 
This problem can be somewhat compensated for by the preparation of water–soluble 
prodrugs such as phosphates, however, the relatively low availability of Amaryllidaceae 
congeners from natural sources has ensured that significant efforts have been directed 
towards total synthesis. Unfortunately, because of the complexity of targets, existing 
approaches are somewhat lengthy (12-18 steps) and suffer from impracticality for large 
scale preparation, given the overall yields of 2-7%. The few syntheses with the higher 
yields do not provide the necessary flexibility to perform variation in different parts of 
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the target compounds in order to generate libraries of analogues. Therefore there are three 
goals that the syntheses of analogues of the aforementioned compounds need to target: (i) 
to establish the minimal pharmacophore required for anticancer activity and elucidate the 
mode of action, (ii) to produce water-soluble version of these compounds, and (iii) to 
devise short and practical routes to biologically active compounds. 
There are currently two general approaches to the analogues: the first one is the 
modification of the most abundant natural congener of this family – narciclasine (1). This 
approach was extensively developed by Pettit, the discoverer of pancratistatin. The 
attractiveness of such a route to study the pharmacophore lies in the relatively fast access 
to the desired compounds. This approach will be discussed in a Section 2.1.3.4. 
The second approach, which is somewhat related to total synthesis effort, is to produce 
fully synthetic analogues of Amaryllidaceae congeners from commercially available 
starting materials. This route allows an approach to analogues that cannot be produced by 
modification of natural congeners and does not rely on limited natural sources. The 
analogues can be divided into three main groups depending on where the major structural 
differences to the natural products are located. In the Section 2.1.3.1, synthetic analogues 
with modification in C-ring will be discussed, followed by synthetic analogues of the B-
ring, Section 2.1.3.2, and A-rings analogues, Section 2.1.3.3. 
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Figure 11. Narciclasine/Pancratistatin nomenclature and numbering. 
 
2.1.3.1. C-ring analogues 
The most explored class of analogues possess variations in the ring C. Because of the 
inherent complexity, namely four contiguous hydroxylated stereogenic centers, it only 
seems logical to explore deoxy analogues as well as compounds with different relative 
stereochemistry of the hydroxyl groups in order to establish a minimum pharmacophore. 
 One of the first synthetic analogues of 2 with a completely deoxygenated C-ring was 
synthesized by Heathcock.63 The main strategy involved the Michael-type 1,4-addition of 
ortho-metalated amide 103 to the 1-nitrocyclohexene 107 to produce aryl 
nitrocyclohexane 104, Scheme 10. Piperonilic acid 102 was converted into its 
diethylamide, selectively ortho-lithiated, borylated, oxidised, and protected to produce 
amide 103. The latter was in turn ortho-metalated and the resulting aryl lithium was 
added to 107 to produce the mixture of cis- and trans- stereoisomers 104 which was 
epimerised to the trans-isomer and reduced to the corresponding amine 105. It was 
cyclized by treatment with s-BuLi and deprotected to produce 106 in seven steps. 
Unfortunately, this model compound was not subjected to any biological studies. This 
approach was supposed to be a model for the actual synthesis of 2, but it is worth to note 
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that such strategy failed to produce the desirable outcome, transamidation of arylamide 
with the amino group, when it was later applied to the synthesis of pancratistatin.42 
 
Scheme 10. Heathcock`s synthesis of a pancrastistatin model. 
Banwell64 developed a new way to analogues of narciclasine and pancratistatin while 
exploring approaches to the synthesis of the skeleton of narciclasine itself. The key 
strategy in his synthesis lies in a Suzuki coupling between boronic acid 113 and 
functionalised 1-bromocyclohexenes 110a and 110b, Scheme 11. The synthetic sequence 
started with dihydroxylation of cyclopentadiene 108 with Pb(OAc)4 followed by 
protection of the diol, and addition of dibromocarbene led to the formation of 109. This 
dibromocyclopropane was rearranged upon reaction with silver isocyanate and trapped 
with methanol to produce a mixture of isomeric bromocyclohexenes 110a and 110b (in 
28% and 40% yield respectively), both of which could be elaborated to natural product 
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analogues. These compounds were separated and subjected to Suzuki coupling with 
boronic acid 113. Carbamate 111 was obtained by acetate reprotection after Suzuki 
coupling of 110a and was subjected to Bischler-Napieralski cyclization with triflic 
anhydride and further deprotected by sodium methoxide to produce 2,7-
dideoxynarcilasine (112) in six steps. Vinylbromide 110b was subjected to the same 
sequence to produce alkene 114. This isomer was stereoselectively borylated (as a result 
of steric hindrance of ketal group), oxidised, and reprotected as a triacetate to produce 
carbamate 115. This compound was submitted to the Bischler-Napieralski reaction to 
furnish triacetate of 1,2-epi-4,7 dideoxypancratistatin (116). Banwell`s strategy thus 
allowed for the synthesis of analogues of narciclasine and pancratistatin utilizing the 
same sequence and starting materials. 
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Scheme 11. Banwell`s synthesis of 2-deoxynarciclasine and 1-epi-4-deoxypancratistatin. 
Significant efforts toward the refinement of the C-ring pharmacophore have been 
reported by McNulty,65-67 whose systematic study led to the recognition of nitrostyrene 
122 as a common intermediate for the synthesis of several different racemic deoxy 
analogues. The first approach was based on a stereoselective intramolecular aldol 
condensation of nitroaldehyde 118,67 Scheme 12. Addition of an organometallic reagent 
generated from ethyl 4-bromobutyrate 117 to nitrostyrene 122 which upon reduction led 
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to aldehyde 118. Submission of this intermediate to solid-phase condensation in the 
presence of neutral alumina yielded nitrocyclohexanol 119 with good stereoselectivity 
(95:5). A series of protection and reduction transformations afforded carbamate 120 
which, after Bischler-Napieralski cyclization and deprotection, afforded 2,3-dideoxy 
trans-dihydrolycoricidine (121) in 8 steps. 
 
Scheme 12. McNulty`s synthesis of 2,3-dideoxy trans-dihydrolycoricidine. 
Latter approaches by McNulty towards the construction of deoxy analogues were based 
on a Diels-Alder reaction between the aforementioned nitrostyrene 122 and different 
dienes.66,65 It was shown that this approach can lead to the formation of the essential 
trans-stereochemical relationship between the aryl ring and nitro group. Independently, 
the same stereoselectivity was reported by Iglesias68 on the similar systems. Two 
different dienes were utilised for the synthesis of two analogues of trans-
dihydrolycoricidine.  
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For the synthesis of 4-deoxy trans-dihydrolycoricidine (126), 2,5-dihydrosulfolane (127) 
as a diene precursor was used in a Diels-Alder reaction with nitrostyrene 122 in the 
presence of Lewis acidic ZnCl2,
66 Scheme 13. The cycloadduct was reduced with 
aluminum amalgam and transformed to carbamate 123, which was further epoxidised to a 
mixture of - and -epoxides 124. Nucleophilic trans-diaxial opening of both isomers, 
followed by acetylation led to the same stereochemical relationship in diacetate 125. The 
same result for selective ring opening of similar system was reported three years earlier 
by Toke.69 Carbamate 125 was submitted to modified cyclization conditions described by 
Banwell,70 and deacetylated to provide 4-deoxy trans-dihydrolycoricidine (126) in seven 
steps.  
 
Scheme 13. McNulty`s synthesis of 4-deoxy trans-dihydrolycoricidine. 
In order to make the last analogue 133, nitrostyrene 122 was subjected to the 
cycloaddition with Danishefsky`s diene 128 in refluxing toluene to provide 
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cyclohexanone 129 in good yield, Scheme 14. The ketone was reduced to alcohol with 
sodium borohydride and converted via Mitsunobu reaction to nitrocyclohexane 130. The 
nitrogroup was then reduced to carbamate 131, which was subjected to the Bischler-
Napieralski reaction and after demethylation and removal of the ester provided 3- deoxy 
trans-dihydrolycoricidine (133).66 
 
Scheme 14. McNulty`s approach to 3-deoxy analogues of trans-dihydrolycoricidine. 
Pandey71 reported an enantioselective photochemical approach towards pancratistatin 
analogues. His synthesis started from D-quinic acid 134, which was transformed into 
ketal 135 and subjected to several protecting group manipulations, followed by sodium 
periodate cleavage of unprotected diol moiety to produce hydroxy ketone 136, Scheme 
15. A mesylation-elimination sequence of the free hydroxyl produced enone 137, which 
served as the C-ring component in this synthesis.  Michael addition of carbamate 138 to 
this enone followed by silyl protection of the enol led to key intermediate 139, which in 
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turn was submitted to photocyclization in the presence of 1,4-dicyanonaphthalene (DCN). 
This transformation established the necessary trans ring juncture in tricycle 140. Steric 
hindrance of the -face resulted in selective reduction of the carbonyl to establish the 
correct stereochemistry in the C-ring of the product. Further protection and ruthenium-
catalyzed oxidation of the benzylic position afforded amide 141, which after protection 
yielded the final product 2,7-dideoxypancratistatin (142). 
 
Scheme 15. Pandey`s synthesis of 2,7-dideoxypancratistatin. 
In order to perform the synthesis of a further deoxygenated analogue of 7-
deoxypancratistatin,72 Hudlický utilized the route previously developed in his group 
towards 7-deoxypancratistatin (11),56 Scheme 16. The synthesis started with whole-cell 
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oxidation of bromobenzene 3 followed by acetonide protection of the resulting diol, 
which was converted to aziridine 144 followed by dehalogenation. Nucleophilic opening 
of this aziridine with cuprate 143 in the presence of a Lewis acid led to amide 100, which 
in turn was deprotected to diol 145. Hydrogenation of alkene moiety with hydrogen on 
palladium on carbon was followed by Bischler-Napieralski cyclization and base-
catalyzed deprotection to provide 1,2,7-trideoxypancratistatin (147). Synthesis and 
biological studies of this compound along with those synthesized by McNulty, (Scheme 
13, Scheme 14), completed all possible deoxy models of the C-ring of Amaryllidaceae 
compounds. Biological results will be discussed in section 2.1.4.  
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Scheme 16. Hudlický`s synthesis of 1,2,7-trideoxypanratistatin. 
Since lycorine (8) showed some activity in anticancer assays and it possesses relative 
stereochemistry in positions 10b, 1, and 2 (narciclasine numbering) opposite to those of 
pancratistatin, it seemed reasonable to explore biological activity of the enantiomer of 7-
deoxypancratistatin in anticancer assays. In order to synthesize such compounds and 
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study their activity, Hudlický and Akgun29 utilised the toluene dioxygenase (TDO) 
enzyme, which can discriminate between the dihydroxylation of aromatic compounds 
based on relative size of their substituents. p-Bromoidoobenzene 148 was submitted to 
the whole-cell oxidation and after selective radical reduction provided a mixture of 
bromocyclohexadienediols 4 and ent-4, Scheme 17. Submission of this mixture to a 
nitroso hetero-Diels-Alder reaction and reduction led to a mixture of conduramines 149, 
which upon acylation and enzymatic resolution provided enantiomerically pure 149, 
Scheme 17. This conduramine was transformed to aziridine ent-144, the enantiomer of 
which was successfully utilised before for the synthesis of 7-deoxypancratistatin (11).56 
The same conditions were applied in case of this compound to provide ent-11 and 
enabled the study of its biological activity, which turned out to be one order of magnitude 
less active that natural congener. 
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Scheme 17. Hudlický`s synthesis of ent-7-deoxypancratistatin. 
DeShong73 developed a palladium-catalyzed racemic approach towards pancratistatin-
type compounds. It consists in coupling between aryl fragments and the Pd -allyl 
complex formed from allyl carbonate of type 152, Scheme 18. The synthesis began with a 
hetero-Diels Alder reaction between cyclohexadiene 150 and an acylnitroso compound 
formed in situ to provide bicyclic oxazine 151, which was reduced with molybdenum 
hexacarbonyl and protected with ethyl chloroformate to give allylic alcohol 152. This 
compound underwent Hiyama coupling with silane 98 to furnish intermediate 46 and its 
regioisomer (not shown) in a 1:1.6 ratio. After isolation the desired isomer was submitted 
to a Bischler-Napieralski cyclization followed by installation of the trans-diol moiety by 
treatment peacid epoxidation and ring opening to yield compound 154. 
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Scheme 18. DeShong`s synthesis of 3,4,7-dideoxypancratistatin. 
Banwell74, 75 used chiral diol 4 to secure access to a few unnatural enantiomers of 
narciclasine-type compounds. The strategy utilised for the formation of the core of the 
compound was similar to that used by Hudlický25, 26 and relies on tandem Suzuki 
coupling and lactam formation between arylboronic ester 165 and different chiral vinyl 
bromides to provide access to narciclasine type compounds in a short sequence, Scheme 
19. Diol 4 was protected as p-methoxybenzyl acetal 155, which was selectively 
dihydroxylated. Protection of the diol with methoxymethyl groups and reductive ring 
opening of the PMB-acetal gave vinylbromide 156. Further manipulation of protective 
groups secured access to the key intermediate 157. Subjection of this alcohol to 
Overmann rearrangement conditions produced amine 159, which served as building block 
for ent-narciclasine (ent-1), Scheme 20. Mesylation of alcohol 157 followed by azidation 
and hydrolytic Staudinger reaction provided building block 162 for synthesis of ent-3-
epi-lycoricidine (167), Figure 12.  
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Scheme 19. Banwell`s approach to a common building block in the synthesis of ent-
analogues. 
The aromatic building block 165 for coupling was produced in seven steps starting from 
piperonal (75), which was efficiently transformed to diethylamide 103 via Corey–
Gilman–Ganem oxidation, Scheme 20. It was subjected to a typical 
metallation/borylation/oxidation sequence and protection conditions, further ortho-
metallation, halogenation and deprotection with Meerwein`s reagent provided phenol 
ester 164. After protection with methoxymethyl group it was borylated with 
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pinacolborane in presence of a palladium catalyst. Boronate 165 was submitted to an one-
pot Suzuki coupling and amide formation to form the skeleton of the final compound, 
which upon acidic deprotection provided ent-narciclasine (1). A similar strategy was 
applied to the synthesis of several other analogues, Figure 12. 
  
Scheme 20. Banwell`s synthesis of ent-narciclasine. 
 
Figure 12. Different analogues of ent-narciclasine. 
Kornienko76 designed a synthesis of truncated analogues that lacked the cyclohexane 
structure of the C-ring. This approach began with Sharpless asymmetric dihydroxylation 
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of ethyl sorbate 168 followed by acetonide protection to produce a chiral acrylic acid 
ester 169, Scheme 21. Stereoselective conjugate addition of aryl cuprates led to 
compounds 170a and 170b, enolates of which were subjected to azidation reaction, which 
unfortunately led to a mixture of diastereomers. After reduction of the mixture of azides 
171 with lithium aluminium hydride and protection as carbamate, the required trans-
isomer of 172 was purified. Standard reprotection with acetates (before the key Bischler-
Napieralski cyclization) led to triacetate 173. The procedure for the cyclization, originally 
designed by Banwell,64 was modified and studied in some detail. Changing the base to 2-
chloropyridine led to a clean conversion to imidate 174. Subsequent demethylation with 
trimethyliodosilane and basic hydrolysis provided compounds 175a and 175b - open C-
ring analogues of 11 and 2 respectively. 7-Deoxy analogue 175a was carried further to 
periodate assisted cleavage of diol to produce truncated cyclic analogue 176. 
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Scheme 21. Kornienko`s synthesis of truncated C-ring analogues of 7-
deoxypancratistatin. 
Kim77 has been studying the effect of complete aromatisation of C-ring on the biological 
activity of narciclasine and pancratistatin. Because of the lack of any chiral centers it was 
possible to develop a short scalable route towards these compounds. Synthesis began 
with complete benzylation of 2,3,4-trihydroxybenzaldehyde 179, followed by Pinnick 
oxidation of the intermediate to the carboxylic acid, which underwent a Curtius 
rearrangement to aniline 178, Scheme 22. Coupling of this product with acyl chloride 
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made in situ from 6-iodopiperonylic acid (56) provided amide 179. In order to undergo 
intramolecular coupling the secondary amide 179 needed to be transformed to the tertiary 
amide 180, which was achieved by alkylation of 179 with SEMCl. Direct arylation was 
achieved in high yield in the presence of palladium acetate, tris(o-tolyl)phosphine and 
silver salt as a base. One-pot global deprotection of the coupled product 181 was 
achieved by hydrogenation and treatment with trifluoroacetic acid to furnish the final 
trihydroxy product 182 in low yield. Kim also described an analogous synthesis of three 
aromatic dihydroxy analogues (not shown), neither of these componds displayed 
anticancer activity. 
 
Scheme 22. Kim`s approach to C-aromatic analogues. 
Hudlický78, 79 designed a synthetic pathway towards a variety of compounds, which are 
homologues of 7-deoxypancratistatin at position C-1. The syntheses originated from 
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chiral diol 4, which upon protection was immediately submitted to an aziridination 
reaction following the procedure developed by Yamada80 and Evans81 to provide 
aziridine 183 in moderate yield, Scheme 23. Radical dehalogenation in the presence of 
tributyltin hydride led to vinylaziridine 70, which upon epoxidation with m-
chloroperbenzoic acid in refluxing 1,2-dichloroethane yielded a mixture of 
diastereomeric epoxides in a 3:1 ratio (major diastereomer 184 shown). After fractional 
recrystallization, the major isomer was submitted to epoxide opening reaction with the 
alkynylalane, formed from alkyne 191.The product of epoxide opening was protected 
with tert-butyldimethyl triflate without isolation to provide 185 in good yield. Selective 
reduction of the alkyne moiety to the cis-alkene was achieved upon treatment with borane 
and after isolation, alkene 186 was submitted to solid phase silica gel-catalyzed aziridine 
opening.82, 83 The product of this opening, namely phenantrene 187, was isolated in 
moderate yield and submitted to oxidative cleavage in order to produce dialdehyde 188. 
This transformation was achieved by sequential treatment with osmium tetroxide, 
reduction of the ketoalcohol with sodium borohydride, and cleavage of diol with sodium 
periodate. Transient dialdehyde 188 was not isolated but instead was allowed to undergo 
the cyclization to hemiaminal 189. The next step involved the oxidation of the 
hemiaminal to amide 190 in order to furnish the complete skeleton of the final product. 
This intermediate 190 was used as a point of divergence to produce, via oxidation and 
deprotection, carboxylic acid 193a and methyl ester 193b. Reduction of aldehyde 181 
with sodium borohydride and acetylation led to alcohol 192b, and acetate 192a 
respectively, following deprotection.  
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Scheme 23. Hudlický`s approach towards C-1 homologues of pancratistatin. 
43 
Alonso84, 85 developed yet another general strategy towards different analogues of 
pancratistatin and applied it towards the synthesis of 2-epi-7-deoxypancratistatin (197) 
and 2,4-diepi-7-deoxypancratistatin (198), Scheme 24. The strategy was identical to the 
one described previously for pancratistatin, (see Figure 10). The [3+3] annulation was 
performed with a derivative of piperonal (75), and dihydroxyacetone (83) to produce 
protected cyclohexanone 194. A divergence point between synthesis of pancratistatin and 
its analogues lies in the nature of the stereoselective reduction of the carbonyl function in 
194. Because of steric hindrance from the acetonide protecting group  the reduction gave 
the opposite stereoselectivity than that observed with a similar reduction,53 which led to 
the synthesis of the natural product. Reduction of the nitro group, deprotection and 
reprotection afforded intermediate 195, which was submitted to cyclization under the 
standard Banwell procedure64 followed by deprotection to provide to 2-epi-7-
deoxypancratistatin 197 in racemic form. A similar strategy was applied to the synthesis 
of racemic 2,4-diepi-7-deoxypancratistatin (190): intermediate 194 was submitted to a 
base-induced epimerization of the C-4 free hydroxyl group, followed by the same 
reduction-deprotection-cyclization sequence as described above. These compounds can 
also be prepared in an enantiopure form by utilisation of previously developed 
enantioselective protocol.53  
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Scheme 24. Alonso`s synthesis of epi 7-deoxypancratistatin analogues. 
 
2.1.3.2. B-ring analogues 
Chapleur86 was one of the first to systematically study the pharmacophore of 
pancratistatin. He utilized the chiral pool approach towards open B-ring analogues or 
seco-analogues. Methyl D-glucopiranoside (199) was subjected to protection, azidation 
and regioselective oxidative opening to produce bromide 200, Scheme 25. Reprotection 
and sequential elimination led to intermediate 201. The key step of this sequence was the 
transformation of pyranoside 201 via Ferrier rearrangement to provide cyclohexane core, 
which upon Luche reduction provided azido alcohol 202. 
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Scheme 25. Chapleur`s synthesis of open B-ring analogues. 
In order to establish the correct stereochemical relation of hydroxyl groups in 202, the C-
2 hydroxyl (pancratistatin numbering) was subjected to a Mitsunobu reaction, followed 
by the reduction of azide, which led to the protected conduramine 203, which was 
coupled to piperonylic acid (102) and deprotected to provide open-chain analogue 204. 
This compound was shown to be completely inactive.  
Hudlický87 synthesisized the previously unknown 10-epi-7-deoxypancratistatin (210) in 
order to compare the effect of cis-junction of the B-ring on anticancer activity, Scheme 
26. Synthesis started from the common intermediate aziridine 70, used before in few total 
syntheses of Amaryllidaceae alkaloids. It was transformed to cyclic sulfate 206 which 
was opened with ammonium benzoate, to provide upon protection and hydrolysis trans-
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diol 207. Formation of the lithium salt of this compound was followed by immediate aza-
Payne rearrangement and, after alkylation with piperonyl bromide (205), provided 
epoxide 208. Intramolecular opening of the epoxide catalyzed by Lewis acid provided the 
skeleton of the final compound 209 with the required cis-stereochemistry. Finally 
oxidation of the benzylic position and deprotection provided 10-epi-7-deoxypancrastatin 
(210). Anticancer assays of this analogue showed comlete lack of activity/ 
  
Scheme 26. Hudlický`s synthesis of 10-epi-7-deoxypancrastatin. 
Chapleur88 studied the effect of replacement of nitrogen in the lactam moiety by oxygen 
on biological activity. Ortho-metallated amide 211 was reacted with protected D-
glucuronolactone (212) followed by selective acid-catalyzed acetonide deprotection led to 
polyol 213, which was oxidised with sodium periodate and was subjected to DBU-
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induced Knoevenagel condensation and acetate protection, Scheme 27. The resulting 
enone 214 was subjected to Luche reduction, which unfortunately did not appear to be 
stereoselective. Removal of acetate and exposure to acid conditions led to a smooth 
formation of the lactone and deprotection of acetonide group. Two lactones, 216 and 217, 
were separated and subjected to biological testing. Although this is one the shortest 
syntheses of the pancratistatin analogues, it did not lead to lactone 216 stereoselectively, 
and both of these compounds showed lack of any anticancer activity. 
 
Scheme 27. Chapleur`s synthesis of lactone analogues. 
Hudlický used the strategy previously developed in his group for the synthesis of 7-
deoxypancratistatin (11)56 for the synthesis of analogues with open C and B-rings.26The 
key step was oxidation of intermediate tetraols 219 in order to produce open ring 
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analogues of 11, Scheme 28. Oxidative cleavage was followed by reduction to produce 
diols 220, then depending on a protecting compound was either deprotected completely to 
provide an amine 221 or protected with t-butoxycarbonyl group to produce 222. Both of 
these compounds were subjected to biological studies, which showed that only 222 was 
slightly active, section 2.1.4. 
 
Scheme 28. Hudlický`s synthesis of truncated ring-opened analogues. 
Fessner89 used a biocatalytical approach towards synthesis of sugar-based heterocyclic 
analogue 228, Scheme 29. He utilised whole-cell oxidation of naphtalene (223) with 
recombinant E.Coli JM109 (pDTG121) as a first step. The product of oxidation, diol 225, 
was isolated as a single enantiomer in good yield and subjected to ozonolysis. Dialdehyde 
226 was, without isolation, carried through the sequential enzymatic aldol reaction with 
dihydroxyacetone phosphate 224, dephosphorylation, and oxidation to produce a mixture 
of desired pyranoside 228 and the by-product furanoside 229 in 4 steps. Unfortunately, 
despite enzyme screening, no selective way to form 228 were found.  
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Scheme 29. Fessner`s biocatalytic approach towards analogues of 7-deoxypancratistatin. 
Complementary to the efforts of Chapleur, Kornienko90, 91 described an approach to the 
analogues of pancratistatin that completely lack the amide moiety but retain 
stereochemical relation between A- and C-ring. The synthesis started by selective 
benzylation of D-xylose 230 to a protected hemiacetal 231, which was submitted to a 
Wittig reaction, and oxidation followed by the second Wittig reaction, Scheme 30. 
Conjugate addition of aryl cuprate 239 to the acrylic ester 232 led to the stereoselective 
formation (ratio >50:1) of product 233. In order to cyclize C-ring of this compound, the 
ester moiety was reduced and transformed to the alkene by means of Grieco 
elimination.92 Ring-closing methathesis of two terminal alkenes was achieved by 1st 
generation Grubbs catalyst (240) and led to the general precursor 235, which can be 
selectively transformed to alkene analogue 237, alkane 236, or diol 238 depending on 
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conditions. By varying arylcuprates different analogues were obtained and all were 
assayed for anticancer activity with complete lack of any activity.  
 
Scheme 30. Kornienko`s approach to an open B-ring analogues. 
Further studies towards refining of pharmacophore were performed by McNulty.93 The 
key step of his approach consisted of Evans aldol reaction, which allowed the 
establishment, in one step, of the correct stereochemistry at C10b and C1 carbons. 
Synthesis started by the installation of Evans auxiliary onto phenylacetic acid 243, 
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Scheme 31. Product of this reaction 244 was submitted to aldol reaction in presence of 
magnesium chloride with chiral aldehyde 242, produced from tartaric acid, to provide 
product 245 with 95:5 selectivity. Reductive removal of the auxiliary group and 
reprotection with benzylidene acetal led to acetal 246. Regiolselective oxidative cleavage 
of the acetal with N-bromosuccinimide provided a convenient leaving group which was 
replaced by azide and followed by reduction and concomitant O to N benzoyl migration, 
thus ensuring the installation of the amide fragment in product 247. Two different 
deprotection condtions led to product 248a and 248b respectively. These open-chaing 
analogues displayed no anticancer activity.  
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Scheme 31. McNulty`s synthesis of truncated B- and C–ring analogues.  
2.1.3.3. A-ring analogues 
Analogues of A-ring modifications comprise the most underrepresented group of the 
analogues of isocarbostyril Amaryllidaceae congeners. The main reason is that most 
synthetic efforts were focused on solving the complexity of B- and C-rings therefore less 
challenging A-ring modifications received little attention. 
Only a few compounds are known that represent A-ring modification of pancratistatin. 
One of the first examples is the 7,8-dideoxypancratistatin (254) synthesized by 
Hudlický,72 Scheme 32. General strategy was similar to the synthesis of actual 4,56 but 
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different aryl cuprate 255 was used. Bischler-Napieralski cyclization of tetraacetate 251 
would expect to form of two regioisomers 252 and 253. But in fact only one isomer , 
namely 252, was formed in the course of reaction and after deprotection it afforded 254. 
Activity of this compound was shown to be two orders of magnitude lower than 
pancratistatin. 
 
Scheme 32. Hudlický`s synthesis of 7,8-dideoxypancratistatin. 
The effect of complete removal of methylenedioxy fragment from A-ring was later 
studied by the same group.82 It was reasoned that indole moiety has similar steric and to 
some extent electronic properties of original arylmethylenedioxy fragment. In order to 
produce such analogue 259 vinylaziridine 70 was subjected to silica gel-catalyzed 
54 
nucleophilic opening by methyl 2-indolecarboxylate (260) to produce cyclohexene 256, 
Scheme 33. Iodolactonization of this alkene followed by basic hydrolysis with lithium 
methoxide led to formation of epoxide. In order to remove the tosyl protecting group 
amide was transformed into t-butoxycarbamate 258 and submitted to one-electron 
reduction to remove tosyl group, followed by prolonged exposure to wet silica-gel upon 
heating furnished the final indole -carboline 249. Indole substitution rendered 
compound completely inactive. 
 
Scheme 33. Hudlický`s synthesis of indole analogue of pancratistatin. 
Further development of modification of A-ring was based on a [2+2+2] cycloaddition 
strategy.94,95 This time the effect of replacement of methylenedioxy moiety with silyl 
groups was studied. Synthesis was based on nucleophilic opening of vinylaziridine 70 
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with alane generated from TMS acetylene (268), Scheme 34. The resulting enyne 261 
was then selectively dihydroxylated with osmium tetroxide and transformed to a cyclic 
sulfate 262. Nucleophilic opening of sulfate with ammonium benzoate established the 
required trans-diol stereochemistry followed by selective desilylation of terminal alkyne 
and alcohol protection to provide 263. Alkylation of amide moiety with propargyl 
bromide led to the key dialkyne 264, which was submitted to [2+2+2] cycloaddition with 
bis(TMS)acetylene (269) catalyzed by cyclopentadienyl cobalt dicarbonyl. This reaction 
furnished skeleton of the desired product 265 in good yield. 
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Scheme 34. Hudlický`s synthesis of disilyl pancratistatin analogue. 
In order to oxidise the benzylic position by high-valent ruthenium reagents, protecting 
group exchange was performed and, after oxidation, phenanthridone 266 was obtained. 
Detosylation and sequiential basic and acidic hydrolysis led to bis-trimethylsilyl-7-
deoxypancratistatin 267, completely inactive in anticancer assays. 
Alonso85 developed general organocatalytic [3+3] route towards synthesis of A-ring 
analogues. The early stages of synthesis followed his general approach towards 
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nitrocyclohexanones such as 271 from furfural (270), Scheme 35. Protection and 
reduction of nitro group in 271 was followed by acylation with acryloyl chloride in order 
to furnish starting material 272 for the intramolecular Diels-Alder reaction. Chlorination 
of furan with N-chlorosuccinimide helped to facilitate formation of Diels-Alder product 
273 as well as subsequent aromatisation. Deprotection of the acetonide was followed by 
reduction at C-2 to ensure correct relative stereochemistry, and further reprotection with 
acetates. Finally, aromatisation was achieved by treatment with sodium methoxide and 
led simultaneously to the complete deprotection of the ester groups. Analogue 274, with a 
free phenolic group was subsequently transformed to protected version 275 and both of 
these compound were submitted to anticancer testing and showed no activity. 
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Scheme 35. Alonso`s synthesis of 7,9-dideoxypancratistatin analogues. 
2.1.3.4. Semi-synthesis from natural products. 
Because of the relatively high abundance of narciclasine in common perennials of 
temperate climate such as Narcissus pseudonarcissus and Narcissus poeticus10 in 
comparison with other congeners, it has always been considered an attractive route to 
utilize 1 as a starting material for synthesis of analogues. One of the first effort in this 
field was reported by Mondon and Krohn,7 who studied hydrogenation and other 
transformations of narciclasine to different derivatives. Synthesis of these compounds and 
biological studies performed on them constited one of the first examples of refining the 
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pharmacophore of Amaryllidaceae congeners. Several of the compounds produced in this 
study showed activity comparable with narciclasine itself in assays against cancer cell 
lines, especially trans-dihydronarciclasine (9), other derivatives such as cis-
dihydronarciclasine (276), iso-narciclasine (277), and 7-methylnarciclasine (278), 
showed significantly reduced activity in comparison with natural compounds, Figure 13. 
 
 
Figure 13. First synthetic derivatives of narciclasine. 
During their studies Mondon and Krohn first observed selective protection of the syn-diol 
to its ketal to form compounds of type 279, Scheme 36. Selective oxidation of the allylic 
alcohol in position C-2 lead to unstable ketone (not shown) which upon reduction 
provided mixture of protected 2-epi-narciclasine 280 and 279.  
60 
 
Scheme 36. Synthesis of protected 2-epi-narciclasine.  
Further development in the area of hydrogenation of narciclasine and 7-deoxynarciclasine 
was later provided by Pettit96, 97 in order to improve the selectivity of hydrogenation 
towards the most active congener, namely trans-dihydronarciclasine (12). Despite 
screening of different catalysts and condtions,97 the best selectivity was obtained with 
palladium on carbon, but is still remains low (9:276:277=51:47:2) on milligram scale. 
Upon scaling the reaction, the ratio of 12:276 drops to 30:62. 
Systematic studies on the conversion of narciclasine to different analogues were 
performed by Pettit.9, 48, 97-102 His major goal was to convert narciclasine (1) to 
pancratistatin (2), since his group has been largely involved in the discovery and the 
modification of pancratistatin skeleton. This task seems to be trivial, as the only 
difference is the presence of a hydroxyl group at C-1 and the absence of a double bond. 
In theory, this transformation can be achieved by stereoselective hydration of 
narciclasine, Figure 14. 
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Figure 14. Theoretical transformation of narciclasine to pancratistatin. 
In order to study this transformation Pettit performed studies on face-selective 
dihydroxylation of narciclasine. Depending on protection groups pattern, selectivity 
between - and -face dihydroxylation can be achieved. His studies showed102 that 
unprotected narciclasine (1) as well as acetate protected 281a upon different 
dihydroxylation conditions, including Upjohn and Sharpless asymmetric procedures, 
provided selective -face dihydroxylation and yielded 10b-(R)-hydroxypancratistatin 
(285), Scheme 37. Different attempts to reduce the benzylic hydroxyl upon 
hydrogenolysis conditions in order to produce 2 did not provide the desired product. 
Later Pettit98 studied radical approaches to reduce thiocarbonate derivative 283 but 
instead 10b-(S) epi-pancratistatin (284) was produced. 
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Scheme 37. Selective dihydroxylation and synthesis of 10b-(S) epi-pancratistatin. 
Introduction of a more sterically demanding protecting group, such as an acetonide, can 
alter the selectivity of dihydroxylation preferentially to -face. Pettit101 showed that upon 
exposure of narciclasine acetonide 279 to Sharpless asymmetric dihydroxylation 
conditions led to product 286 and its -diastereomer in the ratio of 2:1, Scheme 38. 
Deprotection of the major product under acidic conditions led to another hydroxylated 
analogue -10b-(S)-1-epi-pancratistatin (287). In order to achieve the inversion of the C-1 
position in this structure the cyclic sulfate 288 was formed by treatment of 286 with 
thionyl chloride and subsequent oxidation. Unfortunately, nucleophilic opening of the 
cyclic sulfate 288 with cesium benzoate at position C-2, afforded only 10b-(S)-1-epi-2-
epi-pancratistatin (289).  
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Scheme 38. Selective -dihydroxylation of narciclasine. 
In 2001 Pettit developed48 a relay synthesis of pancratistatin (2) form narciclasine (1). 
The first steps of which consisted in stepwise protection of narciclasine by acetonide and 
acetates to form the protected intermediate 290, Scheme 39. Protected narciclasine was 
submitted to the epoxidation with mCPBA in phosphate buffer. Face selective 
epoxidation led to epoxide 291, which was in turn submitted to hydrogenation on Pd/C. 
Unfortunately, this step turned to be a bottleneck of the synthesis and provided a mixture 
of products, amongst which the desired diol 292 was produced in only 28% yield. This 
diol was transformed to a cyclic sulfate 293, and then was followed by nucleophilic 
opening with cesium benzoate and acid deprotection to produce C-1 benzoate of 
pancratistatin 294. Upon basic hydrolysis the ester was hydrolyzed to produce 
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pancratistatin (2) in 10 steps from narciclasine (1). Despite quite a low yield this study 
provided essential data about biological activity, since all of the intermediates were 
subjected to anticancer cell assays. C-1 benzoate ester (294) in particular has shown the 
highest activity of all known analogues and congeners of Amaryllidaceae alkaloids, see 
2.1.4.2. 
 
Scheme 39. Relay synthesis of pancratistatin form narciclasine. 
Later the same strategy of nucleophilic opening of sulfate 293 was utilised by Marion 
from Pierre Fabre Laboratories103 to generate a library of nitrogenated derivatives of 
pancratistatin. Cyclic sulfate 291 was produced the way described by Pettit,48 and was 
subjected to nucleophilic opening by sodium azide, and deprotected to provide 1-azido-
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pancratistatin 295 which can, in turn, be reduced to amine 296, Scheme 40. Library of 
different amides and amines, Figure 15, was generated from 296. Some of these 
compounds have shown significant biological activity exceeding that of narciclasine 
itself. Most pronounced activity was shown by compounds with flat lypophylic 
substituents at position C-1, such as benzamide, see 2.1.4.2. 
 
Scheme 40. Amino C-1 analogues. 
 
Figure 15. Library of amino C-1 derivatives. 
Synthesis of two more analogues stemmed from a study on the separation of lycoricidine 
(10) and trans-dihydrolycoricidine (13) from bulbs of P. Littorale by Pettit.99 Protection 
of the chromatographically inseparable mixture of these compounds as acetonides led to 
the mixture of 301 and 302, Scheme 41. Further protection with t-butyldimethylsilyl 
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group and reduction of amide moiety with lithium alumohydride produced separable 
mixture of amines 303 and 304. Upon deprotection, the two new analogues without 
amide moiety 305 and 306 were isolated as their respective hydrochloride salts and 
subjected to biological studies. 
 
Scheme 41. Pettit`s synthesis of amine analogues. 
Kiss104 extensively studied various structural modifications of narciclasine (1) to produce 
series of 28 diverse analogues. Some of the compounds which have shown anticancer 
activity are presented on Figure 16. He utilized a previously described strategy in order to 
generate selectively protected C-2 and C-7 substituted esters 307-309, 4-substituted 
amides 310, and 2-epi-amines 311, 312. Stability toward hydrolysis as well as anticancer 
activity of all of these derivatives were studied.  
All of the studies presented above show the wealth of methods developed toward the 
modification and synthesis of different analogues of Amaryllidaceae congeners. Some of 
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these syntheses demonstrated to be very efficient in terms of the step count and yield, but 
synthetic efficiency cannot be a single criterion for the estimation of success in the field 
of synthesis of bioactive molecules. Therefore the next part will be dedicated to 
discussion of biological activity of produced analogues as well as possible ventures in 
this field. 
 
Figure 16. Narciclasine semisynthetic derivatives. 
 
2.1.4. Biological studies and search for pharmacophore. 
2.1.4.1. Biological effects and mechanism of action. 
Members of Amaryllidaceae family have been recognized for a long time in folk 
medicine for the treatment of cancer related illnesses. Narciclasine was reported by 
Ceriotti105 to have antimitotic activity on a murine sarcoma cell line (Sarcoma 180), as 
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well as inhibition of growth of wheat grain radicles. Isolation of isocarbostyril family of 
Amaryllidaceae alkaloids was guided by anticancer assays, mainly by murine P-388 
lymphocytic leukemia. These congeners have shown to have ED50 values as low as 0.01 
g/ml, they also exhibit activity against a wide panel of different cancer cell lines in 
vitro, as well as in vivo, particularly against the melanoma sub-family.9  
The natural Amaryllidaceae isocarbostyril compounds 1, 2, and 10-13 displayed 
promising antiviral activity in vitro against flaviviruses such as Japanese encephalitis, 
Yellow fever and Dengue fever viruses, and bunyaviruses such as Punta Toro and Rift 
Valley.96, 106 Futhermore, pancratistatin, narciclasine and 7-deoxypanratistatin have also 
shown some effect in vivo against mice infected with Japanese encephalitis, which 
constitutes one of the rare examples of non-immunomodulatory treatment of Japanese 
encephalitis.96 Narciclasine was shown by McNulty107 to be an inhibitor of CYP3A4 
human cytochrome, while structurally similar trans-dihydronarciclasine does not exhibit 
inhibitory activity towards several types of human cytochromes. This study can be 
important for future preclinical development of drugs based on the isocarbostyril 
pharmacophore. Some antifungal activity of narciclasine101 and antiparasitic activity of 
pancratistatin and 7-deoxynarciclasine108 has been observed in vitro, unfortunately all 
activity in assays had a narrow therapeutic window in comparison with activity of these 
compounds against cancerous cells. Further discussion will be focused solely on 
anticancer properties.  
Narciclasine and its congeners display several different mechanisms of action against 
cancerous and leukemia cells studies including apoptotis (programmed cell death), 
impaired cell proliferation, and decreased cell migration activity.109, 110 Simultaneously, 
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these compounds show little or no activity towards healthy cell lines, therefore presenting 
the possibility that these compounds could be developed into selective anticancer agents 
and prospective drugs. Naturally, the mechanism of action of these molecules attracted 
significant attention from the chemical and biological communities, which can serve to 
deepen our knowledge about cell proliferation and differentiation between healthy and 
cancerous cells. 
Early studies of the mechanism of action of narciclasine performed by Carrasco111 
demonstrated inhibition of eukaryotic ribosomal protein biosynthesis. These studies have 
been performed on Saccharomyces cerevisiae and rabbit reticulocytes (immature red 
blood cells). Experiments with 14C and 3H labeled peptides have shown, that narciclasine 
inhibits poly U-directed phenylalanine synthesis in ribosomes of rabbit reticulocytes as 
well as polypeptide synthesis in yeast polysomes, without affecting prokaryotic E.Coli 
cells. Furthermore, narciclasine may interact with peptidyl transferase in an eukaryotic 
large ribosomal subunit (60S) in the area known as the “anisomycin” area. It 
competitively binds to the same site as anisomycin (300) and to a lesser extent with 
trichodermin (301) – another potent protein synthesis inhibitor, Figure 17. Further 
evidence of a similar mode of action is the fact that a mutant yeast strain with resistance 
for 300 and 301, also exhibits cross-resistance for narciclasine.112, 113 Studies of the 
interaction of narciclasine and its semisynthetic derivatives were performed by Baez and 
Vasquez with tritium-labeled compounds114 and further supported specific interaction of 
narciclasine with the 60-S ribosome subunit.  
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Figure 17. Structures of inhibitors of cellular mechanisms. 
One of the most interesting effects is the pronounced selective cytotoxicity of 
isocarbostyril congeners. It has been shown in the independent studies of Pandey110 and 
Van Goietsenoven109 that narciclasine and pancratistatin have a pronounced cytotoxicity 
and selectively induce apoptosis in cancer cell lines but are 200 times less toxic against 
normal cell lines. According to Pandey,115 pancratistatin causes disruption of the 
mitochondria. He therefore reasoned that pancratistatin targets parts of the mitochondria, 
and their disruption activates apoptosis. Pandey postulated that the selectivity was caused 
by the ability of pancratistatin to differentiate between mitochondria of cancerous cells 
and normal ones. 
More recently, Van Goietsenoven proposed109 that narciclasine (1) targets the ribosomal 
translation elongation factor eEF1A. This particular factor is responsible for the transport 
of aminoacyl tRNAs and the nuclear export of proteins. The disruption of eEF1A can 
cause irreversible damage and promote cell death. This hypothesis was supported by 
molecular docking studies, as well as binding studies on isolated human recombinant 
eEF1A and similar yeast elongation eEF2. Also, the fact that cancerous cells overexpress 
this particular factor can explain selectivity of narciclasine towards cancerous cells. 
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2.1.4.2. Anticancer activity of diverse analogues of Amaryllidaceae 
congeners 
Initial studies towards refinement of cytotoxic pharmacophore of the Amaryllidaceae 
alkaloids relied on the comparison between compounds isolated from natural sources and 
those produced by semisynthesis. Seminal work on the refinement of pharmacophore was 
performed by Mondon and Krohn7 which revealed that trans B/C ring juncture is essential 
for activity; cis-dihydronarciclasine (276) is less active by an order of magnitude then 
trans-dihydronarciclasine (12), whilst isonarciclasine (277) was inactive. The 
methylation of the hydroxyl at position C-7 reduces the activity of narciclasine. 
Unfortunately, no inhibition concentrations were reported in the article, however these 
values were presented later,9 see Table 1, Table 3. 
The evaluation of anticancer and antineoplastic activity of natural compounds, semi-
synthetic and synthetic derivatives were performed by different groups on various cell 
lines, and the assays were reported with different units of measurement. It was decided to 
include only compounds, which constitute actual structural analogues, rather than 
prodrugs which undergo in vivo transformation to an active form. One of the most 
prominent examples are cyclic phosphates synthesized by Pettit,100 which have shown 
relatively low inhibitory activity in vitro but were much more efficient on live models.116 
In order to make direct comparison of the results of assays, different values of inhibition 
from a variety of sources were compiled in a few tables, based on which part of 
pharmacophore was being altered. Data will be presented in the tables as  mean values of 
all in vitro IC50/ED50/GI50 values reported for the compound and normalised as M.  
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Table 1. Activity of compounds isolated from natural sources. 
Name of compound Mean value of 
IC50/ED50/GI50 
(M) 
Difference from parent structure Ref. 
Narciclasine (1) 0.0155  9 
Pancratistatin (2) 0.0955  9 
trans-dihydronarciclasine(12) 0.0126  9 
Lycoricidine (10) 0.145 Lacks 7-hydroxyl 9 
7-deoxypancratistatin (11) 0.100 Lacks 7- hydroxyl 26 
trans-dihydrolycoricidine 
(13) 
0.0676 Lacks 7- hydroxyl 9 
(313) 
0.91 3-hydroxybutric acid on C-1 117 
(314) 
5.8 3(-Glucopyranoside)-
hydroxybutric acid on C-1 
117 
(315) 
4.3 Epimer on C-3 position  118 
 
The removal of 7-hydroxyl consistently lowers the activity of all congeners by one order 
of magnitude. Hydroxyl on the position C-1 in pancratistatin is also deleterious to activity 
in about 5-10 times in comparison with narciclasine and trans-dihydronarciclasine. 
Relatively polar substituents on position 1 such as 3-hydroxybutyryl also lower activity, 
as well as the alteration of stereochemistry of C-3 hydroxyl.  
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Table 2. C-ring analogues.  
Name of compound Mean value of 
IC50/ED50/GI50 
(M) 
Difference from parent structure Ref. 
(316) 
0.72 Acetate ester on position 2 97 
(317) 
1.01 Acetate ester on position 2, 3, 4 97 
(318) 
1.93 Acetate ester on position 2, 3, 4 97 
307a 0.51 Acetate ester on position 2 104 
307b 0.17 Benzoate ester on position 2 104 
307c 0.04 Propanoate ester on position 2 104 
307d 0.07 isobutiric ester on position 2 104 
308a 0.75 Acetate ester on position 2, 7 104 
308b 3.4 Benzoate ester on position 2, 7 104 
309a 3.0 -Glucoside on position 7 104 
309b Inactive -Glucoside on position 7 104 
309c 16.7 Methyl acetate on position 7 104 
309d 15.0 Acetic acid on position 7 104 
309e 7.4 2-methylenenapthalene on 
position 7 
104 
310a Inactive Lacks amide  104 
310b Inactive Lacks amide, acetate on nitrogen 104 
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310c Inactive Lacks amide, urea on nitrogen 104 
311 Inactive 2-epi ethylamine 104 
311 Inactive 2-epi ethylamine, cis-B/C junction 104 
294 <0.0023 C-1 benzoate ester 48 
193a 2.3 C-1 homologue alcohol, lacks 7-
hydroxyl 
79 
192b 0.56 C-1 homologue acetate ester, 
lacks 7-hydroxyl 
79 
193a Inactive C-1 carboxylic acid methyl ester, 
lacks 7-hydroxyl 
79 
193b Inactive C-1 carboxylic acid, lacks 7-
hydroxyl 
79 
297 0.018 isobutylamine on C-1 103 
298 0.017 Benzylamine on C-1 103 
299 0.03 Cyclohexylcarboxylic acid amide 
on C-1 
103 
300 0.007 benzoic acid amide on C-1 103 
175a,b Inactive open C-ring, lacks C-3 hydroxyls 76 
176 Inactive Pyranoside replaced C-ring, lacks 
C-2, C-3, C-4 hydroxyls, C-1 epi 
76 
147 Inactivea Lacks C-1,C-2, C-7 hydroxyls 72 
197, 198 Inactive 197  epi C-2, 198 epi C-2, C-4, 
both lack C-7 hydroxyl 
84 
133 Inactive Lacks C-1,C-3, C-7 hydroxyls 65 
126 2.3b Lacks C-1,C-4, C-7 hydroxyls 66 
                                                     
a For all tested cell lines except, ED50 = 5.0 M for murine leukemia P388. 
b Average for 4 cell lines, results against NCI 60 panel was 2-3 magnitudes lower than 2. 
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121 Inactivec Lacks C-1,C-2, C-3, C-7 
hydroxyls 
66 
ent-11 10-fold less 
active than 11 
 72 
ent-1, ent-10, 167,  Inactived   119 
180 Inactive Aromatic C-ring 77 
 
Significant information on the pharmacophore was obtained during biological studies of 
C-ring analogues. Esterification of hydroxyls at positions C-2, -3, -4 decreases activity by 
one or two orders of magnitude, depending on substituents. Changes of stereochemistry 
at positions C-2, -3, and -4 of hydroxyl or absence of any of these groups significantly 
deteriorates activity, therefore confirming the importance of all three groups in the 
molecule in a specific stereochemical array. The installation of lipophilic groups at C-1 
does not deteriorate activity, whilst polar groups, such as carboxylic group render 
compounds inactive. The notable example of the beneficial effect of lipophilic groups is 
C-1 benzoate (294). It is unclear whether ester 294 serves as a prodrug and just delivers 
pancratistatin to the active site, but the later discovery103 of benzamide 300 and benzyl 
amine 298 with comparable activity shows that this aromatic ring might be a part of the 
pharmacophore. 
Table 3. B-ring analogues. 
Name of compound Mean value of 
IC50/ED50/GI50 
Difference from parent structure Ref. 
                                                     
c ED50>153 M for murine leukemia P388. 
d 0-15% inhibition at 2M for 7 cell lines. 
76 
(M) 
292 Inactivee Lacks amide oxygen  97 
292 hydrochloride 13.0 Lacks amide oxygen 97 
293  5.7 Lacks amide oxygen 97 
293 hydrochloride 7.7 Lacks amide oxygen 97 
216 Inactive Nitrogen replaced with oxygen 88 
217 Inactive Nitrogen replaced with oxygen, 
epi-stereochemistry of 4a 
88 
204 Inactive No bond 10a-10b 86 
236-238 Inactive No amide fragment, open B-ring 91 
210 Inactive 10b-epi configuration 26 
222 12.0 Truncated B and C-ring 26 
248a, 248b Inactive Truncated B and C-ring 93 
iso-narciclasine (277) 11.8 Double bond 10b-4a 9 
cis-dihydrolycoricidine  95.5 Cis B/C junction, lacks C-7-
hydroxyl 
9 
cis-dihydronarciclasine(276)  3.8 Cis B/C junction, 9 
 
In order to retain biological activity, the B-ring must remain unchanged. Any alteration in 
functional groups, such as replacement of amide moiety or truncation of rings led to 
complete disappearance of anticancer activity. Conversion of stereochemical relation of 
B/C ring from trans to cis-junction significantly reduces activity and unexpectedly 
                                                     
e IC50>36 M. 
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isomerisation of position of double bond to 10b-4a in isonarciclasine (277) renders 
compound inactive. 
Table 4. C-ring analogues.  
Name of compound Mean value of 
IC50/ED50/GI50 
(M) 
Difference from parent structure Ref. 
254 12.5 Lacks C-7 hydroxyl, oxygen on 
position C-8 
72 
259 60.1 Indole replacement of A-ring 82 
267 Inactive TMS on position C-8,C-9 95 
274 Inactive Lacks C-7 hydroxyl, methylene 
dioxy bridge, hydroxyl on C-8 
85 
275 Inactive Lacks C-7 hydroxyl, methylene 
dioxy, Carboxybenzyl on C-8 
85 
 
These results, however limited, nevertheless show that the significant changes in A-ring 
lead to decrease or complete disappearance of anticancer activity. Replacement of 
methylenedioxyarene fragment with bioisostere indole fragment82 led to three orders of 
magnitude drop in activity. Removal of any of oxygenated substituents on position C-
8/C-9 or replacement with substantially different functional groups also lowers activity. 
In fact, the only untested position for replacement or introduction of the new functional 
groups is C-10.  
General information on the pharmacophore of the isocarbostyril group of Amaryllidaceae 
alkaloids with all these studies started to take shape. Two sites for possible modification, 
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without risk of significantly reducing activity, are positions C-1 and C-10. Therefore our 
goal is to design new efficient and general ways towards these two types on analogues.  
 
Figure 18. Model of pharmacophore presented on pancratistatin.  
 
2.2. Aromatic dioxygenases 
2.2.1.  Discovery of aromatic dioxygenases. 
The majority of animal and fungi organisms are capable of metabolizing aromatic 
compounds and transforming them to benign compounds via trans-diol 320 via transient 
intermediate epoxide 319. It was believed that the bacterial degradation pathway involved 
the same intermediates, Figure 19. Gibson120 was the first to show that some bacterial 
strains, namely Pseudomonas Putida F1, have an alternate aromatic degradation pathway. 
This pathway involves cis-dihydroxylation of the aromatic compounds for example 
toluene to the cis-cyclohexadiene diol (316), followed by oxidation by catecholde 
hydrogenase to catechol 317 and further degradation to non-aromatic compounds. This 
bacterial strain is able to utilize aromatic compounds as the sole source of carbon and 
energy.  
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Figure 19. Possible oxidation pathways in eukaryotic and prokaryotic organisms. 
Several years later, Gibson121 created a mutant strain Pseudomonas Putida 39/D (Pp 
39/D), which lacks the enzymes necessary for the oxidative transformation of cis-diol 321 
to catechol 322 and therefore accumulates larger quantities of the transient metabolite 
321. This unusual type of 3,5-cyclohexadiene 1,2-diols (cyclohexadiene diols) is 
produced by bacteria with high enantioselectivity (> 98% er). The absolute configuration 
of 321 was proven by its oxidative degradation of to the known compounds.122 In 1989 
Gibson123 identified the gene sequence responsible for the production of toluene 
dioxygenase enzyme (TDO) complex and transferred them into appropriate plasmid for 
functional expression in E. Coli. By designing this engineered strain, few major obstacles 
of biotransformation were avoided. First, the requirement for presence of certain aromatic 
molecules such as toluene or chlorobenzene as inducers of TDO expression was removed. 
The use of inducers with Pp 39/D inevitably led to contamination of the desired 
metabolite with cyclohexadiene diols, derived from inducers. Natural host of enzyme, Pp 
39/D, has a relatively slow growth and expression rate of required enzyme, which 
decreases the space/time yield. The recombinant strain E. Coli JM109 (pDTG601), was 
created to overexpress the TDO enzyme upon treatment with sugar -
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isopropylthiogalactopyranoside (IPTG). Creation of this strain allows to streamline the 
production of cell mass and enzyme complex for biotransformation and significantly 
increases space/time yield of production of cyclohexadiene diols. 
The structure of toluene dioxygenase (TDO) enzyme active site is unknown, even though 
X-ray crystal structure of the enzyme from the same family naphthalene dioxygenase 
(NDO) was solved.124 Nevertheless, because of the large number of metabolites 
characterized, some empirical rules were established125 and the stereochemical outcome 
of dihydroxylation of unsymmetrically substituted arenes can be predicted, Figure 20.  
 
Figure 20. Boyd`s model for prediction of regioselectivity of dihydroxylation. 
2.2.2. Utilization of diols in the natural product synthesis.  
In a little over forty years since the first isolation and identification of stable cis-
cyclohexadiene diols, more than 400 substrates produced by the dioxygenase family of 
enzymes were characterized. Only a small fraction of this library of richly functionalized 
compounds has been utilized in organic synthesis. All known metabolites and their 
applications for synthesis have been amply reviewed.126-131 
Despite the acknowledgment by the biological community, chemists has been reluctant to 
include these new fascinating molecules into their manifold of chiral building blocks. The 
first example of application of benzene cyclohexadiene diol (323) in synthesis was that 
reported by Taylor132 from ICI in 1983. He exploited radical polymerization of diene 323, 
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followed by elimination of diol moiety towards synthesis of a polyphenylene polymer. 
The same year the synthesis of indigo from indole was reported by Gibson.133 This 
synthesis also proceeded through the intermediacy of arene diol, but it was produced with 
the help of naphthalene dioxygenase-expressing organism. It is important to note that in 
both of these syntheses the diol functionality was destroyed in the process of forming 
product. 
The first example of incorporation and exploitation of the diol functionality in synthesis 
was presented by Ley134 almost nine years later after Gibson`s discovery in a short 
synthesis of pinitol (325). He used the steric hindrance of the protecting groups on the 
diol for facial selectivity in epoxidation reaction to produce epoxide 324, Figure 21. 
Selective opening of the epoxide led to the protected tetraol 325, which upon further 
functionalization provided racemic pinitol (326). The use of the arene diol functionality 
for steric guidance of further modifications as well as steric and electronic differentiation 
of alkene would prove to be standard strategies in the applications of these arene diols in 
organic synthesis.  
 
Figure 21. Ley`s synthesis of pinitol. 
The next milestone in the application of the arene diols for organic synthesis occurred in 
1988. The first utilization of asymmetric arene diol (321) in enantioselective synthesis 
was performed by Hudlický135 in a formal total synthesis of prostaglandin E2 
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(PGE2329), Figure 22. The key step in the synthesis consists of the oxidative cleavage 
of both double bonds of protected diol 321 by means of ozonolysis. Ketoladehyde 327 
was subjected to an intramolecular aldol reaction and provided enone 328, a formal 
intermediate of prostaglandine E2 (329) synthesis, in only four steps.  
 
Figure 22. Hudlický`s formal synthesis of prostaglandine E2. 
Rich functionality of cyclohexadiene diols can be exploited in a many ways toward the 
synthesis of different classes of complex organic molecules. Key steps of some total 
syntheses will be presented with the emphasis on the diversity of approaches rather than 
diversity of targets. 
One of the earliest and most explored transformations applied to the cyclohexadiene diols 
is the use of the diene moiety in the cycloaddition reactions. Gibson121 was the first to 
report cyclohexadiene diols serve as diene components in the Diels-Alder reaction. 
Hudlický applied this approach extensively to the total synthesis of a variety of natural 
products such as zeylena,136 conduramine A,137 lycoricidine,34, 35 and narciclasine.26, 127 
Last three syntheses share common steps, namely the tendency of diol 4 protected with 
the sterically demanding ketal group, to undergo facial and regioselective [4+2] 
cycloaddition with nitrosyl dienophiles.When applied to protected diol 330, bicyclic 
oxazine 331 was formed, reductive cleavage of N-O bond with sodium amalgam of 
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which was followed by dehalogenation and retention of stereochemistry to provide 
protected conduramine 332, Figure 23.  
 
Figure 23. Hudlický`s approach towards conduramine-type compounds. 
Alternative face selectivity of Diels-Alder cycloaddition reaction can be achieved upon 
performing reaction on unprotected cyclohexadiene diol. This strategy was utilized by 
Banwell138 in the synthesis of (+)-armillavirin. Diol 321, produced by dihydroxylation of 
toluene, was exposed to 19 kbar pressure in the presence of cyclopentenone (333) to 
provide tricyclic adduct 334, Figure 24. Further lengthy modifications provided tricyclic 
ketone 335, which upon subjection to photochemical conditions yielded the product of 
[1,3] acyl rearrangement, namely ketone 336, as the major product. Few more 
transformations yielded natural sesquiterpenoid armillarivin (337).  
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Figure 24. Banwell`s synthesis of armillarivin. 
In addition to Diels-Alder type reactions, cyclohexadiene diols have also been employed 
in a variety of sigmatropic rearrangements and thermal transpositions, as well facilitated 
by metals. Two prominent examples of the latter transformations include reductive and 
oxidative allylic transpositions performed by Micalizio139 and Hudlický.140  
Micalizio utilized reductive titanium-mediated coupling of alkynes with allylic alcohol 
towards total synthesis of phorbasin C. The synthetic sequence started from 
cyclohexadiene diol 4 derived by oxidation of bromobenzene with TDO. Dihydroxylation 
of the less sterically hindered double bond was followed by radical dehalogenation to 
provide diol 339, Figure 25. The key step involved the formation of metallacycle 338 
from TMS-propyne followed by coordination with allylic hydroxyl in 339 and reductive 
transposition to provide 1,4-diene 340, which was then transformed into final product 
(+)-phorbacin C (341). 
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Figure 25. Micalizio`s synthesis of phorbacin C. 
Oxidative allylic transposition was utilized by Hudlický in a short synthesis of the anti-
viral drug Oseltamivir. The starting material for the synthesis was diol 342 produced 
from ethyl benzoate with moderate yield ca. 1g/L. Diol 342 was protected, submitted to 
cycloaddition to provide upon reductionof the N-O bond the key intermediate allylic 
alcohol 343, which upon submission to oxidative transposition (Dauben-Michno reaction) 
mediated by chromium trioxide in acetic anhydride yielded enone 344, Figure 26. Further 
transformations provided access to the Oseltamivir (345) in only seven one-pot 
operations. 
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Figure 26. Hudlický`s synthesis of Oseltamivir. 
Cross–coupling was also recognized and utilized as an efficient way to introduce new 
functionality to the halogen-containing cyclohexadiene diols. One of the most prominent  
examples is the utilization of iodo cyclohexadiene diol 346 by Banwell141 towards a 
family of epoxyquinol-based natural products, Figure 27. In order to produce biosynthetic 
precursors of two complex natural products panepophenatrin (349) and hexacyclinol 
(350), iodo cyclohexadiene diol 346 was submitted to the sequential halobromination, 
Payne rearrangement, and Mitsunobu reaction to provide the key intermediate 347. Stille 
coupling of enone 347 with different vinylstannanes provided two intermediates 348a and 
348b which upon selective deprotection spontaneously underwent dimerization in the 
course intermolecular Diels-Alder reaction to form panepophenatrin (345) and 
hexacyclinol (350) respectively.   
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Figure 27. Banwell`s synthesis of panepophenantrin and hexacyclinol.  
These examples of the synthetic utility of cylohexadiene diols only represent a fraction of 
known syntheses. Cyclohexadiene diols also have been effectively utilized in the 
synthesis of carbasugars,142 morphinan143-145 type alkaloids and many other classes of 
natural products.126-131 Many targets attained from cyclohexadiene diols contain richly 
oxygenated amino cyclitol motif similar to those present in Amaryllidaceae alkaloids and 
therefore present an ideal starting point to develop a general and divergent strategy 
towards synthesis of different analogues of narciclasine and pancratistatin.  
2.3. Polysubstituted pyridines 
Pyridine ring systems are rarely observed in nature with only a limited number of 
complex natural structures containing a pyridine ring such as vitamin B6 and nicotin.
146 
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The pyridine scaffold, however is widespread in the pharmaceutical industry.147-149 The 
biological activity of and wide range of applications for pyridine-containing compounds 
ensures synthetic interest and has led to the development of many approaches towards 
these fascinating molecules.  
General approaches towards de novo synthesis of pyridines can be classified into three 
major categories: (i) cycloaddition, (ii) cyclocondensations, and (iii) rearrangements of 
different types of heterocycles, as shown in Figure 28. In this chapter the objective is not 
to give a comprehensive overview of all existing approaches, but the rather attention will 
be given to the application of more developed approaches to the synthesis of diversely 
substituted pyridines with the particular emphasis on polyoxygenated pyridines, because 
of their resemblance to the aromatic A-ring of the Amaryllidaceae alkaloids and hence 
the relevance to the topic of this dissertation. Some examples of syntheses of natural 
products containing polyoxygenated pyridine fragments will be presented in Section 
2.3.4.  
  
 
Figure 28. General routes towards pyridine ring scaffolds. 
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2.3.1. Cycloaddition reaction for the synthesis of polysubstituted pyridines  
Cycloaddition methods offer many advantages in the synthesis of polysubstituted 
pyridine systems, since these transformations can be performed with high atom economy 
and their convergence allows, in principle, the regioselective preparation of 
pentasubstituted pyridines. One of the most widely used and prominent examples of a 
cycloaddition reaction is the [4+2] cycloaddition process also known as the Diels-Alder 
reaction. Nitrogen can be present in either the diene or the dienophile fragment of the ring 
to be formed and therefore three different retrosynthetic disconnections of the same 
hetero-Diels-Alder approach to pyridines are shown on the Figure 29. The first and one of 
the most developed approaches is the utilization of 2-azadiene with different dienophiles. 
Due to electron-withdrawing nature of nitrogen this reaction usually proceeds as an 
inverse electron demand Diels-Alder reaction. This reaction can be performed with 
isolated 2-azadiene but much more common is the application of different heterocycles 
bearing a 2-azadiene fragment and a leaving group such as 1,2,4-triazine (352) or 
oxazinone (354). Other versions of hetero-Diels-Alder reations include the reaction 
between 1-azadienes (eneimines) and alkene fragments, and diene fragment with 
azadienophile such as imine. Imine and 1-azadiene fragments can be easily produced in 
situ from nitrogen nucleophiles and aldehydes, thus rendering these Diels-Alder 
approaches similar to condensation reactions. 
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Figure 29. Three different variants of hetero-Diels-Alder approach to pyridine. 
The hetero-Diels-Alder reaction was one of the earliest examples of a cycloaddition 
reaction, and its utility has long been recognized and extensively explored for the 
synthesis of natural products. One of the first examples of such a transformation was the 
use of oxazoles as azadiene fragments in what has become known as Kondrat`yeva 
reaction,150 which was extensively used in the synthesis of vitamin B6. Researchers from 
Merck developed their route151 starting from 4-methyl-5-ethoxyoxazole (355) which was 
coupled with maleic anhydride (356), to produce tricyclic anhydride 357, which upon 
treatment with anhydrous hydrogen chloride underwent ring opening and elimination 
yielded diester 358 in moderate yield, Scheme 42. Reduction of this pyridine yielded 
pyridoxine (359). 
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Scheme 42. Example of pyridine ring construction from the synthesis of vitamin B6. 
A general way of production of such highly functionalised pyridines was used to generate 
libraries of polysubstituted pyridines by coupling a range of oxazoles with a variety of 
dienophiles.152 However, one of the major limitations of this approach are the strict 
requirements on the substitution pattern of the oxazole ring. This reaction only proceeds 
successfully if the oxazole contains an electron donating group in the 5- position  (usually 
an alkoxy group) and an alkyl substituent in position 4, therefore severely limiting the 
substitution pattern of the final pyridine.   
Hetero-Diels-Alder reactions based on the use of 1,2,4-triazines as heterodiene fragments 
constitutes another well-studied approach towards polysubstituted pyridines. Early work 
in this field was performed by Neunhoeffer,153 and extensively studied by Boger,154 and, 
as a result, this particular transformation is sometimes known as Boger reaction.150 The 
major difference in this particular transformation is that the presence of the three nitrogen 
atoms that make the diene component very electron deficient; as such, this process can be 
described as an inverse electron-demand Diels-Alder reaction and can be performed with 
electron-rich dienophiles such as enamines, enol ethers and strained alkenes. The 
cycloaddition usually occurs regioselectively between the C-3 and C-6 positions of the 
triazine. An example of such a transformation was utilized by Boger155 towards the 
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synthesis of phomazarin (365).The inverse electron-demand hetero-Diels-Alder reaction 
between the electron poor 1,2,4-triazine 360 and 1,1,2-trimethoxyethene (361) forms the 
transient bicycle 362, which upon retro Diels-Alder elimination formed azadiene 363 and 
finally, upon elimination of methanol yielded pyridine ester 364 with good yield, Scheme 
43. A major limitation of this approach, however, is the requirement of generating 
appropriately substituted triazines, which usually requires several steps.156  
 
Scheme 43. Hetero Diels Alder approach towards the key intermediate in the synthesis of 
phomazarin.  
Alternative [4+2] approaches to a pyridine core have also been extensively studied and 
reviewed.157 It must be noted that unsubstituted 1-azadienes (eneimines) are unstable and 
require stabilizing groups in order to prevent their tautomerization to the more stable 
enamines. Therefore, it is usually not eneimines, but eneoximes158 and enehydrazones159 
that are used as diene fragments. Other eneimines equivalents have been described160 
such as dimethylaminoazadienium iodide 366, which can undergo cycloadditions with 
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different types of dienophiles, including ketene 367, followed by a elimination of the 
amine moiety and aromatization to produce substituted pyridone 369, Scheme 44.  
 
Scheme 44. 1-azadienes as cycloaddition partners in the synthesis of heterocycles. 
Potent inhibitors of electron-transport mitochondrial chain piericidins A1 (375a) and B1 
(375b) and, subsequently, their analogues have been synthesized by Boger161, 162by 
applying the same strategy of an inverse-demand Diels-Alder cycloaddition of N-
sulfonylimine 371, Scheme 45. In order to perform this key transformation, the azadiene 
fragment was produced from -carbonylester 370 by mesylation of the corresponding 
oxime. Reaction of azadiene 371 with tetramethoxyethene (376) led to tetrahydropyridine 
372, which upon treatment with Lewis acid eliminated methanol and yielded 
dimethoxypyridine 373. Further transformation involved a directed ortho-metallation 
(DoM)/borylation/oxidation sequence to the install hydroxyl moiety, followed by 
reduction of the ester group and an Appel reaction to form pyridine 374. Coupling this 
building block to the alkyl side chain and deprotection provided both natural products. 
The same building block was used towards the synthesis of analogues of these natural 
products.157 
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Scheme 45. Boger`s synthesis of piericidins. 
Pyridines can also be synthesized by a [4+2] cycloaddition between azadienophiles such 
as imines and nitriles and dienes.163, 164 Additional electronic activation of imines is 
necessary in order to undergo a Diels-Alder reaction and this is usually achieved by 
treatment with Lewis acids such as Yb(OTf)3, SnCl4, TiCl4, Et2AlCl, etc.
164 Other 
possibilities, such as the use of oximes as imine substitutes, were successfully employed 
by Weinreb165 for the synthesis of pyridylacetic acids. Malonoacyloxime 377 was shown 
to undergo thermal cycloaddition under high dilution to form bicycle 378, Scheme 46. 
Base promoted elimination of cyanide from oxime 378 led to aromatization and 
formation of pyridylacetic acid 379 good yield. 
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Scheme 46. Weinreb`s synthesis of pyridylacetic acids. 
 Another attractive and atom-economical approach towards polysubstituted 
pyridines is their production via [2+2+2] cycloaddition of alkynes and nitriles. In 
principle, this process is symmetry allowed but negative entropy barriers of 
approximation of three different fragments and the activation energy makes purely 
thermal cycloaddition of alkynes and nitriles a rare case. In fact, there is only one 
example of a metal-free transformation of this type, and it is not an actual [2+2+2] 
cycloaddition, but rather a case of an intramolecular sequential ene/Diels-Alder 
reaction.166 The vast majority of these cycloadditions are performed with a metal catalyst, 
which assists the pre-coordination of unsaturated fragment, and lowers entropic and 
enthalpic barriers. The general mechanism of such heterocyclic [2+2+2] cycloaddition is 
similar to their benzene counterparts. A significant number of reviews on the topic of 
pyridine formation via [2+2+2] cycloaddition have been published.167-169  
The first reported case of a cycloaddition for the synthesis of pyridine was described in 
1876 by William Ramsay170 by passing the mixture of acetylene and hydrogen cyanide 
through a red-hot iron tube. However modern metal-catalyzed methods allow for this 
transformation to occur under significantly milder conditions. Rediscovery of this 
cycloaddition was observed with complexes of cyclopentadienylcobalt by Wakatsaki and 
Yamazaki,171 and therefore these complexes are explored often for promoting such 
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cycloadditions and cobalt is the catalyst of choice because of its low cost, wide scope and 
substrate tolerance. 
The general mechanism of the cobalt-catalyzed cycloaddition was studied by 
Bönneman172, 173 and is displayed on Figure 30. Mechanistic details are similar to those in 
the formation of a benzene ring. The first step generates the catalytically active species 
380 from stable precatalyst CpCoL2 which coordinates with two alkyne fragments. The 
coordinated alkynes undergo reversible oxidative coupling with formation of 
metallocyclopentadiene 381. In the last step the unsaturated metallocycle reacts with the 
nitrile or other alkynes (unproductive pathway). After an insertion (383) or cycloaddition 
(384) reaction with nitrile, these intermediates undergo a reductive elimination of the 
reactive metal species and yield the pyridine product 385. There are a few other 
mechanisms that have been proposed, but this particular one is supported by the isolation 
of reactive intermediates and their independent reaction with alkynes. 
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Figure 30. Catalytic cycle of Co-catalyzed [2+2+2] cycloaddition. 
Although many examples of the cobalt-catalyzed reaction have been reported, the 
intermolecular regioselective assembly of two unsymmetrical alkynes with a nitrile to 
yield a single pyridine isomer remains an unsolved synthetic challenge. Major competing 
side-reactions are the oligomerization and trimerization of the alkynes. This obstacle can 
be overcome by performing the reaction in the presence of an excess of the nitrile 
component and using non-terminal alkynes with bulky protective groups, such as 
trimethylsilyl. A significant problem is the competitive formation of two pyridine 
regioisomers. Upon the addition of the monosubstituted alkyne to the nitrile it is common 
to see formation of both 2,4,6-(389) and 2,3,6-substituted pyridines (390), Figure 31. An 
investigation of different catalysts has been conducted,174, 175 and it appears that electron-
rich ligands provide moderate regioselectivity and poor yields, while electron-poor 
ligands provide good yields low regioselectivity. 
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Figure 31. Regioselectivity in the reaction between propyne and propionitrile.  
The best way to circumvent this regioselectivity issue is to perform the coupling on 
tethered α,ω-diynes (391)176 or ω-cyanoalkynes (394),177 with a third building block 
(nitrile or alkyne respectively). Therefore the bicyclic products such as 393 and 396 can 
be produced in a regioselective manner, Scheme 47. The reaction proceeded well with 
electron-rich alkyl and aryl nitriles, with 17:1 regioselectivty for 387, but unfortunately, 
the reaction scope is somewhat limited, and electron poor nitriles do not undergo 
cycloaddition in good yields. In the case of cyanoalkyne 394 only one isomer was 
formed. The regioselectivity of the pyridine ring formation can be predicted, based on the 
formation of metallocyclopentadiene intermediate between two alkynes, followed by 
such addition of nitrile, the nitrogen of the pyridine ring will form a bond with the most 
hindered substituent of alkynes. 
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Scheme 47. Regioselectivity of the cycloaddition on tethered systems. 
One of the most recent and elegant application of the cobalt-catalyzed cycloaddition was 
utilised by Siegel178 for the synthesis of complanadine A (401). The challenge of this 
pseudo-dimeric structure was addressed by utilizing a strategy of sequential 
regioselective additions of TMS-diyne 398 to ,-cyanoalkyne 397a, Scheme 48. The 
first [2+2+2] cycloaddition proceeded under the standard conditions in the presence of 
one equivalent of cyclopentadienyl cobalt dicarbonyl (CpCo(CO)2) in high yield and with 
excellent regioselectivity (25:1) to provide pyridyl alkyne 399. After completing the first 
cycloaddition, desilylation of the pyridine ring was performed and the second 
cycloaddition was observed to have a different regioselectivity, due to the addition of 
PPh3 and utilization of a different building block 397b. After further deprotection steps, 
the synthesis of the final bipyridyl natural product 401 was completed. 
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Scheme 48. Siegel`s synthesis of complanadine A. 
Other building instead of nitriles blocks that can be successfully utilized for the synthesis 
of pyridines are heteroallenes such as isocyanates. Earl and Vollhardt179 applied this 
particular transformation to the total synthesis of the cytotoxic quinoline alkaloid 
camptothecin 405. In order to complete the formation of the pyridone ring, protected 
-isocyanatoalkyne 402 was submitted to a cycloaddition with the silylated pentyne 
403 using CpCo(CO)2, Figure 32. Regioselective formation of a single pyridone 404 was 
observed, which upon further modification provided for two formal approaches towards 
racemic camptothecin (405). 
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Figure 32. Vollhardt`s synthesis of camptothecin. 
The original conditions of the cobalt-catalyzed cycloaddition were somewhat harsh, and 
consisted of refluxing catalyst CpCo(CO)2 and the substrate in xylenes.
171 Prolonged 
exposure to heat and the thermal instability of this catalyst was somewhat overcome by 
making use of excess of the catalyst (up to 100 mol. %) and/or syringe pump addition of 
a mixture of the substrate and the catalyst to the boiling solvent. For example, Vollhardt`s 
synthesis180 of lysergic acid derivatives utilised the cycloaddition of silypropyonamide 
407 with indolonitrile 406 as a key strategy, Figure 33. In order for this reaction to 
proceed successfully 1 equivalent of catalyst was required, prolonged exposure to heat 
and irradiation led to desilylation and low yield of cycloaddition product, pyridine 408.  
 
Figure 33. Vollhardt`s cycloaddition approach towards lysergic acid derivatives. 
As can be seen, a prolonged exposure to the boiling solvent led to a significant 
decomposition of thermally unstable products, especially silylated pyridines, and 
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therefore milder ways of activation of the catalyst were sought. Activation of more 
weakly-bound complexes such as 414 and 415 can be achieved in milder conditions, thus 
the cycloadditions may be performed in more environmentally benign solvents such as 
water.181 This approach has been used by Eaton182 to create library of polysubstituted 
pyridines such as 412, by means of a cycloaddition between nitriles and 1,4-butynediol 
(410) in water-methanol mixture in the presence of water-soluble catalyst 413, Figure 34.  
 
Figure 34. Cycloaddition reactions in water using new cobalt catalysts. 
CpCo(COD) (414) also was shown to be a competent catalyst at room temperature upon 
irradiation with UV-visible light (350-500 nm).169 Sensitive chiral nitriles183 underwent 
cycloaddition under these mild conditions without significant racemization. Another 
approach to improve the yield and reduce the decomposition of sensitive substrates is to 
shorten the reaction time, which can be achieved by applying microwave conditions.184 
Recently, a more stable and efficient catalyst was developed by Malacria and Gandon.185, 
186 Most of the cobalt (0) catalytic systems are air-sensitive and therefore require special 
handling techniques as well as degassed solvents; however, it was discovered that the 
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complex of cobalt cyclopentadienyl with electron deficient alkenes, such as dimethyl 
fumarate, namely CpCo(CO)dmfu (415), can efficiently catalyze the transformation 
under mild thermal conditions and even be recycled after the reaction.178 
Other transition metals can also catalyze [2+2+2] cycloadditions and might represent 
viable alternatives to the widely used cobalt method. These metals, especially ruthenium 
and rhodium, despite their cost, offer a distinctively different electronic preference for 
substituents and therefore offer complementary approach to design of reaction. For 
example, ruthenium (II) catalysts such as Cp*Ru(COD)Cl,187-189 and 
[Cp*Ru(MeCN)3]PF6
190 can catalyze the reaction between 1,6-diynes and electron poor 
nitriles such as cyanoesters, and -halonitriles, something which cannot be attained 
cobalt catalysis. Low valent nickel191 and iron192 catalysts showed opposite 
regioselectivity of cycloaddition to that expected from the common cobalt-catalyzed 
cycloadditions described above. Recent discoveries in the field of cationic rhodium 
complexes193 have shown that the [2+2+2] cycloaddition can be performed at room 
temperature in the presence of rhodium(I) and BINAP-type ligands. For instance, the  
regioselective cycloaddition of terminal electron-rich alkynes such as 416 with electron 
deficient nitriles as well as electron-rich nitriles was discovered by Tanaka,194 Figure 35. 
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Figure 35. Rhodium(I)-catalyzed cycloaddition for the formation of 
polyhydroxypiridines. 
One distinctive case of the metal-facilitated [2+2+2] cycloaddition is the use of 
complexes of low-valent titanium and zirconium for the construction of the pyridine ring. 
The main difference lies in fact that it is not an actual catalytic process but rather the 
nucleophilic addition of organometallic reagents to unsaturated carbon-carbon and 
carbon-nitrogen bonds. Because of different mechanism, this particular type of 
cycloaddition can result in a stepwise regioselective coupling of three unsymmetrical 
fragments, something which cannot be achieved selectively with any other transition 
metal. 
Sato195 utilized divalent titanium species generated in situ and similar to intermediates in 
the Kulinkovich reaction. Due to high oxophilicity of titanium, it coordinates 
regioselectively to the alkylpropiolic amide 420 and phenylacetylene 421 to form adduct 
422, Scheme 49. Addition of tosylcyanide (423) to the metallo-cyclopentadiene 
intermediate 422 proceeds smoothly and after series of rearrangements the titanium 
intermediate 425 can be quenched with a variety of electrophiles, including proton, 
halogens, or alkyl halides, providing tetrasubstituted pyridines in one step in good yields. 
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Scheme 49. Sato`s synthesis of polybubstitued pyridine. 
A similar case was observed for zirconium facilitated reaction. Takahashi196 studied the 
formation of azametallocyclopentadienes 429 upon treatment of internal alkynes and 
nitriles with low-valent zirconium species. The formed intermediates undergo coupling 
with different alkynes in the presence of nickel dichlorodiphosphine to produce 
pentasubstituted pyridines, Scheme 50. Unfortunately, this reaction was observed only 
with alkyl- and aryl-substituted alkynes and nitriles. 
 
Scheme 50. Takahashi`s synthesis of pentasubstituted pyridines. 
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All of these improvements extended the scope of the reaction and allowed for the 
formation of the pyridine core under much milder conditions and with improved 
regioselectivity, but nevertheless, cobalt remains the first catalytic metal of choice for the 
[2+2+2] cycloaddition in the synthesis of complex natural products.  
 
2.3.2. Condensation reaction for the synthesis of polysubstituted pyridines 
Historically, a condensation route is one of the earliest to be discovered and the most 
developed route towards polysubstituted pyridines. Generally it consists of the reaction 
between carbonyl compounds of different degrees of unsaturation and a nitrogen source 
such as a primary amine or ammonia. An overview of different retrosynthetic routes is 
presented in Figure 36. It is not to any extent a comprehensive representation of all 
existing condensation methods, which can be found elsewhere,150, 197 but rather examples 
of syntheses which lead to differently substituted hydroxypyridines. 
 
Figure 36. General condensation strategies towards pyridine core. 
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The Hantzsch reaction is one of the oldest multicomponent reactions and it consists of a 
condensation between two 1,3-dicarbonyl fragments 433, ammonia and aldehydes 435, 
Figure 37. This reaction provide access to a wide range of 1,4-dihydropyridine 
compounds 435, which can be oxidised to the corresponding pyridines 436. The scope of 
the classical Hantzsch reaction is somewhat limited by the fact that the substitution 
pattern of the product will always bear carbonyl/ester substituents at the positions C-3 
and C-5.  
 
Figure 37. Hantzsch synthesis of pyridines. 
New modifications of this transformation have been developed198 to overcome the 
problem in the synthesis of unsymmetrical pyridines. One way to approach it is to utilize 
preformed enamines such as -aminocrotonate 439 and its reaction with ketoester 438 
and aldehyde 437 in order to produce dihydropyridine 440 with high yield, Figure 38. 
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Figure 38. Modified Hantzsch synthesis. 
The related Guareschi-Thorpe synthesis is a convenient way to generate polysubstituted 
2-pyridones. It is conceptually similar to the Hantzsch pyridine synthesis with the 
difference that cyanoacetic derivatives are used as one of the building blocks instead of 
one of the 1,3-dicarbonyls. For example, in order to assemble 2,6-dihydroxypyridine 443, 
cyanoacetamide (442) was subjected to reflux in the presence of methylacetoacetate(441) 
and the basic amine in methanol to provide 2,6-dihydroxypyridine 443 in good yield, 
Figure 39. 
 
Figure 39. Guareschi-Thorpe condensation. 
The Friedlander condensation is one of the most common and reliable methods for the 
preparation of 2-hydroxypyridines. It consists of the condensation between -
aminocrotonate 444 and 1,3-dicarbonyl compounds, Scheme 51. Deshong199 applied this 
method towards the synthesis of 2,4-dihydroxypyridine 445. The synthesis started from 
methylacetoacetate 441, which was converted to aminocrotonate 444 upon treatment with 
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ammonia. The formed enamine 444 was submitted to the reaction with diethylmalonate in 
basic conditions led to desired dihydroxypyridine ester 445.  
 
Scheme 51. Friedlander condensation. 
2.3.3. Isomerisation of different heterocycles and acyclic compounds 
Oxygen-containing five and six-membered heterocycles such as furans, pyrilium salts and 
2-/4-pyrones have been successfully used for the synthesis of pyridines and especially 
hydroxypyridines/pyridones. Aminolysis of readily available 2-furan carbonyl derivatives 
of type 446 leads to nucleophilic ring-opening/ring-closure sequence and yields unstable 
intermediate 449, which upon treatment with acid,200 or prolonged heating201 undergoes 
by aromatization to 3-hydroxypyridines 450 in moderate yields, Figure 40.  
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Figure 40. Aminolysis of furan derivatives to hydroxypiridines. 
An unusual and a little known example of the oxidative rearrangement of furfural (270) 
to dihydroxypyridine 451 was published by Dallacker,202 Figure 41. Sequential treatment 
of furfural with one equivalent of bromine, hydrochloric acid, and then one more 
equivalent of bromine followed by heating with sulfamic acid led to 5-bromo-2,3-
dihydroxypyridine (451) in good yield in a one pot-operation.  
 
Figure 41. Synthesis of 5-bromo-2,3-dihydroxypyridine from furfural. 
Six-membered oxygen containing heterocycles such as pyrylium cations, 2- and 4-
pyrones also have been successfully used for synthesis of pyridine scaffolds. Different 
sources of nitrogen can be used for such transformations. Standard aminolysis with 
methylamine in a sealed tube with methoxy derivative of comenic acid (452) led to 4-
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pyridone carboxylic acid 453 in excellent yield,203 Figure 42. Much milder conditions for 
nitrogen replacement were developed by Kvita,204 who observed that upon treatment of 2-
pyrone 454 with hexamethyldisilazane (HMDS) as the nitrogen source in the presence of 
a base at room temperature 2-pyridone 455 can be isolated in good yield without the 
aminolysis of ester group.  
 
Figure 42. Transformation of 4- and 2-pyrones. 
 
2.3.4. Selected syntheses of pyridine-containing natural products and 
biologically active compounds. 
Natural products containing polyoxygenated pyridine rings constitute a relatively small 
group of compounds especially in comparison with isoquinoline and indole alkaloids.146, 
205 In the previous chapters quite a large number of diverse and creative methodologies 
for pyridine synthesis were presented but the ultimate test for every methodology is its 
application to total synthesis. However, most of the syntheses of polyoxygenated 
pyridines do not start with the creation of the pyridine, rather a modification of a simple 
pyridine building block is utilised instead. This occurs due to a large selection of 
available pyridine building blocks and the widespread application of simple 
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commercially available pyridines in medicinal chemistry, fine chemistry, and material 
science. These demands which renders the de novo synthesis of pyridine building blocks 
impractical.   
In this chapter the key steps of syntheses of several pyridine-containing natural 
compounds will be reviewed, which can serve as an inspiration and a guide for the 
synthesis of analogues of narciclasine. One family of such compounds is the piericidines 
antibiotics, potent inhibitors of the mitochondrial respiratory chain in eukaryotic and 
prokaryotic organisms. One approach towards this family was already described in 
previous chapter, Scheme 45. A completely different strategy was utilized by Keaton and 
Phillips,206 in order to provide access to the key pyridine 460, Scheme 52. 2,3-
Dimethoxypiridine (456) was submitted to a DoM/borylation/oxidation sequence, 
followed by protection to provide trialkoxypyridine 457. Futher DoM provided 
bromopyridine 458, which upon treatment with the hindered base lithium 2,2,6,6-
tetramethylpiperidide (LTMP) underwent  migration of the halogen atom also known as a 
halogen-dance.207 Transient aryl lithium intermediate 459 was quenched with methyl 
iodide to provide 460 which after further metallation and stannylation yielded key 
fragment 461. Installation of alkyl side chain by Stille coupling and deprotection yielded 
7-desmethylpiericicdine A1 (462). 
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Scheme 52. Phillip`s synthesis of 7-desmethylpiericidine A1. 
Another family of natural compounds with polyoxygenated pyridines are the atpenins. 
These compounds exhibit their major biological activity as inhibitors of the mitochondrial 
complex II of the respiratory chain. The syntheses of this family of natural products by 
different groups share some similar features, especially the halogen dance, so the seminal 
paper on synthesis of atpenin B by Queginer208 will be omitted and the most recent 
synthesis of atpenin A5 by Nakamitsu209 is described instead. The starting material for 
this sequence, commercially available 2-chloro-3-hydroxypyridine (463) was methylated 
and treated with sodium methoxide, followed by standard DoM/borylation/oxydation 
sequence for the introduction of a hydroxyl, Scheme 53. Iodination of 4-hydroxypyridine 
464 was followed by protection to attain iodopyridine 465, which was subjected to a 
halogen dance reaction in presence of LDA. Product of rearrangement, iodopyridine 466 
was treated with the standard trans-metallation/borylation/oxidation sequence. It is 
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interesting to note, that during the oxidation step the by-product, iodine, performed in situ 
halogenation of 2-pyridone intermediate to provide iodopyridone 467, which was further 
protected and functionalised by means of trans-metallation and coupling with aldehyde 
469. Final oxidation and deprotection yielded atpenin A5 (470) in a relatively short 
sequence. 
 
Scheme 53. Nagamitsu`s synthesis of atpenin A5. 
As can be seen from the two previous examples and some other syntheses of related 
compounds210, 211 the halogen dance reaction is a strategic reaction for selective 
functionalization of pyridine rings and a key step in many total syntheses of natural 
compounds with polyhydroxypyridine fragments. Together the diverse approaches 
towards de novo synthesis of pyridine core combined with different functionalization 
tactics present a powerful tool in the design of complex pyridine-containing molecules. 
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The preceding chapter described previously known approaches towards the synthesis of 
different Amaryllidaceae alkaloids, their structural analogues, the excursion into the field 
of enzymatic dihydroxylation of arenes, as well as diverse approaches towards syntheses 
of polysubstituted pyridines. It is hoped that it provided a sufficient overview of the 
current state of strategies as well as tactics in the field of synthesis of analogues of 
narciclasine and pacrastistatin and provide the background for the importance of research 
presented in the next section.  
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3. Discussion 
3.1. Introduction 
Natural products have always been an indispensable source and inspiration for new drugs 
and have produced significant insight into molecular interactions of different biological 
processes. The Amaryllidaceae alkaloid congeners, in particular the isocarbostyril family, 
present a good example of a family of bioactive compounds with high activity, a largely 
unexplored mechanism of action, and a potential as viable drug candidates. Research in 
this area has been hampered by scarce availability of most of these compounds from 
natural sources and their poor solubility profiles. While the issue of solubility can be 
addressed by the synthesis of soluble phosphate prodrugs, the generation of these 
derivatives still relies on the supply of natural products. Therefore a major goal is to 
develop a general and divergent approach towards analogues of pancratistatin and 
narciclasine. In order to perform this task, a few major issues must be addressed. First of 
all, the synthesis has to provide access to a range of compounds starting from a common 
starting material. Second, the design of the synthesis needs to be efficient in order to 
deliver the desired product in the minimum number of steps. 
A major theme of the discussion will be focused on our efforts to develop and test a few 
distinctly different and general approaches to produce analogues of pancratistatin (2) and 
narciclasine (1) utilising cyclohexadienediol (4) as a common chiral building block. 
Therefore the discussion is separated into three parts. The first one describes our 
approach to C-1 homologues of pancratistatin and synthesis of three new compounds (5a-
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c), Figure 43. This approach is based on a route previously developed in our group 
towards C-1 analogues of 7-deoxypancratistatin.78, 79 Application of a similar strategy, 
differences and modifications on the way to the three novel analogues and their 
anticancer activity are described.  
 
Figure 43. Route towards C-1 homologues of pancratistatin. 
The second part is focused on the approach towards pyridine analogues of pancratistatin 
(472) based on the cobalt-catalyzed [2+2+2] cycloaddition reaction. Our investigation of 
this reaction and attempts to produce and further functionalize analogues based on the 
skeleton of 472 is discussed.  
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Figure 44. [2+2+2] cycloaddition approach towards A-pyridine ring analogues. 
In the last section a convergent synthesis of different aza-analogues (6, 476, 7) of 
narciclasine is described, based on the intramolecular Heck coupling of amides 475 and 
478. These amides were in turn produced from halopyridine carboxylic acids 474 and 475 
and the protected conduramine 473. The main focus of this section will be an 
development of conditions for the Heck reaction and the synthesis of pyridine building 
blocks. 
119 
 
Figure 45. Intramolecular Heck approach to heterocyclic narciclasine analogues. 
The biological activity of these derviatives as well as new information on the minimal 
pharmacophore requirements will be discussed as well as the beneficial effect of certain 
functional groups and new directions for analogues development.  
3.2. Synthesis of C-1 analogues of pancratistatin 
The Hudlický group has dedicated significant efforts towards the synthesis of 
Amaryllidaceae constituents and their unnatural analogues for the past 20 years. Recently 
the group published a series of papers on the synthesis and biological activity of the C-1 
homologues of 7-deoxypancratistatin.78, 79 Two of these compounds, namely the C-1 
hydroxyl (183a) and C-1 acetate (183b) have shown activity against a variety of cancer 
cell lines comparable to those of the natural congener. It is known that the 7-hydroxy 
group plays an important role in the cytotoxicity as Amaryllidaceae isocarbostyril 
congeners with this substituent present are 10-100 times more active towards different 
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cancer cell lines.  The goal of our project therefore was to explore and utilize a similar 
synthetic strategy for the synthesis of a few new analogues of pancratistatin and study the 
influence of different substituents in the position C-1 on the anti-cancer activity.  
 
Figure 46. General retrosynthetic strategy towards C-1 homologues. 
The general strategy of the synthesis is outlined in Figure 46. In order to study different 
substituents on the C-1 position, alcohol 479 would present an ideal common 
intermediate. It could be generated from phenanthrene 480 via an oxidative 
cleavage/oxidative recyclization sequence. Intramolecular opening of aziridine 481 would 
serve as a good route towards functionalized phenanthrene 479. Generation of this 
aziridine 481 was envisioned through selective opening of oxirane 175 by alkyne 482. 
The chiral cyclohexadiene diol 4 which bears all necessary functionality to produce 
previously reported oxirane 17578 and was envisioned as a good starting material for the 
synthesis. 
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The synthesis of intermediate 481 began with the production of the first key intermediate, 
alkyne 482. The shortest and the most convenient way to approach this compound was to 
start from readily available piperonal (75). Introduction of the hydroxyl group was 
envisioned via DoM/borylation/oxidation sequence. Several of the total syntheses of 
pancratistatin and narciclasine have relied on this strategy to introduce the required 7-
hydroxyl group.27, 42, 52 Most of these transformations were performed with tertiary 
amides of piperonylic acid, which were proven to be cumbersome to reduce to the 
corresponding aldehydes. In order to shorten the synthetic sequence a directing group was 
sought, which could be deprotected directly to produce aldehyde under mild conditions. 
Two different directing group have been described in the literature for direct ortho-
metalation of piperonal: 1,3-dimethylimidazolidine 483212 and cyclohexylimine 485.213  
 
Scheme 54. Studies of DoM of 1,3-dimethylimidazolidine. 
In our hands, intermediate 483 failed to perform the transformation in the previously 
reported yields, Scheme 54. Different conditions and organometallic reagents for the 
metallation were tried and these attempts are summarized in Table 5. Aside from the fact 
that the yields of the desired transformation were low, also the synthesis of intermediate 
483 itself was proven to be cumbersome. The original paper reported distillation of 
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product at low pressure (108 °C/5*10-3 Torr); we performed column chromatography, 
which proved to be impractical on a large scale.  
Table 5. Ortho-metallation conditions. 
Conditions,solvent RLi; eq.; (additive) Yield,% 
−78 °C→r.t. → −78 °C, 
Et2O (lit. procedure) 
t-BuLi; 2; 30 
−78 °C →−10 °C, THF t-BuLi; 2 22 
−78 °C →0 °C →−78 °C, 
Et2O 
t-BuLi; 1.2 20 
−78 °C →r.t., Et2O n-BuLi; 1.2 (TMEDA) 26 
−78 °C →r.t., Et2O n-BuLi; 2 (TMEDA) 34 
−78 °C →r.t., THF n-BuLi; 1.2(TMEDA) 30 
−78 °C →r.t., THF n-BuLi; 2(TMEDA) 39 
  
We tested therefore a second approach with the introduction of a cyclohexylimine 
auxiliary 485, Scheme 55. Isolation of intermediate 485 did not pose any problems, since 
it was a solid and  was easily recrystallized from methanol. ortho-Metallation was 
performed at -78 °C, and after borylation, oxidation and hydrolysis provided the desired 
hydroxyladehyde 484.  
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Scheme 55. Ortho-metallation of cyclohexylimine 485. 
Methylation of phenol 484 was performed with dimethyl sulfate in the presence of 
potassium carbonate, yielding methoxyaldehyde 486, Scheme 56. This compound was 
allowed to react with carbon tetrabromide in the presence of triphenylphosphine to 
provide dibromoalkene 487, which after treatment with nBuLi provided desired alkyne 
482 in 5 steps from piperonal in good overall yield. The largest scale, this sequence was 
performed on, provided 40 g of alkyne in a single run. 
 
Scheme 56. Synthesis of alkyne 482. 
The chiral epoxyaziridine 175 was prepared by a previously described route developed in 
the Hudlický group.78 The product of enzymatic dihydroxylation of bromobenzene (3), 
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the chiral diol 4, was protected as acetonide 183 and immediately subjected to 
aziridination protocol under the Yamada-Evans conditions,80, 81 Scheme 57. Complete 
facial selectivity was achieved as a result of the steric hindrance of the ketal. The bromine 
atom was removed under radical reduction conditions with tri-n-butyl tin hydride to 
provide N-tosyl aziridine 70 in good yield. Epoxidation of the alkene moiety was 
performed by treatment with m-chloroperbenzoic acid in refluxing dichloroethane. This 
epoxidation did not provide complete facial selectivity, but instead led to a 3:1 mixture of 
diastereomers in favour of the desired isomer 184. This ratio was increased by three 
successive fractional recrystallizations from isopropanol to 6:1-7:1 and produced 10 g of 
epoxyaziridine 184 in a single run.  
 
Scheme 57. Synthesis of chiral epoxiaziridine 184. 
The next step consisted of selective nucleophilic opening of oxirane 184 by the 
alkynylalane formed in situ from the anion dervided from alkyne 482 and 
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dimethylaluminum chloride, Scheme 58. Stringent reaction conditions and carefully 
controlled temperature had to be used to ensure selective opening of oxirane moiety in 
the presence of the aziridine ring. The alkyne 490 was somewhat unstable and the yield 
was significantly increased (from 42 to 70%) if the crude reaction mixture is directly 
submitted to the next protection step with t-butyldimethylsilyl triflate.  
The next step was to perform selective reduction of alkyne 490 to the Z-alkene 481. The 
original conditions for the reduction of 7-deoxyanalogues78 consisted of reduction with 
boranes. Unfortunately, reaction of dicyclohexyl borane with alkyne 491 did not lead to 
the desired product, probably because of the steric hindrance of the methoxy group. 
Catalytic hydrogenation is one of the most common ways to generate Z-alkenes;214 we 
discovered that this particular reaction was sensitive to the steric environment of the triple 
bond, i.e. reduction of the TBS-protected alcohol 491 did not lead to reproducible yields. 
Much more successful results were observed during the reduction of alcohol 492. 
Nevertheless, over-reduction of the alkyne posed a significant problem and screening of 
conditions and solvents for selective reduction was performed. 
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Scheme 58. Selective opening of epoxide and further reduction. 
Lindlar catalyst and palladium on carbon in methanol led to significant over-reduction. 
Reduction of substrate in the ethyl acetate did not proceed well, but it was discovered that 
addition of 20 mol. % of quinoline to 20 mol. % Lindlar catalyst and reduction in 
methanol allowed for selective reduction and nearly quantitative conversion with 
negligible amounts of by-products was observed. After protection with a tert-
butyldimethylsilyl group the key intermediate 481 was submitted to silica-gel catalysed 
closure, Figure 47. This step consisted of adsorption of compound on pre-dried silica-gel 
and heating at 120 °C for 24-36 h. It was discovered that traces of quinoline (ca. 5%) 
from the reduction step led to a significant increase in yield, albeit with a prolonged 
reaction time. Our hypothesis for this phenomenon is that quinoline neutralises inherent 
acidity of silica-gel and therefore reduces unwanted decomposition of the acid-labile 
groups in compound 481.  
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Figure 47. Solid phase silica-gel-catalyzed closure. 
After securing access to phenanthrene 480, our next goal was to perform oxidative 
cleavage of the olefin bond which upon oxidative cyclization, was expected to form 
hemiaminal 494, Figure 48. The original conditions developed for 7-deoxypancratistatin 
analogues for cleavage of this type of bonds (OsO4/IO4
-) did not lead to a clean 
transformation and therefore different conditions were screened. 
 
Figure 48. Oxidative cleavage and recyclization of phenathrene 480. 
Ozonolysis is one of the most convenient ways to cleave double bonds. But an important 
issue is the selectivity of double bond oxidation using ozone. Electron–rich aromatic 
rings are prone to oxidation by ozone and therefore standard conditions of ozonolysis, i.e. 
the appearance of a blue colour of excess of ozone in solution, are too destructive for the 
selective transformation. Therefore, selective indicator such as Sudan Red 7b215 was 
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introduced as an indicator to ensure selective cleavage of the alkene. Reductive 
quenching was performed with sodium borohydride to provide a mixture of diol 495 and 
hemiaminal 496 in 2:1 ratio, Scheme 59. It was found that this particular reaction turned 
out to be sensitive to the solvent; upon performing the reaction in methanol significant 
decomposition to polar by-products was observed. Transformation of diol 495 to 
hemiaminal 496 was investigated next. Screening of different conditions for selective 
benzylic oxidation was performed. The only conditions that led to good conversion to 
hemiaminal 496 were the use manganese dioxide in dichloromethane. The next goal was 
to oxidize the heminaminal moiety to an amide to complete the skeleton of the desired 
target. It required selective protection of the primary alcohol in 496 in the presence of the 
hemiaminal, which was achieved by reaction with acetic anhydride with pyridine in 
dichloromethane and yielded a mixture of acetateprotected anomeric hemiaminals 497 in 
87% yield. Different oxidation conditions were tried, including IBX, Dess-Marin 
periodinane, PDC, but the best yield was obtained with the milder oxidation conditions of 
tetrapropyl ammonium perruthenate and N-morpholine oxide, also known as the Ley-
Griffith oxidation.216 Desired amide 498, the common intermediate for the synthesis of all 
C-1 homologues of pancratistatin, was isolated with 84% yield. 
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Scheme 59. Conversion of phenanthrene 480 to amide 498. 
Having secured access to this fully protected C-1 acetoxymethyl pancratistatin, 
deprotection steps were studied. Detosylation of 498 was performed by means of 
reductive cleavage with sodium napthalenide to provide amide 499 in 62% yield, alcohol 
by-product 479 was also isolated in small quantities from this reaction, Scheme 60. 
Screening of standard demethylation conditions217 were performed, including sodium 
thiolate,218 boron tribromide52 and lithium chloride;25 only the latter conditions provided 
the desired phenol 500 successfully. Deprotection of the acetate group in 499 was also 
studied in order to provide access to a different ester substituent on position C-1. 
Removal of acetate group proceeded smoothly upon treatment of 499 with a concentrated 
aqueous solution of sodium hydroxide in methanol. 
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Scheme 60. Production of common intermediate 479. 
Removal of the silyl group did not pose any problems and was performed under standard 
conditions with tetrabutyl ammonium fluoride (TBAF). The last step, however, posed 
some difficulties, since the previously reported conditions79 for selective deprotection of 
acetonide led to deprotection of the acetate as well and formation of C-1 pancratistatin 
homologue 5a, Scheme 61. Treatment of acetonide 501 with trifluoroacetic acid at 0 °C 
provided C-1 acetate 5b in excellent yield.  
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Scheme 61. Deprotection sequence towards C-1 pancratistatin homologue 5a and acetate 
5b. 
The next goal was to produce the benzoate ester of C-1 pancratistatin homologue, since it 
has been known that this particular group plays a beneficial role in anticancer activity of 
Amaryllidaceae congeners. Benzoylation of alcohol 479 was performed with benzoyl 
chloride and provided ester 503, which was submitted to deprotection conditions, similar 
to those employed before for C-1 acetate 5a, to yield C-1 benzoate 5c in three steps, 
Scheme 62. Synthesis of the three analogues was performed with 17 steps in the longest 
linear sequence. Biological studies of these three analogues 5a, 5b, 5c were performed on 
a panel of cancer cell lines and will be discussed in Section 3.5. 
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Scheme 62. Synthesis of benzoyl acetate 5c. 
 
3.3. [2+2+2] Cycloaddition approach to pyridine analogues of 
pancratistatin 
After performing the synthesis and anticancer evaluation of the C-1 analogues, our 
attention was drawn towards the synthesis of much less explored analogues of the A-ring 
of pancratistatin. Since it is common practice to utilise a pyridine fragment as a 
bioisostere of a benzene ring for improving pharmacokinetics,219 we decided to design a 
general route towards pyridine analogues of pancratistatin. Our attention was drawn to a 
[2+2+2] cycloaddition strategy167-169 of pyridine ring formation, since it offers general 
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versatility and has been shown to work successfully in the synthesis of similar bis-
silylated analogues of pancratistatin.94, 95  
 The general retrosynthetic scheme is outlined on Figure 49. bis-Silylated pyridine 472 
was considered the most convenient intermediate to provide access to polyoxygenated 
pyridine analogue 506 through oxidation reactions. Synthesis of the key heterocyclic 
intermediate 472 was envisioned via a cobalt-catalyzed [2+2+2] intermolecular 
cycloaddition between bis(trimethylsilyl)acetylene (269) and nitrile 471. This 
cyanoalkyne 471 in turn can be attained by functionalization of aziridine 70 by means of 
nucleophilic opening, selective dihydroxylation of the double bond, and alkylation of the 
amide with the nitrile fragment. Aziridine 70 is a common intermediate in the synthesis 
of Amaryllidaceae alkaloids in the Hudlický group and was generated in three steps from 
cyclohexadiene diol 4. 
 
Figure 49. Retrosynthetic scheme for the [2+2+2] strategy of pyridine ring analogues. 
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Synthesis of aziridine 70 was discussed in the previous Section 3.2, Scheme 57. Aziridine 
70 was submitted to a protocol previously developed in the Hudlický group92 of 
nucleophilic opening of the aziridine moiety with a large excess of alkynylalane 
generated in situ from lithium trimethylsilyl acetylide and aluminium chloride, Scheme 
63. Simultaneously, the acetonide was hydrolyzed during this reaction, which required 
reprotection to provide tosylamide 508 in good yield. Selective dihydroxylation of the 
alkene fragment in the presence of the alkyne was performed by treatment with osmium 
tetroxide in presence of N-methylmorpholine N-oxide. This reaction was performed in 
dichloromethane, unlike the usual conditions,220 which involve polar solvent system. 
These were the only conditions that provided a reasonable conversion without significant 
decomposition of the product 509. Benzoylation of diol 509 provided protected alkyne 
510 in good yield. 
 
Scheme 63. Synthesis of alkyne 510. 
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Our next goal was to study the alkylation of the amide fragment in tosylamide 510 to 
yield -cyanoalkyne 471, Scheme 64. Conditions originally developed on the Hudlický 
group94, 221 for the synthesis of dialkyne 264 consisted of desilylation with a non-basic 
reagent, tetrabutyl ammonium triphenyldifluorosilicate (TBAT), followed by alkylation. 
In this particular case two different routes were studied: (i) desilylation of amide 510 
followed by alkylation with chloroacetonitrile in the presence of sodium 
bis(trimethylsilyl)amide or (ii) alkylation of amide 510 with chloroacetonitrile followed 
by desilylation of formed -cyanoalkyne 512. The second route was shown to be more 
efficient in terms of cleaner conversion, and overall yield. 
 
Scheme 64. Synthesis of key intermediate 471. 
Having secured the access to the key intermediate -cyanoalkyne 471, the cobalt-
catalyzed cycloaddition with bis-trimethylsilylacetylene (269) was studied, Scheme 65. In 
order to prevent side-reactions, such as the unproductive cycloaddition of two molecules 
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of 471 and decomposition of the labile precatalyst CpCo(CO)2 the reaction was 
performed by slow addition of the solution of 269, 471 and CpCo(CO)2 to the refluxed 
solution of 269 and CpCo(CO)2 in xylenes under irradiation with visible light. Syringe 
pump addition over long periods of time (36 h), as was used in the previous 
approaches,94, 221 did not lead to better results.  
 
Scheme 65. Synthesis of pyridine skeleton via [2+2+2] cycloaddition. 
 
Figure 50. Two required oxidation transformations of 472.  
In order to install the functional groups required to mimic pancratistatin (2) in the 
tricyclic pyridine 472 two different oxidations were required to occur. First of all, 
replacement of the silyl groups by hydroxyls was envisioned. This approach was based 
on the fact that silicon group can serve as a masked oxygen and can be replaced in the 
well-known Tamao-Fleming oxidation.222 A variety of different conditions was 
attempted, see Table 6, but unfortunately these conditions did not lead to the formation of 
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the desired product 513, the only isolated products were either remaining unreactive 
starting material or formation of protiodesilylated pyridine 515 (by 1H NMR), Figure 51. 
 
Figure 51.Tamao-Fleming oxidation of bis-silylated pyridine 472. 
It has also been observed that upon prolonged exposure to air of sample pyridine 472 the 
same by-product 515 started to form. All of these observation and some precedents from 
the literature223 on silylated pyridines led to the conclusion that the trimethylsilyl group is 
not a viable group for performing the transformation to the hydroxyl functionality. 
Table 6. Conditions for the oxidations of silyl groups (Tamao-Fleming reaction). 
 Reagents Solvent  Product 
KF, H2O2, 
NaHCO3 
THF 472 (SM) 
KF, H2O2, 
NaHCO3 
THF/MeOH 515 
KF*HF, H2O2 MeOH 515 
KF*HF, H2O2, 
NaHCO3 
MeOH 515 
 
Further studies on the model pyridine 472 were performed in order to establish general 
conditions for benzylic oxidation. The first conditions attempted were those previously 
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established in the Hudlický group for a similar system:93, 216 with catalytic ruthenium 
trichloride and sodium periodate in biphasic solvent mixture, Figure 52. Unfortunately no 
reaction occurred under this conditions. The second approach was based on well-
known224 selenium dioxide oxidation of benzylic positions. But upon prolonged reflux 
with SeO2 in ethyl acetate only monodesilated pyridine 515 was isolated. 
 
Figure 52. Attempts to oxidise benzylic position in 472. 
Our next our attempt was driven towards oxidation of anionic intermediate 516, which 
was envisioned to form upon treatment of pyridine 472 with a strong base such as LDA, 
Figure 53. Different electrophiles were used and the scope of them is presented in Table 
7. 
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Figure 53. Deprotonation and functionalization of pyridine 472. 
The first attempt at oxidation was performed by molecular oxygen, however, no reaction 
was observed. The same results were observed with oxaziridine 517. In order to observe 
some incorporation of deuterium, anion 516 was quenched with deuteromethanol, but the 
only isolated product was the debenzoylated pyridine 519. Finally, in order to prove the 
formation of the transient anion 516, the reaction was performed with TMSCl, the reagent 
known to trap anions in situ, but once again only starting material was recovered.  
Table 7. Attempts to functionalize benzylic position in pyridine 472. 
Electrophile Product 
O2 No reaction 
 
No reaction 
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CD3OD deprotection 
TMSCl No reaction 
 
The last attempt to transform the benzylic position was envisioned via base-induced 
elimination of p-toluenesulfinate to form imine 518, which was expected to serve as a 
precursor for the formation of amide group, Figure 54.  
 
Figure 54. Base-induced formation of imine 518. 
The reaction was expected to proceed at high temperatures, so the base of choice had to 
be thermally stable and easy to remove upon purification. We decided to use KOtBu, 
which can be easily sublimed and has the basicity sufficient to facilitate such 
rearrangement. Since the benzoates protecting groups in the pyridine 472 were 
incompatible with strong base such as KOtBu, exchange of protection group was 
performed in a short sequence, Scheme 66. Deprotection by K2CO3 in methanol afforded 
diol 519, followed by reprotection with the acetonide group provided bis-acetonide 
pyridine 520, Scheme 66. Treatment of this compound with KOtBu did not lead to 
formation of the imine but rather desilylation and elimination of the acetonide group was 
observed. 
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Scheme 66. Synthesis of pyridine 521. 
In order to supress these unwanted reactions, desilylation of 520 was performed and 
isolated pyridine 521 was submitted to an NMR scale reaction in the presence of 
CD3ONa. Formation of a new peak was observed in the alkene region, characteristic for 
the C-1 position, therefore we concluded that elimination of the acetonide occurred 
before elimination of p-toluene sulfinate on the NMR time scale. At this point it became 
clear that the cycloaddition route we pursued, requires major revisiting. Tricyclic alkene 
522, which was observed in minute quantities shares a similar structural pattern to 
narciclasine (1), so we decided to focus our attention on the synthesis of A-ring aza-
analogues of narciclasine following a different route.  
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Figure 55. Base-induced elimination of acetonide in pyridine 521. 
3.4. Synthesis of pyridine analogues of narciclasine via intramolecular 
Heck approach 
Our plan was to gain access to narciclasine aza-analogues in a convergent and short way, 
to produce several analogues having different position of nitrogen in the aromatic A-ring, 
and to study their biological activity. Our first goal was to design and perform the 
synthesis of 7-aza-8,9-dideoxynarciclasine 6 and its N-oxide 476, which was of particular 
interest, since we thought, that N-O moiety can serve as a bioisostere for the hydroxyl in 
position C-7 of narciclasine and improve water solubility. After testing the validity of this 
approach, the synthesis of the more complex analogue 10-azanarciclasine (7) would be 
performed. 
 
Figure 56. Aza-analogues of narciclasine. 
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3.4.1. Synthesis of 7-aza-8,9-dideoxynarciclasine. 
In order to synthesize the desired analogues, we proposed to use an intramolecular Heck 
approach as one of the shortest and the most general approaches towards the narciclasine 
skeleton. Synthesis of both pyridine 5 and N-oxide 476 was envisioned via intramolecular 
coupling of tertiary amide 475, which in turn was expected to be produced by coupling of 
3-iodopicolinic acid 474 and protected conduramine 473, Figure 57. Cyclohexadiene diol 
4 was envisioned to be an ideal starting material for synthesis of conduramines such as 
473. 
 
Figure 57. Retrosynthetic scheme towards 7-aza-8,9-dideoxynarciclasine 6. 
One of the most convenient ways to access halopyridinecarboxylic acid derivatives is to 
produce them via directed ortho-metallation (DoM).225 In general, it requires the 
formation and hydrolysis of a strong directing group, such as a tertiary amide, which 
lengthens the synthesis. Nevertheless, it was observed by Queginer226 that in some cases 
unprotected pyridinecarboxylic acid can serve as a suitable substrate in DoM reaction 
with lithium tetramethylpiperidide (LTMP) as a base. This particular ortho-metallation 
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proceeds in good yield, but transformation of lithium 3-iodopicolinate (524) to the 
corresponding acid was reported to be surprisingly low-yielding, Scheme 67. This low 
yield can be attributed to the inherent instability of the free acid; in our hands samples of 
acid 474 produced by this procedure discoloured and started to decompose significantly 
upon standing at room temperature for a few days. Carson227 modified this procedure in 
order to isolate pure lithium salt 524 in high yield. Since carboxylates can serve as a 
partners in amide coupling reactions228 and salt 524 was significantly more stable than 
acid 474, we decided to use it as a precursor for the coupling.  
 
Scheme 67. Directed ortho-metallation of picolinic acid. 
Our next goal was to produce the amine partner for coupling. Hudlický and Olivo137 
developed an efficient route towards this type of compounds with effective utilisation of 
hetero-Diels-Alder reaction of dienes with nitroso compounds formed in situ. The 
synthesis started with the formation of the acetonide protected cyclohexadiene diol 525 
which, without purification, was submitted to Diels-Alder reaction with the nitroso 
compound generated from t-butyloxycarbohydroxamic acid (BocNHOH)229 to yield 
oxazine 526 with good yield, Scheme 68. Reduction of bicyclic oxazine 526 with sodium 
amalgam provided alcohol 527 with all stereocenters in a configuration identical to 
narciclasine. Further protection of the alcohol group was performed with TBSCl and 
imidazole in CH2Cl2 to provide completely protected conduramine 528. Unfortunately 
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several conditions for the amide coupling including CDI, DCC/HOBT and SOCl2/Et3N 
did not lead to coupling of amide 528 to 3-iodopicolinic acid 474. Therefore selective 
deprotection of the t-butyloxycarbamate group was performed with trifluoacetic acid to 
yield the free amine 473. 
 
Scheme 68. Synthesis of protected conduramine 473. 
Coupling of amine 473 with lithium carboxylate 524 was achieved under standard 
conditions with HBTU and diisopropylethylamine (DIPEA) in dry DMF, Scheme 69. The 
moderate yield of this reaction can be attributed to the steric hindrance of the iodo group 
and the generally lower reactivity of salts in coupling reactions. The next step consisted 
of transforming the secondary amide 529 to the protected amide 475 and this reaction 
proceeded in high yield.  
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Scheme 69. Amide coupling of A- and C-ring precursors. 
In all published intramolecular Heck approaches to the narciclasine or lycoricidine 
skeleton32, 34, 36, 39, 40 the actual transformation is performed on a tertiary amide or imide 
and salts of silver or thallium are used as a base in order to facilitate the cationic 
pathway.230 We decided to focus our attention on silver salts, since thallium salts are 
extremely toxic and less desirable for production of pharmaceuticals. Screening of 
different conditions for Heck coupling of amide 475 to naphthyridinone 530 was 
performed, Figure 58. 
 
Figure 58. Heck intramolecular coupling. 
Different phosphines, solvents, and bases were tried and the best yield was obtained in 
toluene in presence of dppe, Table 8. This reaction seems to be especially sensitive to the 
phosphine ligands, which is in accordance literature precendent that indicates bidentate 
phosphines tend to perform well in cationic pathway.230  
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Table 8. Screening of Heck conditions. 
Conditions  Outcome  
Pd(dppf)2Cl2, dppf, Ag3PO4 dioxane, 60°C, 24 
h 
No reaction 
Pd(OAc)2, dppe, Ag3PO4, Et3N toluene, 80
oC, 
18 h 
Traces of 530  
Pd(OAc)2, PPh3, Et3N, AgNO3, MeCN, 24 h, 
r.t to 80oC 
No reaction 
Pd(OAc)2, dppe, AgNO3, Cs2CO3, toluene, 24 
h, 110oC 
530, 35% (45 % brsm) 
Pd(OAc)2, BINAP, Ag3PO4, Et3N toluene, 
80oC, 18 h 
No reaction 
 
After developing the conditions for the key cyclization, our attention was driven towards 
deprotection of naphthyridinone 530 to desired compound 7-azanarcyclasine 6, Scheme 
70. Desilylation was performed under standard conditions with TBAF, followed by acidic 
deprotection of the acetonide and t-butyloxycarbamate group to attain the hydrochloride 
of the desired 7-aza-8,9-dideoxynarciclasine 6*HCl. Upon reaction neutralization with 
concentrated ammonia and column chromatography was isolated free base 6.  
 
Scheme 70. Deprotection of naphthyridinone 530. 
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Study of the formation of N-oxide 476 from pyridine 6 was performed as shown Figure 
59. Various conditions were tried231 and the reaction turned out to be sensitive not just to 
the oxidant but also for the solvent in which reaction was performed, Table 9. The best 
conditions for transformation were found to be in use of recrystallized mCPBA as an 
oxidant in a mixture of dichloromethane and methanol. Conversion was slow and the 
reaction was low-yielding in general. Surprisingly enough, the solubility of pyridine 6 in 
water was observed to be much higher than corresponding N-oxide 476. Biological 
studies were performed on 7-azanarciclasine 6, the corresponding hydrochloride, and N-
oxide 476, and will be discussed in Section 3.5. 
 
Figure 59. Selective oxidation of pyridine 6. 
Table 9. Conditions screening for formation of N-oxide 476. 
Conditions  Outcome  
mCPBA, CH2Cl2 decomposition 
mCPBA, CH2Cl2:MeOH=5:1 Traces of 476 and inseparable 
impurities  
mCPBA, CH2Cl2:MeOH=10:1 Very slow conversion  
mCPBA, CH2Cl2:MeOH=8:1 20% conversion to 476 in 48 h, 
25% in a 120 h 
TFA, H2O2 30% aq. Decomposition 
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TFA, UHP (urea*H2O2), CH2Cl2 No reaction 
UHP, CH2Cl2 No reaction 
TFAA, UHP, CH2Cl2:MeOH Traces of 476 and inseparable 
impurities 
 
3.4.2. Synthesis of 10-azanarciclasine 
After developing a short route to heterocyclic analogues of narciclasine we decided to test 
this approach on the synthesis of more complex target, namely 10-azanarciclasine (7). 
For the synthesis of 7 the convergence of our previous approach allowed to use of the 
same intramolecular Heck approach from amide 478, and use of the same conduramine 
473 as a precursor for the C-ring, Figure 60. The the only challenge was to develop a 
short and efficient synthesis of bromonicotinic acid 477. We envisioned that this acid 
could be obtained by submission of bromopyridine 532 to the condition of the halogen 
dance or halogen scrambling with strong base, followed by quenching of the anionic 
intermediate with CO2. Directed ortho-metallation of dioxolopyridine 533 followed by a 
borylation/oxidation/methylation sequence should provide access to bromopyridine 532. 
In turn, the synthesis of pyridine 533 from furfural in two step was already published.202  
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Figure 60. Retrosynthetic analysis for the synthesis of 10-azanarciclasine (7). 
The key intermediate for this synthesis had to meet two requirements: (i) the presence of 
2,3-dihydroxyl moiety in the pyridine ring, (ii) to be accessible in a short synthetic route 
from a common chemical. Synthesis of 6-bromo[1,3]dioxolo[4,5-b]pyridine (533) was 
published by Dallacker202 complied with both of these conditions. In our hands, the 
intermediate 2,3-dihydroxy-5-bromopyridine (534) was obtained by treatment of furfural 
(270) with bromine and sulfamic acid under acidic conditions in a 65% yield, slightly 
higher than in the original publication (48%), and after treatment with CH2Br2 a 
methylenedioxy bridge was installed in low yield. This yield, while low, is in accordance 
with limited examples of similar reactions in the literature.232  
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Scheme 71. Synthesis of intermediate 533. 
Our next goal was to synthesise 6-bromo-7-methoxy[1,3]dioxolo[4,5-b]pyridine (532) 
from pyridine 533, Scheme 72. The most logical way was to perform the sequence DoM 
with LTMP, followed by borylation with B(OMe)3 and in situ oxidation with the urea-
hydrogen peroxide complex. It is worth mentioning, that this oxidation is sensitive to 
moisture and in the presence of usual oxidants for such transformation, such as 30% aq. 
H2O2, led to complete protiodeborylation and only starting material 533 was isolated. 
Transient 4-hydroxypyridine 536 was not isolated but instead submitted directly to the 
methylation step without purification. In order to perform selective O-alkylation, 
diazomethane was used, since reaction did not proceed selectively with dimethylsuflate, 
methyl iodide, and Meerwein salt. The desired methoxypyridine 532 was isolated in  a 
moderate yield and despite the persisting presence of unidentified impurity was 
successfully employed in the next steps.  
 
Scheme 72. Synthesis of intermediate 532. 
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Having secured access to the key intermediate 532, the next goal was to the study 
halogen dance reaction of this bromopyridine upon treatment with LTMP, Figure 61. In 
order to provide evidence of formation of aryllithium intermediate 537 it was quenched 
with two electrophiles, methanol and DMF to provide isomeric halopyridines 538 and 
aldehyde 539 respectively. Spectroscopic NMR characteristics of 538 and 539, were 
sufficient to provide the definitive proof of structure of regioselective formation of 
aldehyde 539.  
 
Figure 61. Halogen dance reaction. 
The halogen dance reaction on similar systems has some precedence in the literature, 
especially in the field of total synthesis of polyoxygenated pyridine natural products (see 
section 2.3.4). However, it is worth mentioning that all published procedures report the 
direct addition of the substrate to the organometallic reagent (LTMP). In our hands these 
conditions did not provide the desired product, but at low temperature (−90 – −80°C) led 
to simple deprotonation of -position, and at higher temperatures (−75 – −70°C) 
decomposition was observed. Reverse slow addition of LTMP to the substrate 532 led to 
conversion to the intermediate aryllithium intermediate 537, which is in accordance with 
the current hypotheses of the mechanism of this reaction.233 In order to prove this 
observation we decided to match products of electrophile quench, obtained by halogen 
dance reaction of 532, with the product of the direct addition of base to 2-bromopyridine 
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538. To our satisfaction both of these reaction proceeded well and yielded upon quench 
with CO2 the same lithium carboxylate 540, Figure 62. 
 
Figure 62. Formation of carboxylate 540 upon different conditions. 
In order to attain the key intermediate for the Heck reaction, namely amide 478, we 
decided to proceed to the coupling of amine 473 without isolation of the carboxylic acid 
salt 540, Scheme 73. Bromopyridine 532 was used as the starting material, since it 
provided shorter access to the desired compound. Compound 532 was submitted to the 
halogen dance reaction in the presence of LTMP, followed by electrophilic quench with 
solid CO2. The reaction proceeded well, and was immediately followed by transformation 
to the amide 478 under conditions of HBTU coupling. For the intramolecular Heck 
cyclization, conditions similar to those described before were used. The only difference 
was that the reaction was performed at lower temperature and therefore a longer reaction 
time was required. Due to this modification the fully protected 10-azanarciclasine (542) 
was isolated in higher yield than the corresponding 7-azacompound. 
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Scheme 73. Synthesis of the fully functionalized skeleton of 10-azanarciclasine. 
Deprotection of naphthyridinone 542 was performed under the same conditons as C-1 
analogues, see Scheme 62. Demethylation of 542 was achieved by treatment with fused 
lithium chloride in DMF at 100 °C, Scheme 74. Product 543 was isolated and submitted 
to desilylation conditions in the presence of TBAF, which led to a clean conversion to 
alcohol 544, which in turn was submitted to acid-catalyzed deprotection conditions in 
order to remove the acetonide and the t-butyloxycarbonyl group. Different conditions for 
deprotection were tried: strong acid such as HCl in methanol led to a significant 
decomposition of the starting material, and weaker acids such as formic or trifluroacetic 
did not lead to deprotection. The best results were obtained with excess of wet (H2O 5% 
v/v) trifluoroacetic acid, yielding 7 in good yield.The synthesis of this analogue was 
achieved in 11 steps of longest linear sequence (9 one-pot reactions). 
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Scheme 74. Deprotection of 10-azanarciclasine. 
 
3.5. Biological activities of unnatural analogues 
The strategies described above provided access to the three new analogues of 
pancratistatin with substituent on C-1 and three new analogues of narciclasine with a 
nitorgen placement in the A-ring. These new Amaryllidaceae constituents were tested in 
vitro against a panel of cancer cell lines through collaboration with the groups of Dr. 
Kornienko and Dr. Rodelj from New Mexico Institute of Mining and Technology, NM, 
Dr. Pandey from University of Windsor, ON, and the group in the Center for Research 
and Drug Develoment, BC.  
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Figure 63. Unnatural analogues of pancratistatin and narciclasine. 
The C-1 analogues of pancratistatin were expected to have high activity since our group 
has previously reported79 that C-1 analogues of 7-deoxypancratistin (11), namely the 
alcohol 192a and acetate 192b, displayed antiproliferative activity equal to that of the 
parent compound 11. Since the parent compound 2 of our analogues displays activity 10-
100 times higher than 11, we had reasonable expectations that our C-1 compounds and 
especially benzoate 5c would display activity similar to the benzoate ester 294 because of 
their very similar structures. The results of the antiproliferative activity are presented in 
Table 10. 
Table 10. Activity of C-1 analogues with narciclasine as standard (IC50, EC50, M)  
Cell line (type of 
cancer) 
Compound 5a Compound 5b Compound 5c Narciclasine (1) 
BxPC-3 0.22 ± 0.01 0.07 ± 0.01 0.01 ± 0.00 0.05 ± 0.01 
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(Pancreatic)  
DU-145 (Prostate) 0.09 ± 0.01 0.06 ± 0.01 0.01 ± 0.00 0.03 ± 0.01 
NCI-H460 (Lung) 0.09 ± 0.01 0.07 ± 0.01 0.03 ± 0.01 0.05 ± 0.03 
MCF-7 (Breast) 0.24 ± 0.10 0.52 ± 0.47 0.08 ± 0.01 0.06 ± 0.03 
HCC1954 (Breast) 0.163 0.086 0.011  
Jurkat (Leukemia) 0.266 0.211 0.007  
 
As it can be seen from the table, C-1 benzoate homologue 5c displays particularly strong 
antiproliferative activity, exceeding even the natural congener narciclasine (1), which is 
amongst the most active natural products in this family. It further underlines the 
previously observed48, 103 increased beneficial effect of large lipophilic groups, especially 
benzoates, on the position C-1, on activity. At the same time, despite the pronounced 
activity, our pancratistatin homologue compound 5c did not quite reach activity of C-1 
benzoate pancratistatin ester (294). These results show that there are some limitations on 
the length and size of the lipophilic group on the position C-1. 
Parallel studies have also been performed on different cancer lines, namely colorectal 
cancer HCT 116 and osteosarcoma Saos-2 cell lines and are presented in the following 
Figure 64. The difference between 7-deoxypancratistatin C-1 homologue alcohol 192a 
and acetate 192b, and their respective pancratistatin counterparts 5a and 5b can be clearly 
seen, with the latter being significantly more active. This fact once again shows the 
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importance of the presence of the 7-hydroxyl group in order to display high 
antiproliferative potency. 
 
Figure 64. Cytotoxicity of C-1 analogues in dose dependant manner. 
Next goal was to test the heterocyclic analogues of narciclasine we prepared. Three 
compounds were tested against a panel of cell lines and the results are presented in Table 
11. It can be seen from the table, that 7-aza compounds show no activity (IC50>100 M) 
against two different cancer cell lines. This result might be explained by the belief that 
requirement of the C-8 and C-9 alkoxy groups that may be necessary to retain activity. A 
second reason might be that these compounds have very different physicochemical 
properties from parent narciclasine, such as high aqueous solubility and low lipophilicity. 
Table 11. Activity of 7-aza analogues of narciclasine (IC50, M, extrapolated)  
Cell line (type of 
cancer) 
Compound 6 Compound 
6*HCl 
Compound 
476 
HeLa (Cervical)  452  152 300 
159 
MCF-7 (Breast) 331 196 183 
 
Testing performed by CDRD on a two different cancer cell of all four azaanalogues 
confirmed our previous observations, Table 12. 7-aza compounds displayed no 
cytotoxicity at low micromolar concentrations and, in turn, 10-azanarciclasine showed 
only reduced activity in comparison with the natural congener narciclasine. These results 
further support our conclusion about requirements of fully oxygenated A-ring for 
retaining anticancer activity and that nitrogen in A-ring plays deleterious role in 
pharmacophore.  
Table 12. Activity of 7-aza and 10-aza analogues of narciclasine (IC50, M) 
Cell line (type of 
cancer) 
Compound 6 Compound 
6*HCl 
Compound 
476 
Compound 7 
Jurkat (Leukemia)  Inactivef  Inactive Inactive 0.5 
HCC1954 (Breast) Inactive Inactive Inactive 0.5 
 
                                                     
f Showed no cytotoxicity at 2.7 M concentration. 
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4. Conclusions and Future work 
The Amaryllidaceae constituents narciclasine (1) and pancratistatin (2) are 
isocarbostyril natural products which possess strong anticancer activity. In the course of 
the present study three different approaches towards analogues of these two natural 
products based on chemoenzymatic methods were studied. Two of these of approaches 
resulted in efficient synthetic routes and led to the synthesis of several structurally diverse 
C- and A-ring analogues of pancratistatin and narciclasine repsectively.  
The synthesis of six new analogues was accomplished and two of these analogues, 
namely C-1 acetate 5b and C-1 benzoate 5c have shown significant activity against a 
panel of cancer cell lines. The two truncated heterocyclic analogues, 7-aza-8,9-
dideoxynarciclasine 6 and its N-oxide 476 displayed no activity, and one heterocyclic 
analogue 7 showed only low activity.  
Derivatization at the C-1 position was shown to be beneficial in increasing the 
potency of natural compounds. Also it was shown that truncated 7-aza analogues do not 
possess any antiproliferative activity and therefore the alkoxy groups, are likely a 
requirement for the minimal pharmacophore. Bioisosteric replacement with nitrogen 
apparently plays a deleterious role in the anticancer activity of compound, but in the same 
time azanarciclasine analogues exhibit higher aqueous solubility than natural compounds 
1 and 2.  
Future studies are necessary in order to further probe the minimal pharmacophore 
requirements of the aromatic A-ring and to refine the synthesis of the C-ring analogues in 
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terms of step count and overall efficiency. New route to the C-1 analogues will be 
required, in order to refine existing synthesis, to avoid toxic reagents, and shorten step 
count to meet strict demands of pharmaceutical industry. Also, the C-1 pancratistatin 
analogues could be obtained through efficient borylation and hydroboration 
transformation of narciclasine-type compounds. The reason for that, is that narciclasine 
compounds can be synthesised in much more efficient ways and can also be isolated from 
natural sources. 
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5. Experimental section 
5.1. General Experimental section. 
Reactions were carried out under inert atmosphere in oven-dried or flame-dried glassware 
unless stated otherwise. LiCl was fused under vacuum immediately before use. Solvents 
were distilled prior to use: CH2Cl2, DMF, iPr2NEt, and pyridine from CaH2, MeOH from 
magnesium methoxide, THF and DME from Na/benzophenone, toluene from Na, 
quinoline from Zn. Qualitative TLC was done with precoated silica gel aluminum sheets 
(EMD silica gel 60 F254), detection by UV or by spraying with “CAM” solution (5 g of 
(NH4)6Mo7O24·4H2O, 1 g of Ce(SO4)2, 100 mL of 10% H2SO4) or 0.5% aqueous KMnO4 
solution followed by heating. Melting points are uncorrected. Flash chromatography was 
performed using silica gel SiliaFlash P60 from Silicycle (40–66 μm). Optical rotation was 
measured in a 1-dm cell at 20-25 ˚C and 589 nm, concentration c in g/100 mL, specific 
rotation measurements are given in deg cm3g-l dm-l and were recorded on a Perkin-Elmer 
341 polarimeter, IR spectra were recorded on Perkin-Elmer FT-IR 1600 Series Spectrum 
One instrument in KBr pellets or as thin films. 1H NMR and 13C NMR spectra were 
recorded at 300 or 600 MHz and 75 or 150 MHz, respectively, and were calibrated on the 
solvent residual peak or TMS signal (CDCl3 - 7.28 ppm; DMSO - d6 - 2.51), the 
chemical shifts are reported in ppm. Data are reported as (s = singlet, d = doublet, t = 
triplet, q = quartet, m = multiplet, br = broad); coupling constants(s) in Hz, integration. 
5.2. Detailed experimental section. 
4-methoxy-1,3-benzodioxole-5-carbaldehyde (486)  
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Dimethyl sulfate (22.7 mL, 240 mmol) was added to a mixture of K2CO3 (55.2 g, 400 
mmol) and phenol 484213 (33.2 g, 200 mmol) in acetone (260 mL). The reaction mixture 
was stirred under reflux until consumption of starting material (TLC, approximately 4 h). 
Then reaction mixture was cooled and inorganic salts were removed by filtration and 
rinsed with acetone (2×100 mL). The solution was evaporated, redissolved in CH2Cl2, 
washed sequentially with 10 % solution of NaOH, water, and saturated solution of NaCl, 
then organic solution dried over anhydrous Na2SO4 and evaporated to obtain compound 
486 (30.2 g, 84%) as pale brown crystals, which was used without further purification.  
Rf 0.65 (Hexanes/EtOAc 9:1); mp 102-104 °C (EtOH); [Lit. value234 103-105 °C 
(EtOH)]; 1H NMR (CDCl3, 300MHz): s, 1H.49 (d, J = 8.3 Hz, 1H), .62 (d, 
J = 8.3 Hz, 1H), 6.05 (s, 2H), 4.14 (s, 3H). 
5-(2,2-dibromovinyl)-4-methoxy-1,3-benzodioxole (487) 
 
Triphenylphosphine (64.0 g, 244 mmol) in CH2Cl2 (100 mL) was added dropwise to a 
stirring solution of CBr4 (40.5 g, 122 mmol) in CH2Cl2 (150 mL) at 0 °C (ice bath). After 
15 min of stirring, a solution of aldehyde 486 (11.0 g, 61.0 mmol) in CH2Cl2 (50 mL) 
was added dropwise. Upon completion the reaction was reduced in volume to 100 mL 
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and slowly poured into vigorously stirred hexanes (1400 mL). Then mixture was filtered 
through short plug of silica, washed with a mixture of hexanes:EtOAc (10:1, 200 mL) 
and evaporated. Subjection of this material to flash column chromatography (Eluent 
hexanes/EtOAc 9:1) and concentration of the relevant fractions gave 487 (16.11 g, 
78.6%) as a white solid. 
Rf 0.9 (Hexanes/EtOAc 9:1); mp 38 - 40 °C (pentane); IR (KBr, cm-1)  3448, 2981, 
2948, 2934, 2900, 2876, 2838, 2770, 1625, 1605, 1471, 1427, 1384, 1350, 1265, 1213, 
1126, 1072, 1045, 979, 960, 939, 929, 848, 829, 788, 767, 729, 644;  1H NMR (CDCl3, 
300MHz)  7.49 (s, 1H), 7.24 (d, J = 8.3 Hz, 1H), 6.57 (d, J = 8.3 Hz, 1H), 5.96 (s, 2H), 
4.02 (s, 3H);  13C NMR (CDCl3, 75MHz) 149.7, 141.1, 136.1, 132.3, 122.5, 121.4, 
102.3, 101.2, 89.0, 59.9; MS (+EI) m/z (%): 338 (49) [81Br+81Br, M]+, 336 (100) 
[81Br+79Br, M]+, 334 (51) [79Br+79Br, M+], 242 (55), 240 (57), 176 (53), 175 (42), 131 
(29); HRMS (+EI) calcd for C10H8Br2O3: 333.8820; found 333.8845; Anal. Calcd for 
C10H8Br2O3: C, 35.75; H, 2.40. Found C, 35.99; H, 2.41. 
5-ethynyl-4-methoxy-1,3-benzodioxole (482) 
 
To a solution of 487 (19.38 g, 57.68 mmol) in THF (350 mL) was added solution of 
nBuLi (52.9 mL, 2.5 M, 130 mmol) at -78 °C. After 20 min of stirring at −78 °C, the 
reaction mixture was warmed to room temperature over a period of 2 h. A saturated 
solution of NH4Cl (40 mL) was poured into reaction mixture, which was later extracted 
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by CH2Cl2 (3 × 50 mL). The combined organic phases were dried over Na2SO4, filtered 
and evaporated. The crude compound was purified by flash chromatography 
(hexanes:EtOAc 2:1) and 482 was obtained as white crystals (8.5 g, 81.7%).  
Rf 0.9 (Hex:EtOAc 2:1); mp 77-78 °C (pentane); IR (KBr, cm-1) 3278, 3254, 3000, 
2945, 2901, 2846, 2794, 1620, 1600, 1469, 1433, 1336, 1267, 1229, 1077, 1043, 979, 
950, 930, 797; 1H NMR (CDCl3, 300MHz) 7.01 (d, J = 7.9 Hz, 1H), 6.50 (d, J = 8.29 
Hz, 1H), 5.98 (s, 2H), 4.11 (s, 3H), 3.20 (s, 1H); 13C NMR (CDCl3, 75MHz)  150.1, 
144.8, 136.2, 128.0, 108.1, 102.9, 101.3, 79.9, 79.4, 60.0; MS (+EI) m/z (%): 176 [M]+ 
(100), 175 (29), 131 (16), 53 (18); HRMS (+EI) calcd for C10H8O3: 176.0473; found, 
176.0475; Anal. calcd for C10H8O3: C, 68.18; H, 4.58. Found C, 68.27; H, 4.55. 
(3aS,4R,5R,6R,7S,7aR)-6-[(4-methoxy-1,3-benzodioxol-5-yl)ethynyl]-2,2-dimethyl-8-
[(4-methylphenyl)sulfonyl]hexahydro-4,5-epimino-1,3-benzodioxol-7-ol (490) 
 
To a solution of alkyne 482 (1.580 g, 8.95 mmol) in toluene (30 mL) at -50 °C n-BuLi 
(3.80 mL, 2.35 M, 8.95 mmol) was added dropwise. After 15 min of stirring Me2AlCl 
(9.0 mL, 1.0 M, 8.95 mmol) was added dropwise. The reaction mixture was warmed to 0 
°C within 1 h and stirred for an additional 40 min at 0 °C. The reaction mixture allowed 
to warm room to temperature and stirred for 40 min. The reaction mixture was cooled to -
30 °C and a solution of epoxide 184 (1.510 g, 4.47 mmol) in toluene (20 mL) was added 
dropwise. The reaction mixture was stirred for 1 h and was allowed to warm to room 
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temperature overnight. The reaction mixture was cooled to 0 °C by ice bath and quenched 
with 1 N HCl (1 mL), followed by ice-cold water (1 mL) and 1 N HCl (2 mL). Reaction 
mixture was filtered through a plug of Celite® and extracted with EtOAc (3 × 20 mL). 
The combined organic phases were dried over Na2SO4, filtered and evaporated. The 
crude product was purified by column chromatography (gradient hexanes/EtOAc 5:1-
>3:1) to give product as colorless oil (1.02g, 44%).  
Rf 0.3 (Hex/EtOAc 2:1);[]24D + 78.4 (c = 1.0, CHCl3); IR (film, cm-1) 3482, 3093, 
2986, 2935, 2900, 1620, 1599, 1470, 1434, 1404, 1383, 1332, 1307, 1260, 1225, 1186, 
1183, 1071, 985; 1H NMR (CDCl3, 300 MHz)  7.83 (d, J = 8.3 Hz, 2H), 7.39 (d, J = 8.3 
Hz, 2H), 6.88 (d, J = 8.1 Hz, 1H), 6.47 (d, J = 8.3 Hz, 1H), 5.96 (s, 2H), 4.48 (d, J = 6.2 
Hz, 1H), 4.19 (t, J = 5.7 Hz, 1H), 4.06 (s, 3H), 3.98-3.95 (m, 1H), 3.44-3.41 (m, 1H), 
3.26 (d, J = 6.8 Hz, 1H), 3.24 (dd, J = 5.0, 2.1 Hz, 1H), 3.08 (d, J = 8.7 Hz, 1H), 2.48 (s, 
3H), 1.51 (s, 3H), 1.34 (s, 3H); 13C NMR (CDCl3, 75 MHz) 149.7, 145.4, 144.4, 136.3, 
134.1, 130.1, 127.9, 127.2, 110.1, 108.8, 102.8, 101.3, 87.6, 80.5, 75.5, 70.3, 69.0, 60.0, 
42.3, 40.2, 31.9, 27.3, 25.1, 21.7; MS (+FAB) m/z (%): 514 (24) [M+H]+, 513 (13) [M]+, 
258 (12), 238 (11), 230 (14), 179 (26), 155 (28), 149 (23), 43 (100); HRMS (+FAB) 
calcd for C26H28NO8S
+ [M+1]+: 514.1436; found, 514.1502.  
 
(3aS,4R,5R,6R,7S,7aR)-6-[(Z)-2-(4-methoxy-1,3-benzodioxol-5-yl)vinyl]-2,2-
dimethyl-8-[(4-methylphenyl)sulfonyl]hexahydro-4,5-epimino-1,3-benzodioxol-7-ol 
(492) 
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To a solution of compound 490 (427 mg, 0.83 mmol) in MeOH (20 mL) was added 
quinoline (11 mg, 0.09 mmol). The solution was charged with Lindlar catalyst (5%, 100 
mg) and allowed to stir under H2 (1 atm) for 45 min. After consumption of starting 
material (NMR), the reaction mixture was filtered through a pad of Celite®, washed with 
CH3OH (3 × 30 mL), evaporated, and used without further purification. Analytical 
sample was purified by column chromatography (hexanes/EtOAc 3:1). 
Rf 0.4 (hexanes/EtOAc 2:1); []20D + 2.7 (c = 1.78, CHCl3); IR (film, cm-1) 3482, 2987, 
2934, 2900, 1621, 1598, 1470, 1434, 1404, 1382, 1332, 1260, 1218, 1162, 1070, 1043; 1H 
NMR (CDCl3, 300 MHz)  7.74 (d, J = 8.3 Hz, 2H), 7.32 (d, J = 8.3 Hz, 2H), 6.60 (d, J 
= 11.4 Hz, 1H), 6.55 (d, J = 8.1 Hz, 1H), 6.46 (d, J = 8.0 Hz, 1H), 5.98 (d, J = 1.2 Hz, 
1H), 5.96 (d, J = 1.2 Hz, 1H), 5.73 (t, J = 11.2 Hz, 1H), 4.43 (d, J = 6.2 Hz, 1H), 4.16-
4.13 (m, 1H), 3.96 (s, 3H), 3.72-3.68 (m, 1H), 3.18 (d, J = 6.4 Hz, 1H), 3.15-3.10 (m, 
1H), 3.08 (d, J = 6.4 Hz, 1H), 2.84 (d, J = 9.2 Hz, 2H), 2.43 (s, 3H), 1.49 (s, 3H), 1.30 (s, 
3H). 13C NMR (CDCl3, 75MHz) 148.9, 145.2, 141.3, 136.6, 134.3, 130.0, 128.1, 127.9, 
127.8, 122.5, 122.2, 109.7, 102.6, 101.0, 75.8, 70.1, 69.3, 59.7, 43.1, 40.5, 37.8, 27.1, 
24.7, 21.7.MS (+FAB) m/z (%) [M]+: 517 (16), 516 (42), 515 (29), 514 (15), 386 (25), 
285 (14), 284 (15), 269 (15), 203 (30), 165 (61), 91 (100); HRMS (+FAB) calcd for 
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C26H30NO8S [M+1]
+: 516.1692; found, 516.1666. Anal. calcd for C26H29NO8S: C, 60.57; 
H, 5.67. Found C, 60.33; H, 5.55. 
 (3aS,4R,5R,6R,7S,7aR)-7-{tert-butyl[dimethylsylil]oxy}-6-[(Z)-2-(4-methoxy-1,3-
benzodioxol-5-yl)vinyl]-2,2-dimethyl-8-[(4-methylphenyl)sulfonyl]hexahydro-4,5-
epimino-1,3-benzodioxol (481) 
 
To a solution of alcohol 492 (1.07 g, 2.07 mmol) in 30 mL of CH2Cl2 was added Et3N 
(0.58 mL, 4.15 mmol) at 0 °C and t-butyldimethylsilyl triflate (0.53 mL, 2.29 mmol) was 
added dropwise. After complete consumption of starting material (TLC) reaction mixture 
was quenched by water (10 mL), and extracted with CH2Cl2 (3 × 20 mL). The combined 
organic phases were washed with 10 % citric acid (5 mL), brine (5 mL), dried over 
Na2SO4, and concentrated to afford 481 as pale yellow oil (1.26 g, 97%). The Compound 
was used without further purification. Analytical sample was purified by silica gel 
chromatography (hexanes/EtOAc 4:1). 
Rf 0.85 (hexanes:EtOAc 2:1); []24D − 18.5 (c = 2.0, CHCl3); IR (KBr, cm-1) 3446, 
2986, 2954, 2931, 2887, 2856, 1622, 1600, 1470, 1435, 1382, 1332, 1257, 1218, 1163, 
1071, 1043; 1H NMR (CDCl3, 300MHz):  7.78 (d, J = 8.2 Hz, 2H), 7.30 (d, J = 8.2 Hz, 
2H), 6.67 (d, J = 8.0 Hz, 1H), 6.60 (d, J = 11.5 Hz, 1H), 6.39 (d, J = 8.0 Hz, 1H), 5.96-
5.93 (m, 2H), 5.65 (t, J = 11.5 Hz, 1H), 4.39 (d, J = 5.9 Hz, 1H), 3.98 (s, 3H), 3.89 (t, J = 
6.03 Hz, 1H), 3.67 (t, J = 6.3 Hz, 1H), 3.12 (d, J = 6.6 Hz, 1H), 2.98-2.91 (m, 2H), 2.45 
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(s, 3H), 1.52 (s, 3H), 1.34 (s, 3H), 0.78 (s, 9H), 0.00(s, 3H), −0.08 (s, 3H); 13C NMR 
(CDCl3, 75 MHz): 148.7, 144.4, 141.4, 136.3, 135.0, 129.7, 129.6, 127.8, 127.6, 122.9, 
122.4, 109.3, 102.3, 100.8, 71.8, 71.4, 59.6, 43.4, 39.7, 39.2, 27.7, 25.7, 25.5, 21.6, 18.0, 
-4.6, -4.8; MS (+FAB) m/z (%) [M]+: 628 (8), 514 (13), 343 (17), 256 (10), 228 (10), 215 
(19), 165 (36), 73(100); HRMS (+FAB) calcd for C32H44NO8SSi [M+1]+: 630.2557, 
found 630.2492; Anal. calcd for C32H43NO8SSi: C, 61.02; H, 6.88. Found C, 61.28, H, 
7.02. 
 
N-((1R,2S,3S,4S,4aR,11bR)-4-{[tert-butyl(dimethyl)silyl]oxy}-3,3-dimethoxy-7-
methoxy-1,2,3,4,4a,11b-hexahydrophenanthro[2,3-d][1,3]dioxol-1-
yl)benzenesulfonamide. (480) 
 
Olefin 481 (0.100 g, 0.561 mmol), quinoline (15 mg, 0.12 mmol) and silica gel (500 mg), 
which has been activated in advance by heating under vacuum for 24 h at 150 °C, was 
charged into flask and suspended in CH2Cl2 (10 mL), The solvent was removed in vacuo 
and the flask containing silica gel supporting the adsorbed reactants was heated at 120 °C 
under nitrogen atmosphere and stirred for 36 h. After this time the reaction mixture was 
purified directly by column chromatography (hexanes/EtOAc 4:1) to give olefin 480 as a 
clear and colorless oil (0.074 g, 74%).  
170 
Rf 0.45 (hexanes: EtOAc 2:1); []24D = − 25.1 (c = 1.0, CHCl3); IR (KBr, cm-1) 3275, 
2983, 2953, 2932, 2889, 2857, 1633, 1614, 1599, 1479, 1384, 1361, 1331, 1221, 1158, 
1092, 841; 1H NMR (CDCl3, 300MHz)  7.43 (d, J = 8.1 Hz, 2H), 7.13 (d, J = 8.1 Hz, 
2H), 6.65 (dd, J = 9.8, 3.4 Hz, 1H), 6.22 (s, 1H), 5.92 (d, J = 1.5Hz, 1H), 5.82 (d, J = 
1.5Hz, 1H), 5.74 (dd, J = 9.8, 1.5 Hz, 1H), 4.59 (d, J = 8.8Hz, 1H), 4.28 (m, 1H), 4.11 (s, 
1H), 4.02-3.99 (m, 1H) 3.97 (s, 3H), 3.80-3.70 (m, 1H), 2.79-2.78 (m, 1H), 2.61-2.56(m, 
1H), 2.41 (s, 3H), 1.73 (s, 1H), 1.45 (s, 3H), 1.34 (s, 3H), 0.88 (s, 9H), 0.10 (s, 3H), 0.05 
(s, 3H); 13C NMR (CDCl3, 75MHz) 147.5, 142.1, 139.5, 138.6, 135.5, 129.4, 129.8, 
126.8, 125.3, 120.5, 119.7, 109.2, 104.8, 100.7, 79.1, 78.3, 70.3, 59.7, 53.7, 42.4, 39.1, 
27.8, 26.3, 25.7, 21.5, 18.0, −5.03, −5.06. MS (+FAB) m/z (%): [M]+ 629 (3), 129 (13), 
111 (12), 99 (13), 57 (100); HRMS (+FAB) calcd for C32H43NO8SSi [M]
+: 629.2479; 
found, 629.2472. 
 
N-[(3aS,4R,5R,6S,7S,7aS)-7-{[tert-butyl(dimethyl)silyl]oxy}-6,6'-
bis(hydroxymethyl)-7'-methoxy-2,2-dimethyl-3,4,5,6,7,7a-hexahydro-5,5'-bi-1,3-
benzodioxol-4-yl]-4-methylbenzenesulfonamide (495) 
 
To a solution of 480 (0.254 g, 0.404 mmol) in MeOH (50 mL) a few crystals of Sudan 
Red 7B were added. The solution was cooled down to −80 °C and oxygen-ozone mixture 
was bubbled through until the disappearance of the pink color. The consumption of 
starting material was also checked by TLC. A stream of nitrogen was bubbled through 
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reaction mixture for 5 min. sodium borohydride (0.250 g, 6.67 mmol) was slowly added 
and reaction mixture was gradually warmed from −80 °C to room temperature. The 
solvent was removed in vacuo and the residue was redissolved in CH2Cl2 (50mL), 
neutralized by 10% citric acid and washed with water (50 mL). The organic phase was 
separated, dried over Na2SO4, filtered and evaporated. The crude product was subjected 
to column chromatography (hexanes/EtOAc 1:1) to yield 495 as white crystalline solid 
(0.1643 g, 61%) and 496 as mixture of anomers (80 mg, 30%).  
Rf 0.45 (hexanes/EtOAc 1:1); mp 121-123 °C (CHCl3); []20D − 30.8 (c = 1.09, CHCl3); 
IR (KBr, cm-1) 3472, 3386, 3172, 2927, 2855, 1622, 1482, 1385, 1332, 1255, 1220, 
1158, 1095, 1057, 837; 1H NMR (CDCl3, 600MHz)  7.51 (d, J = 7.8 Hz, 2H), 7.13 (d, J 
= 7.8 Hz, 2H), 6.57 (s, 1H), 5.96 (s, 1H), 5.90 (s, 1H), 5.44 (d, J = 7.0 Hz, 1H), 4.77 (d, J 
= 11.8 Hz, 1H), 4.42 (d, J = 11.9 Hz, 1H), 4.27-4.24 (m, 1H) 4.17-4.10 (m, 2H), 4.00 (s, 
3H), 3.95-3.86 (m, 1H), 3.70 (dd, J =11.9, 6.1 Hz, 1H), 3.59 (dd, J =11.8, 6.3 Hz, 1H), 
3.37 (dd, J = 11.8, 3.9 Hz, 1H), 2.92 (br s, 2H), 2.39 (s, 3H), 2.00-1.96 (m, 1H), 1.56 (s, 
3H), 1.32 (s, 3H), 0.92 (s, 9H), 0.14 (s, 3H), 0.11 (s, 3H); 13C NMR (CDCl3, 150MHz): 
149.1, 142.1, 141.6, 139.2, 135.1, 132.4, 128.8, 126.8, 124.6, 109.7, 103.5, 101.0, 79.9, 
79.0, 71.5, 61.3, 60.0, 57.0, 55.2, 47.3, 38.2, 27.4, 25.9, 25.8, 21.5, 18.0, 21.6, 21.0, 18.0, 
−4.8, −5.0; MS (+FAB) m/z (%): 664 [M-H]+ (6), 648 (7), 372 (11), 302 (11), 254 (21), 
248 (12), 73 (100), HRMS(+EI) calcd for C32H47NO10SSi [M]
+: 665.2690; found 
665.2803; Anal. calcd for C32H47NO10SSi: C, 57.72; H, 7.11. Found C, 57.76; H, 6.99.  
(3aS,3bR,10bR,11S,12S,12aS)-12-{[tert-butyl(dimethyl)silyl]oxy}-11-
(hydroxymethyl)-6-methoxy-2,2-dimethyl-4-[(4-methylphenyl)sulfonyl]-
3,3b,4,5,10b,11,12,12a-octahydrobis[1,3]dioxolo[4,5-c:4',5'-j]phenanthridin-5-ol 
(496) 
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To a solution of alcohol 495 (0.100 g, 0.15 mmol) in CH2Cl2 (100 mL) was added MnO2 
(268 mg, 3 mmol). The reaction mixture was vigorously stirred until total consumption of 
starting material (TLC). The reaction mixture was filtered through a plug of Celite® and 
washed with CH2Cl2 (3 × 100 mL). Solvent was removed in vacuo, affording 496 as 
white solid (87mg, 87 %, mixture of anomers).  
Rf 0.5 and 0.65 (hexanes:EtOAc 1:1); mp 106-116 °C (CHCl3); IR (KBr, cm-1) 3452, 
2985, 2954, 2931, 2894, 2857, 1624, 1483, 1384, 1341, 1251, 1163, 1077, 839; (NMR of 
the major anomer) 1H NMR (CDCl3, 300MHz)  7.55 (d, J = 8.1 Hz, 2H), 7.03 (d, J = 
8.1 Hz, 2H), 6.65 (s, 1H), 6.08 (s, 1H), 5.92-5.91 (m, 2H), 5.26 (dd, J = 9.9, 5.4 Hz,1H), 
4.38 (t, J = 3.0 Hz, 1H) 4.25-4.21 (m, 2H), 4.11 (s, 3H), 3.74 (dd, J = 11.0, 7.9 Hz, 1H), 
3.37 (dd, J = 11.0, 3.6 Hz, 1H), 2.87 (dd, J = 12.9, 5.1 Hz, 1H), 2.33 (s, 3H), 2.16 (br s, 
1H), 2.15 (br s, 1H), 2.06 (s, 1H), 1.44 (s, 3H), 1.37 (s, 3H), 0.92 (s, 9H), 0.15 (s, 3H), 
0.10 (s, 3H); 13C NMR (CDCl3, 150MHz) 150.0, 142.9, 140.5, 138.3, 134.0, 130.0, 
128.9, 127.2, 121.3, 109.4, 101.0, 100.2, 78.9, 76.4, 73.5, 68.1, 59.9, 59.3, 53.1, 48.1, 
34.4, 27.9, 26.2, 25.7, 21.4, 17.9, −4.8, −5.1; MS (+EI) m/z (%): [M-Ts-H2O]+ 491 (15), 
432 (13), 302 (22.2), 302 (10.5), 247 (31.1), 246 (19.9), 43 (100); HRMS (+EI) calcd for 
C32H45NO10SSi [M]
+: 663.2533; found 663.2549; Anal. Calcd for C32H45NO10SSi: C, 
57.90; H, 6.83. Found C, 58.02; H, 7.03. 
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{(3aS,3bR,10bR,11S,12S,12aS)-12-{[tert-butyl(dimethyl)silyl]oxy}-5-hydroxy-6-
methoxy-2,2-dimethyl-4-[(4-methylphenyl)sulfonyl]-3,3b,4,5,10b,11,12,12a-
octahydrobis[1,3]dioxolo[4,5-c:4',5'-j]phenanthridin-11-yl}methyl acetate (497) 
 
Pyridine (0.050 g, 0.63 mmol) was added to a solution of hemiacetal 496 (0.048 g, 0.072 
mmol) in CH2Cl2 (3 mL), followed by addition of acetic anhydride (0.0295 g, 0.29 
mmol). The reaction mixture was stirred until consumption of starting material (TLC). 
The reaction mixture was quenched with water (5 mL) and extracted by CH2Cl2 (3 × 4 
mL). The combined organic phases were dried over Na2SO4, filtered and evaporated. The 
crude product was subjected to column chromatography (eluent hexanes/EtOAc 4:1) 
affording 497 as colourless oil (0.043 g, 87 % mixture of anomers). 
Rf 0.9 and 0.8 (Hexanes/EtOAc 1:1); IR (KBr, cm
-1) 3462, 2984, 2953, 2931, 2896, 
2857, 1743, 1624, 1481, 1371, 1342, 1330, 1250, 1222, 1164, 1077, 840; (NMR of the 
major anomer) 1H NMR (CDCl3, 600MHz)  7.56 (d, J = 8.2 Hz, 2H), 7.08 (d, J = 8.0 
Hz, 2H), 6.66 (s, 1H), 6.012 (s, 1H), 5.94 (m, 2H), 5.31 (dd, J = 10.0, 5.1 Hz, 1H), 4.37 
(m, 1H) 4.22-4.21 (m, 1H), 4.08 (s, 3H), 3.96 (s, 1H), 3.91 (dd, J = 11.4, 4.4 Hz, 1H), 
3.05 (s, 1H), 2.91 (dd, J = 13.2, 4.5 Hz, 1H), 2.35 (s, 3H), 2.15 (s, 1H), 1.93 (s, 3H), 1.47 
(s, 3H), 1.38 (s, 3H), 0.93 (s, 9H), 0.15 (s, 3H), 0.11 (s, 3H); 13C NMR (CDCl3, 
150MHz): 150.0, 143.0, 140.6, 138.5, 134.1, 129.8, 128.9, 127.2, 121.3, 109.3, 
101.0, 100.1, 78.9, 76.3, 73.3, 67.2, 61.2, 59.9, 53.2, 45.6, 33.8, 29.7, 26.3, 25.7, 25.5, 
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21.4, 20.8, 17.9 −5.0, −5.2; MS (+FAB) m/z (%): [M−H2O]+ 688 (47), 230 (12), 117 
(17), 302 (11), 247 (31), 117 (17), 73 (100); HRMS (+FAB) calcd for C34H46NO10SSi [M 
- H2O]
+: 688.2612; found 688.2642; Anal. calcd for C34H47NO11SSi: C, 57.85; H, 6.71. 
Found C, 57.80; H, 6.67. 
 
{(3aS,3bR,10bR,11S,12S,12aS)-12-{[tert-butyl(dimethyl)silyl]oxy}-6-methoxy-2,2-
dimethyl-4-[(4-methylphenyl)sulfonyl]-5-oxo-3a,3b,4,5,10b,11,12,12a-
octahydrobis[1,3]dioxolo[4,5-c:4',5'-j]phenanthridin-11-yl}methyl acetate (498) 
 
A pre-dried solution of N-methylmorpholine-N-oxide (0.100 g, 0.85 mmol) in CH2Cl2 (20 
mL) was added to hemiaminal 497 (0.030 g, 0.042 mmol) in CH2Cl2 (10 mL), followed 
by activated crushed molecular sieves (0.5 g, 4 Å). After stirring for 15 min, a few 
crystals of tetrapropylammonium perruthenate were added and reaction was stirred until 
consumption of starting material (TLC). The reaction mixture was filtered through a plug 
of Celite® and washed with CH2Cl2 (3 × 50 mL). The combined organic phases were 
evaporated and subjected to column chromatography (hexanes/EtOAc 2:1) affording 498 
as colorless oil (0.025 g, 84 %)  
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Rf 0.65 (eluent hexanes/EtOAc 1:1); []24D + 41.4 (c = 0.9, CHCl3); IR (KBr, cm-1): 
3450, 2984, 2953, 2930, 2857, 1742, 1710, 1614, 1484, 1360, 1253, 1169, 1090, 1021, 
839; 1H NMR (CDCl3, 300MHz)  8.20 (d, J = 8.3 Hz, 2H), 7.29 (d, J = 8.3 Hz, 2H), 
6.73 (s, 1H), 6.06 (s, 1H), 6.02 (s, 1H), 4.83 (dd, J = 7.9, 5.5 Hz, 1H), 4.46 (s, 1H), 4.26 
(t, J = 11.1, 1H), 4.17-4.13 (m, 1H), 4.12-4.08 (m, 1H), 4.04 (s, 3H), 4.00-3.95 (m, 1H), 
3.47 (dd, J = 13.1, 3.3 Hz, 1H), 2.66-2.63 (m, 1H), 2.43 (s, 3H), 2.08 (s, 1H), 1.48 (s, 
3H), 1.33 (s, 3H), 0.89 (s, 9H), 0.15 (s, 3H), 0.13 (s, 3H); 13C NMR (CDCl3, 150MHz) 
153.4, 144.8, 143.4, 138.8, 136.7, 136.1, 128.9, 128.7, 126.8, 117.8, 
109.1, 102.0, 100.1, 79.0, 76.3, 66.9, 60.9, 60.7, 60.4, 59.7, 43.4, 36.5, 27.9, 26.1, 25.7, 
21.6, 20.9, 18.0, −4.9, −5.1; MS (+EI) m/z (%): 639 (3.1), 549 (6.6), 492 (3.4), 434 (2.9), 
374 (3.9), 43 (100); HRMS (+EI) Calcd for C33H42NO11SSi
+ [M−CH3]+: 688.2248; found 
688.2436. 
((3aS,3bR,10bR,11S,12S,12aS)-12-{[tert-butyl(dimethyl)silyl]oxy}-6-methoxy-2,2-
dimethyl-5-oxo-3,3b,4,5,10b,11,12,12a-octahydrobis[1,3]dioxolo[4,5-c:4',5'-
j]phenanthridin-11-yl)methyl acetate (499) 
 
To a solution of 498 (0.064 mg, 0.09 mmol) in dry DME (7 mL) at −50 °C was added 
dropwise a solution of Na/naphthalene in DME (0.5 M), until a light green color persisted 
and total consumption of starting material was observed (TLC). The solution was stirred 
for 10 minutes before the reaction was quenched with NH4Cl (satd. aq., 1 mL). The 
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reaction was warmed to room temperature and extracted with CH2Cl2 (6 × 15 mL). The 
combined organic phases were dried over Na2SO4, filtered, and concentrated. The 
products 499 and 479 were isolated by column chromatography (gradient hexanes/EtOAc 
2:1 → 1:1) as clear and colorless oil 499 (0.030 g, 62%) and white crystalline solid 479 
(0.002 g; 5%). 
Rf 0.28 (hexanes: EtOAc 1:1); []20D + 32.4 (c = 1.0, CHCl3); IR (KBr, cm-1) 3417, 
3228, 3109, 2987, 2953, 2932, 2897, 2858, 1743, 1676, 1617, 1481, 1385, 1366, 1339, 
1250, 1222, 1169, 1088, 1071, 1057, 1033, 840; 1H NMR (CDCl3, 600MHz)  6.69 (s, 
1H), 6.06 (s, 1 H), 6.01 (s, 1H), 5.92 (s, 1H), 4.57 (s, 1H), 4.23 (d, J = 7.5 Hz, 1H), 4.19-
4.18 (m, 1H), 4.16-4.14 (m, 1H), 4.07 (s, 3H), 3.42 (dd, J =13.8, 8.3 Hz, 1H), 3.31 (dd, J 
=13.8, 3.6 Hz, 1H), 2.66-2.65 (m, 1H), 2.11 (s, 3H), 1.45 (s, 3H), 1.39 (s, 3H), 0.91 (s, 
9H), 0.16 (s, 3H), 0.15 (s, 3H); 13C NMR (CDCl3, 150MHz) 152.4, 
145.4, 137.5, 135.5, 116.2, 109.9, 101.8, 99.9, 78.3, 77.8, 67.0, 61.1, 60.9, 52.5, 41.9, 
35.1, 28.2, 26.1, 25.69, 25.65, 20.9, 18.0, −5.0, −5.1; MS (+FAB) m/z (%): 552 (12), 551 
(36), 550 [M+1]+ (100), 246 (10), 220 (11), 117 (101); HRMS (+FAB) calcd for 
C27H40NO9Si [M+1]
+: 550.2472; found 550.2459.  
((3aS,3bR,10bR,11S,12S,12aS)-12-{[tert-butyl(dimethyl)silyl]oxy}-6-hydroxy-2,2-
dimethyl-5-oxo-3,3b,4,5,10b,11,12,12a-octahydrobis[1,3]dioxolo[4,5-c:4',5'-
j]phenanthridin-11-yl)methyl acetate (500) 
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To a solution of 499 (0.039mg, 0.071 mmol) in DMF (5 mL) was added LiCl (0.05 mg, 
1.2 mmol), followed by three cycles freeze-pump-thaw. The reaction mixture was heated 
to 120 °C for 2.5 h. The reaction mixture was cooled to room temperature, diluted with 
water (100 ml) and extracted with diethyl ether (10 × 15 mL). The combined organic 
phases were dried over Na2SO4, filtered, and concentrated. The product was isolated by 
column chromatography (hexanes:EtOAc, 3:1) as a clear and colorless oil which 
solidifies after drying (25.7 mg, 68%). 
Rf 0.8 (hexanes: EtOAc 1:1); mp 68-69° C (CHCl3); []20D − 35.2 (c = 1.0, CHCl3); IR 
(KBr, cm-1) 3402, 3348, 3285, 3212, 3087, 2987, 2953, 2933, 2899, 2859, 2795, 1743, 
1627, 1601, 1464, 1389, 1366 , 1353, 1341, 1301, 1250, 1226, 1171, 1081, 1032, 940, 
838, 778; 1H NMR (CDCl3, 600MHz) 12.68 (s, 1H) 6.53 (s, 1H), 6.26 (s, 1H), 6.07 (s, 
2H), 4.57 (s, 1H), 4.30 (dd, J = 11.1, 3.3 Hz, 1H), 4.22 (t, J = 11.0 Hz, 1H) 4.21-4.18 (m, 
2H), 3.50 (dd, J = 14.4, 7.8 Hz, 1H), 3.36 (dd, J = 14.4, 3.7 Hz, 1H), 2.70-2.69 (m, 1H), 
2.11 (s, 3H), 1.49 (s, 3H), 1.41 (s, 3H), 0.91 (s, 9H), 0.17 (s, 3H), 0.16 (s, 3H); 13C NMR 
(CDCl3, 150MHz) 153.1, 146.9, 133.9, 133.0, 110.0, 107.3, 102.3, 97.3, 
78.4, 77.6, 67.0, 61.10, 53.2, 41.7, 33.9, 28.3, 26.0, 25.7, 20.9, 18.0, −5.0, −5.1; MS 
(+EI) m/z (%): 536 [M+1]+(9), 535 (25), 360 (17), 256 (11), 231 (10), 218 (19), 205 (21), 
149 (25), 43 (100); HRMS (+EI) calcd for C26H37NO9Si [M]
+: 535.2238; found 
535.2248.  
[(3aS,3bR,10bR,11S,12S,12aR)-6,12-dihydroxy-2,2-dimethyl-5-oxo-
3,3b,4,5,10b,11,12,12a-octahydrobis[1,3]dioxolo[4,5-c:4',5'-j]phenanthridin-11-
yl]methyl acetate (501) 
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The compound 500 (0.052 g, 0.097 mmol) was taken up in THF (2.5 mL) and cooled to 0 
°C. A solution of TBAF in THF (1 M, 0.107 mL, 0.107 mmol) was added dropwise over 
1 min. The reaction mixture was stirred until total consumption of starting material was 
observed (TLC). The reaction mixture was quenched with water (5 ml) and extracted 
with CH2Cl2 (6 × 15 mL). The combined organic phases were dried over Na2SO4, filtered 
and evaporated. The final product was isolated by column chromatography 
(hexanes/EtOAc 1:1) as a white crystalline solid (38 mg, 95%).  
Rf 0.3 (hexanes/EtOAc 1:1); mp > 200 °C (CH2Cl2 - CH3OH); []24D + 6.2 (c = 0.48, 
DMSO); IR (KBr, cm-1) 3449, 3270, 2988, 2911, 1743, 1672, 1625, 1600, 1466,1443, 
1357, 1307, 1245, 1231, 1166, 1087, 1071, 1032, 844; 1H NMR (DMSO-d6, 600MHz)  
13.35 (s, 1H), 8.55 (s, 1H), 6.61 (s, 1H) 6.08 (s, 1H), 6.06 (s, 1H), 5.50 (d, J = 3.6 Hz, 
1H) , 4.34 (br. s, 1H), 4.25 (d, J = 4.8 Hz, 1H), 4.20 (dd, J = 11.4, 3.6 Hz, 1H), 4.16 - 
4.15 (m, 1H), 4.13 (d, J = 11.4 Hz, 1H) 3.51 (dd, J = 15.0, 8.4 Hz, 1H), 3.19 (dd, J = 
14.4, 3.6 Hz, 1H), , 2.03 (s, 3H), 1.41 (s, 3H), 1.31 (s, 3H); 13C NMR (DMSO-d6, 
150MHz) 146.3, 135.0, 132.6, 109.0, 107.7, 102.4, 97.6, 77.9, 
76.9, 65.2, 61.2, 53.4, , 34.3, 28.3, 26.4, 21.2; MS (+EI) m/z (%): 422 (24) [M+1], 421 
(100) [M+], 248 (34), 247 (60), 232 (27), 231 (32), 218 (11), 206 (17), 145 (14); HRMS 
Calcd for C20H23NO9 [M]
+: 421.13728; found 421.13792; Anal. calcd for C20H23NO9: C, 
57.00; H, 5.50. Found C, 57.18, H, 5.48. 
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 [(1S,2S,3R,4S,4aR,11bR)-2,3,4,7-tetrahydroxy-6-oxo-1,2,3,4,4a,5,6,11b-
octahydro[1,3]dioxolo[4,5-j]phenanthridin-1-yl]methyl acetate (5b) 
 
The compound 501 (0.038 g, 0.09 mmol) was taken up in CH2Cl2:CH3OH mixture (1:1, 4 
mL) and cooled to 0 ˚C. Trifluoroacetic acid (2 mL) was added dropwise and the reaction 
mixture was stirred until consumption of starting material was observed (TLC). The 
reaction mixture was dried in vacuo, triturated with CH2Cl2 (3 × 15 mL) and finally dried 
under high-vac. The final product was isolated by column chromatography on silica gel 
(deactivated by 10% w/w of water, eluent CH2Cl2:CH3OH 10:1) as a white crystalline 
solid (0.031 g, 90%).  
Rf 0.3 (CH2Cl2:CH3OH 10:1); mp > 200 °C (CH2Cl2 - CH3OH); []24D + 36.8 (c = 
0.2,THF); IR (KBr, cm-1) 3459, 3287, 3214, 2991, 2923, 1750, 1709, 1670, 1628, 1595, 
1466, 1436, 1384, 1342, 1264, 1227, 1196, 1090, 1070, 1034; 1H NMR (DMSO-d6, 
600MHz)  13.26 (s, 1H), 7.40 (s, 1H), 6.59 (s, 1H), 6.08 (s, 1H), 6.06 (s, 1H), 5.17 (m, 
1H), 5.10-5.09 (m, 2H), 4.40 (m, 1H), 4.16 (dd, J = 10.9, 3.5 Hz, 1H), 4.11 (s, 1H), 3.84 
(m, 1H), 3.71 (m, 1H), 3.52 (dd, J = 13.6, 9.8 Hz, 1 H), 3.26 (m, 1H), 2.66 (m, 1H), 2.03 
(s, 3H); 13C NMR (DMSO-d6, 150MHz) 146.3, 135.7, 132.5, 
107.5, 102.4, 97.8, 73.1, 71.2, 68.9, 61.8, 51.6, 40.5, 36.5, 21.3; MS (+EI) m/z (%): 381 
[M]+ (12), 321 (16), 279 (12), 277 (99), 276 (11), 256 (12), 247 (11), 205 (13), 201 (16), 
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199 (12), 185 (13), 183 (11), 179 (21), 167 (14), 149 (37), 129 (12), 123 (11), 69 (100); 
HRMS (+EI) calcd for C17H19NO9: 381.1060; found 381.1055; 
 
(1S,2S,3R,4S,4aR,11bR)-2,3,4,7-tetrahydroxy-1-(hydroxymethyl)-1,3,4,4a,5,11b-
hexahydro[1,3]dioxolo[4,5-j]phenanthridin-6(2H)-one (5a) 
 
The compound 501 (48 mg, 0.11 mmol) was taken up in CH2Cl2-CH3OH mixture (1:1, 4 
mL) and 2 drops of concentrated HCl were added. The reaction was stirred until total 
consumption of starting material was observed (TLC). The reaction mixture was 
neutralized by dropwise addition of saturated solution of NaHCO3 and evaporated to 
dryness. The final product was isolated by column chromatography on silica gel 
(deactivated by 10% of water, eluent CH2Cl2:CH3OH 5:1) as white crystalline compound 
(36 mg, 92%).  
mp >200 °C (CH2Cl2-CH3OH); Rf 0.4 (CH2Cl2: CH3OH 5:1); []20D= + 48.0 (c = 0.5, abs 
DMSO); IR (KBr, cm-1) 3386, 2917, 1670, 162, 1598, 1466, 1439, 1384, 1352, 1304, 
1228, , 1089, 1077, 1064, 1032; 1H NMR (DMSO-d6, 300MHz)  13.25 (s, 1H), 7.31 (s, 
1H), 6.55 (s, 1H), 6.07 (s, 1H), 6.06 (s, 1H), 5.02 (m, 3H), 4.47 (dd, J =6.4, 4.0 Hz, 1H), 
4.18 (m, 1H), 3.91 (m, 1H), 3.82 (m, 1H), 3.67 (m, 1H), 3.43 (m, 1H), 3.14 (m, 1H), 2.37 
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(br. s, 1H); 13C NMR (DMSO-d6, 150MHz) 146.1, 136.7, 132.2, 107.4, 
102.4, 97.9, 73.2, 71.4, 69.5, 57.7, 51.8, 44.3, 36.9; MS (+EI) m/z (%) 339 [M]+: (0.4), 85 
(39), 84 (80), 83 (57), 68 (13), 66 (100); HRMS (+EI) calcd for C15H17NO8: 339.0954; 
found 339.0925. 
 
(3aS,3bR,10bR,11S,12S,12aS)-12-{[tert-butyl(dimethyl)silyl]oxy}-11-
(hydroxymethyl)-6-methoxy-2,2-dimethyl-3b,4,10b,11,12,12a-
hexahydrobis[1,3]dioxolo[4,5-c:4',5'-j]phenanthridin-5(3aH)-one (479) 
 
To a solution of 499 (0.170 g, 0.309 mmol) in methanol (5 mL) was added solution of 
NaOH (aq. 40%, 0.5 mL) and stirred until total consumption of starting material was 
observed (TLC). The reaction was quenched with solution of NH4Cl (sat. aq., 1 mL). The 
mixture was evaporated and the residue was extracted with CH2Cl2 (6 × 15 mL). The 
combined organic phases were dried over Na2SO4, filtered, and concentrated. The final 
product was isolated by column chromatography (gradient hexanes:EtOAc 2:1 to 1:1) as 
a white crystalline solid (0.125 mg; 80%). 
Rf 0.2 (hexanes/EtOAc 1:1); mp 148-149 °C (CHCl3); []D20 +32.6 (c = 0.63, CHCl3); IR 
(KBr, cm–1)  3416, 2987, 2952, 2932, 2893, 2857, 1660, 1618, 1501, 1481, 1439, 1384, 
1350, 1295, 1250, 1220, 1169, 1083, 1056, 841; 1H NMR (CDCl3, 600MHz)  6.61 (s, 
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1H) 6.05 (s, 1H), 6.00 (s, 1H), 5.86 (s, 1H), 4.68(s, 1H), 4.20 (d, J =4.5 Hz, 1H), 4.14 
(dd, J =8.2, 5.0 Hz, 1H), 4.08 (s, 3H), 3.95 (dt, J = 10.1, 6.0, 1H), 3.67-3.66 (m, 1H), 3.49 
(dd, J =13.8, 8.4 Hz, 1H), 3.28 (dd, J =13.8, 3.7 Hz, 1H), 2.53-2.52 (m, 1H), 1.91 (s, 1H), 
1.46 (s, 3H), 1.40 (s, 3H), 0.91 (s, 9H), 0.18 (s, 6H); 13C NMR (CDCl3, 150MHz) 
145.4, 137.3, 136.3, 116.3, 101.7, 99.8, 78.3, 78.0, 67.4, 60.9, 58.8, 52.7, 
45.2, 35.3, 28.1, 26.2, 25.7, 17.9, −4.92, −4.94; MS (+FAB) m/z (%): 508 (14) [M+1], 
507 (37) [M+], 450 (16), 449 (10), 434 (17), 433 (16), 392 (22), 374 (12), 345 (12), 
261(100); HRMS (+FAB) Calc for C25H37NO8Si [M]
+: 507.2289; found: 507.2287. 
 
((3aS,3bR,10bR,11S,12S,12aS)-12-{[tert-butyl(dimethyl)silyl]oxy}-6-methoxy-2,2-
dimethyl-5-oxo-3a,3b,4,5,10b,11,12,12a-octahydrobis[1,3]dioxolo[4,5-c:4',5'-
j]phenanthridin-11-yl)methyl benzoate (503) 
 
To a solution of 479 (0.121 g, 0.24 mmol) in CH2Cl2 (25 mL) was added triethylamine 
(0.04 mL, 0.48 mmol) at 0 °C followed by benzoyl chloride (0.03 mL, 0.26 mmol) and 
crystal of DMAP. The reaction mixture was stirred at 0 ˚C until total consumption of 
starting material was observed (TLC). The reaction mixture was quenched with distilled 
water (10 mL) and extracted with CH2Cl2 (3 × 15 mL). The combined organic phases 
were washed with solution of citric acid (10%, 10 mL), dried over sodium sulfate, 
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filtered, and concentrated. The final product was isolated by column chromatography 
(gradient hexanes/EtOAc 2:1→1:1) as white crystalline powder (0.094 g, 64%). 
Rf 0.4 (hexanes:EtOAc 1:1); mp 90-92 °C (CHCl3); []D20 − 15.1 (c = 1, CHCl3); IR 
(KBr, cm–1)  3467, 3416, 3387, 3069, 2986, 2952, 2932, 2896, 2857, 1722, 1674, 1616, 
1502, 1481, 1453, 1385, 1339, 1273, 1221, 1093, 1071, 1028, 838; 1H NMR (CDCl3, 
300MHz)  8.06 (d, J = 7.2 Hz, 2H), 7.63-7.58 (m, 1H), 7.48 (t, J = 7.5 Hz, 2H), 6.74 (s, 
1H), 6.01-6.02 (m, 3H), 4.68 (s, 1H), 4.53-4.45 (m, 2H), 4.20-4.16 (m, 2H), 4.07 (s, 3H), 
3.53 (dd, J = 13.8, 7.5 Hz, 1H), 3.40-3.35 (m, 1H), 2.86-2.83 (m, 1H), 1.50 (s, 3H), 1.40 
(s, 3H), 0.90 (s, 9H), 0.18 (s, 6H); 13C NMR (CDCl3, 75MHz) 166.4, 163.6,152.4, 
145.4, 135.6, 133.2, 129.8, 129.6, 128.4, 116.1, 110.0, 101.7, 99.9, 78.3, 77.9, 67.2, 61.6, 
60.9, 52.5, 42.1, 35.2, 28.2, 26.1, 25.6, 17.9, −4.9, −5.0; MS (+FAB) m/z (%): 614 (12) 
[M+2+], 613 (36), 612 (89), 179 (12), 105 (100); HRMS Calc for C32H42NO9Si
+ [M]+: 
612.2629; found: 612.2653. 
 
((3aS,3bR,10bR,11S,12S,12aS)-12-{[tert-butyl(dimethyl)silyl]oxy}-6-hydroxy-2,2-
dimethyl-5-oxo-3a,3b,4,5,10b,11,12,12a-octahydrobis[1,3]dioxolo[4,5-c:4',5'-
j]phenanthridin-11-yl)methyl benzoate (504) 
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To a solution of 503 (0.0743 g, 0.122 mmol) in dry DMF (5 mL) was added LiCl (0.050 
g, 1.2 mmol), followed by three cycles of freeze-pump-thaw. The reaction mixture was 
heated to 120 °C for 3.5 h. The reaction was then cooled to room temperature, diluted 
with distilled water (50 ml) and extracted with diethyl ether (6 × 15 mL). The combined 
organic phases were dried over Na2SO4, filtered, and concentrated. The product was 
isolated by column chromatography (hexanes/EtOAc 2:1) as a white crystalline solid 
(0.060 g, 83%). 
Rf 0.8 (hexanes:EtOAc 1:1); mp 141-145 °C (CHCl3); []20D − 63.0 (c = 1.0, CHCl3); IR 
(KBr, cm-1) 3449, 2953, 2931, 2901, 2858, 1721, 1674, 1655, 1637, 1627, 1603, 1461, 
1385, 1351, 1341, 1304, 1271, 1219, 1113, 1081, 837; 1H NMR (CDCl3, 600MHz)  
12.70 (s, 1H), 8.07 (d, J = 8.0 Hz, 2H), 7.62-7.60 (m, 1H), 7.49-7.47 (m, 2H), 6.59 (s, 
1H), 6.11 (s, 1H), 6.06 (s, 1H), 6.02 (s,1H), 4.68 (s, 1H), 4.55-4.54 (m, 2H), 4.23-4.21 
(m, 2H), 3.63-3.59 (m, 1H), 3.43 (dd, J =14.4, 3.5 Hz, 1H), 2.89 (s br, 1H), 1.53 (s, 3H), 
1.42 (s, 3H), 0.91 (s, 9H), 0.16-0.15 (m, 6H); 13C NMR (CDCl3, 150MHz) 170.0, 
166.4, 153.2, 146.9, 134.0, 133.2, 133.1, 129.8, 129.6, 129.4, 110.1, 107.3, 102.3, 97.3, 
78.4, 77.7, 67.2, 61.6, 53.2, 41.8, 34.0, 30.3, 28.4, 26.1, 25.7, 17.9, −4.9, −5.0; MS 
(+FAB) m/z (%): 599 (11) [M+2]+, 598 (29), 597 (8), 596 (4), 179 (11), 73 (100); HRMS 
(+FAB) calcd. for C31H40N1O9Si
+ [M+1]+: 598.2472; found 598.2446; 
 
[(3aS,3bR,10bR,11S,12S,12aR)-6,12-dihydroxy-2,2-dimethyl-5-oxo-
3a,3b,4,5,10b,11,12,12a-octahydrobis[1,3]dioxolo[4,5-c:4',5'-j]phenanthridin-11-
yl]methyl benzoate (505) 
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The compound 504 (0.042 mg, 0.07 mmol) was taken up in THF (2.5 mL) and cooled to 
0 °C. A solution of TBAF in THF (1 M, 0.077 mL, 0.077 mmol) was added dropwise and 
the reaction mixture was stirred until total consumption of starting material was observed 
(TLC). The reaction mixture was quenched by distilled water (5 ml) and extracted with 
CH2Cl2 (6 × 15 mL). The combined organic phases were dried over Na2SO4, filtered, and 
evaporated. The final product was isolated by column chromatography (hexanes/EtOAc 
1:1) as white crystalline solid (0.0272 g, 80%). 
Rf 0.3 (hexanes/EtOAc 1:1); mp > 200 °C (THF); []D21 −40.1 (c = 1.0, THF); IR (KBr, 
cm–1) 3446, 3255, 2986, 2930, 2905, 2854, 1720, 1672, 1626, 1601, 1466, 1384, 1356, 
1343, 1311, 1222, 1166, 1088, 1071, 1027, 713; 1H NMR (DMSO-d6, 600 MHz)  13.36 
(s, 1H), 8.57 (s, 1H), 7.97-7.96 (m, 2H), 7.69-7.67 (m, 1H), 7.56-7.53 (m, 2H), 6.74 (s, 
1H), 6.07 (s, 1H), 5.99 (s, 1H), 5.56 (dd, J = 4.3 Hz, 1H), 4.53 (dd, J = 11.3, 4.3 Hz, 1H), 
4.46-4.45 (m, 1H), 4.43-4.39 (m, 1H), 4.29 (d, J = 5.0 Hz, 1H), 4.19 (dd, J = 8.3, 5.3 Hz, 
1H), 3.63 (dd, J = 14.4, 8.4 Hz, 1H), 3.26 (dd, J = 14.4, 3.6 Hz, 1H), 2.97-2.95 (m, 1H), 
1.45 (s, 3H), 1.33 (s, 3H); 13C NMR (DMSO-d6, 150MHz)  169.9, 166.1, 152.7, 146.3, 
135.0, 133.9, 132.5, 130.0, 129.7, 129.2, 109.0, 107.7, 102.3, 97.9, 78.0, 77.1, 65.5, 62.0, 
53.4, 34.3, 30.3, 28.3, 26.4; MS (+FAB) m/z (%): 484 (4) [M+1]+, 483 (26) [M]+, 248 
186 
(13), 247 (59), 232 (13), 231 (28), 205 (11), 122 (16), 105 (100); HRMS (+FAB) Calc. 
for C25H25NO9 [M]
+: 483.1529; found: 483.1532. 
[(1S,2S,3R,4S,4aR,11bR)-2,3,4,7-tetrahydroxy-6-oxo-1,2,3,4,4a,5,6,11b-
octahydro[1,3]dioxolo[4,5-j]phenanthridin-1-yl]methyl benzoate (5c) 
 
The compound 505 (32 mg, 0.066 mmol) was taken up in a mixture of CH2Cl2:CH3OH 
(1:1, 4 mL) and cooled to 0 ˚C. Trifluoroacetic acid (1 mL) was added dropwise and the 
reaction was stirred until total consumption of starting material was observed (TLC). The 
reaction mixture was dried in vacuo, triturated with CH2Cl2 (3 × 15 ml) and finally dried 
under high-vac. The final product was isolated by column chromatography on silica gel 
(deactivated by 10% of water, gradient CH2Cl2 → CH2Cl2/CH3OH 50:1 → 
CH2Cl2/CH3OH 25:1) as white crystalline solid (0.025 g, 85%). 
Rf 0.6 (CH2Cl2:CH3OH 10:1); mp> 200 °C (CH2Cl2); []D20 − 24.9 (c = 1.0, THF); IR 
(KBr, cm–1)  3423, 3386, 2956, 2921, 2852, 1716, 1672, 1627, 1600, 1466, 1384, 1363, 
1340, 1278, 1095, 1072, 1038, 711; 1H NMR (DMSO-d6, 600MHz)  13.27 (s, 1H), 8.00 
(d, J = 7.7 Hz, 2H), 7.68 (t, J = 7.6 Hz, 1H), 7.57-7.54 (m, 2H), 7.43 (s, 1H), 6.72 (s, 1H) 
6.07 (s, 1H), 6.01 (s, 1H), 5.19 (m, 2H), 5.13 (m, 1H), 4.66 (t, J = 10.7 Hz, 1H), 4.48 (dd, 
J =10.9, 4.0 Hz, 1H), 4.24-4.23 (m, 1H), 3.88-3.87 (m, 1H), 3.75-3.73 (m, 1H), 3.62 (dd, 
J =13.6, 9.9 Hz, 1H), 3.31 (dd, J = 13.8, 4.2 Hz, 1H), 2.85-2.84 (m, 1H); 13C NMR 
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(DMSO-d6, 150MHz)  170.0, 166.3, 152.8, 146.3, 135.8, 133.8, 132.5, 130.3, 129.7, 
129.2, 107.5, 102.4, 98.0, 73.1, 71.2, 69.2, 62.5, 51.6, 36.6; MS (+FAB) m/z (%): 444 (4) 
[M+1]+, 219 (12), 136 (11), 121 (11), 109 (15), 107 (17), 105 (23), 97 (18), 95 (29), 55 
(100); HRMS (+FAB) calcd for C22H22NO9 [M+1]
+: 444.1295; found: 444.1262. 
(3aR,4R,5R,6S,7S,7aR)-7-{(cyanomethyl)[(4-methylphenyl)sulfonyl]amino}-2,2-
dimethyl-6-[(trimethylsilyl)ethynyl]hexahydro-1,3-benzodioxole-4,5-diyl dibenzoate 
(512) 
 
The solution of acetylene 51092 (0.1713 mg; 0.261 mmol) in THF (40 mL) was added 
dropwise solution of NaHMDS in toluene (0.725 M, 0.261mmol; 0.36 mL;) at –70 °C. 
The reaction mixture was allowed to warm up to 0 °C over a period of 20 min and was 
further stirred for 10 min at this temperature. Chloroacetonitrile (33 l; 0.522 mmol) and 
nBu4NI (144.6 mg; 0.391 mmol) were added and solution was allowed to warm to room 
temperature overnight. The reaction mixture was quenched by addition of NH4Cl (satd. 
aq., 10 mL) and extracted with EtOAc (3 × 25 mL). The combined organic phases were 
washed with brine (20 mL), dried over Na2SO4, and the solvent was removed under 
reduced pressure. Flash column chromatography of the residue (hexanes/EtOAc 9:1) 
afforded tosylamide 512 (0.088 g; 48%) as colourless oil. 
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Rf 0.70 (hexanes/EtOAc 2:1); []D20 − 108.1 (c = 1, CHCl3); IR (KBr, cm–1)  3440, 
3293, 3067, 2990, 2937, 2593, 1729, 1601, 1452, 1375, 1353, 1336, 1316, 1274, 1248, 
1221, 1248, 1221, 1160, 1096, 1070, 1040, 926, 890, 853, 815, 710, 666, 545, 564; 1H 
NMR (300 MHz, CDCl3)  8.08 (d, J = 7.5 Hz, 2H), 7.96 (m, 4H), 7.60 (m, 1H), 7.49 
(m, 1H), 7.36 (m, 2H), 7.36 (m, 4H), 6.01 (t, J = 3.0 Hz, 1H), 5.69 (m, 1H), 4.93 (br s, 
1H), 4.42 (m, 1H), 4.33 (m, 2H), 4.07 (br s, 2H), 2.43 (s, 3H), 1.68 (s, 3H), 1.39 (s, 3H), 
−0.02 (s, 9H); 13C NMR (150 MHz, CDCl3) 165.1, 164.8, 144.6, 136.3, 133.7, 133.2, 
129.98, 129.89, 129.88, 129.4, 129.1, 128.7, 128.3, 128.1, 114.7, 110.9, 75.1, 71.2, 68.3, 
34.5, 28.3, 26.0, 21.6, −0.51; MS (+EI) m/z (%): 686 (2), 685 (4), 149 (12), 105 (100); 
HRMS (+EI) calcd for C36H37N2O8SSi
+ [M-CH3]
+: 685.2040; found: 685.2052.  
 
(3aS,4S,5S,6R,7R,7aS)-7-{(cyanomethyl)[(4-methylphenyl)sulfonyl]amino}-6-
ethynyl-2,2-dimethylhexahydro-1,3-benzodioxole-4,5-diyl dibenzoate (471) 
 
To the solution of acetylene 512 (0.093 g; 0.158 mmol) in THF (2 mL) was added  
dropwise solution of NaHMDS in toluene (0.75 M; 0.158mmol; 0.210 mL) at –70 °C. 
The reaction mixture was allowed to warm up to 0 °C over a period of 20 min and was 
further stirred for 10 min at this temperature. Chloroacetonitrile (12 l; 0.19 mmol) and 
nBu4NI (0.0584 g; 0.158 mmol) were added and the solution was allowed to warm to 
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room temperature overnight. The reaction was quenched by NH4Cl (satd. aq., 40 mL) and 
extracted with EtOAc (4 × 40 mL). The combined organic phases were washed with 
brine (20 mL), dried over MgSO4, and the solvent was removed under reduced pressure. 
Flash column chromatography of the residue (hexanes/EtOAc 3:2) afforded tosylamide  
as white crystalline solid (0.044 mg; 44%). 
Rf 0.60 (hexanes/EtOAc 2:1); mp 86 °C (EtOAc/hexanes); []D20 −126.3 (c = 1.35, 
CHCl3); IR (KBr, cm
–1)  3438, 3291, 3067, 2988, 2937, 2593, 1729, 1601, 1452, 1375, 
1353, 1336, 1316, 1274, 1248, 1221, 1248, 1221, 1160, 1096, 1070, 1040, 926, 890, 853, 
815, 710, 666, 545, 564; 1H NMR (600 MHz, CDCl3)  8.06 (d, J = 7.5 Hz, 2H), 7.93 
(m, 4H), 7.60 (m, 1H), 7.52 (m, 1H), 7.47 (m, 2H), 7.36 (m, 4H), 5.98 (t, J = 3.0 Hz, 1H), 
5.69 (m, 1H), 4.92 (br s, 1H), 4.43 (m, 1H), 4.38 (m, 1H), 4.33 (m, 1H), 4.00 (br s, 2H), 
2.44 (s, 3H), 2.11 (s, 1H), 1.68 (s, 3H), 1.39 (s, 3H); 13C NMR (150 MHz, CDCl3)  
165.0, 164.8, 144.7, 136.2, 133.7, 133.3, 129.97, 129.91, 129.88, 129.3, 129.0, 128.7, 
128.4, 128.1, 114.7, 111.0, 75.1, 74.7, 74.0, 71.1, 68.2, 33.5, 28.3, 26.0, 21.6; MS (+EI) 
m/z (%) 614 (1), 613 (3), 246 (13), 171 (12), 155 (5), 105 (100); HRMS (+EI) calcd. for 
C33H29N2O8S: 613.16446; found: 613.16387.  
(3aS,3bR,9bR,10S,11S,11aS)-2,2-dimethyl-4-[(4-methylphenyl)sulfonyl]-7,8-
bis(trimethylsilyl)-3a,3b,4,5,9b,10,11,11a-octahydro[1,3]benzodioxolo[5,4-f]-1,7-
naphthyridine-10,11-diyl dibenzoate (472) 
190 
 
To a solution of CpCo(CO)2 (1 L; 7.5 mol) in BTMSA (269)  (1.5 mL; 0.012 mmol) 
solution of -cyanoalkyne 471 (44 mg; 0.07 mmol), CpCo(CO)2 (1 L; 7.5 mol) 
dissolved in m-xylene (2 mL), and 269 (1 mL; 0.008 mmol) was added dropwise under 
irradiation with visible light at 140 °C over period 2 min. The reaction mixture was 
heated under inert atmosphere for further 24 h. BTMSA and xylene were removed under 
high vacuum and the residue was purified by column chromatography (gradient 
hexanes/EtOAc, 9:1 - 6:1). The product 471 was isolated as slightly yellow crystalline 
foam (26.0 mg, 46.5%). 
Rf 0.34 (hexanes/EtOAc 4:1); mp 110 °C (hexane/EtOAc); []D20 −25.5 (c = 1.45, 
CHCl3); IR (KBr, cm–1)  3435, 3291, 3066, 2983, 2957, 2921, 2851, 1725, 1601, 1528, 
1493, 1452, 1406, 1383, 1361, 1346, 1317, 1275, 1250, 1223, 1167, 1107, 1096, 1065, 
1028, 912, 842, 755, 710, 666, 555, 541; 1H NMR (600 MHz, CDCl3) 7.93 (d, J = 7.9 
Hz, 2H), 7.87 (d, J = 7.5 Hz, 2H), 7.58 (d, J = 8.3 Hz, 2H), 7.54 (m, 2H), 7.37 (m, 5H), 
7.05 (d, J = 7.9 Hz, 2H), 5.83 (dd, J=8.3, 4.2 Hz, 1H), 5.70 (dd, J=6.8, 4.5 Hz, 1H), 4.78 
(d, J=17.4Hz, 1H), 4.65 (m, 2H), 3.81 (dd, J=12.5, 9.4 Hz, 1H), 3.48 (dd, J=12.5, 8.3 Hz, 
1H), 2.31 (s, 3H), 1.54 (s, 3H), 1.38 (s, 3H), 0.31 (s, 9H), 0.03 (s, 9H); 13C NMR (150 
MHz, CDCl3) 171.4, 165.23, 165.18, 151.8, 142.9, 138.9, 137.6, 133.5, 133.4, 129.83, 
129.80, 129.3, 129.1, 128.5, 128.4, 127.5, 126.3, 110.6, 75.1, 74.4, 71.1, 69.8, 60.8, 52.8, 
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38.5, 29.7, 27.9, 25.5, 21.5, 0.98, 0.86; MS (FAB) m/z (%) 800 (2), 294 (2), 105 (100), 91 
(11); HRMS (+FAB) calcd for C42H51N2O8SSi2
+: 799.2905; found: 799.2971.  
 
(3aS,3bR,9bR,10S,11S,11aR)-2,2-dimethyl-4-[(4-methylphenyl)sulfonyl]-7,8-
bis(trimethylsilyl)-3a,3b,4,5,9b,10,11,11a-octahydro[1,3]benzodioxolo[5,4-f]-1,7-
naphthyridine-10,11-diol (519) 
 
To a solution of 472 (42 mg, 0.052 mmol) in the mixture of CH2Cl2:MeOH (4 mL; 1:1) 
K2CO3 (22 mg; 0.16 mmol) was added, and  reaction mixture was stirred until 
disappearance of starting material (TLC). Then the reaction mixture was filtered, 
evaporated and the residue was purified by column chromatography (gradient 
hexanes:EtOAc, 2:1 to 1:1). The product was isolated as a transparent foam (19.2 mg, 
62%). 
Rf 0.2 (hexanes/EtOAc 2:1); []D21 − 26.5 (C = 1.0, CHCl3); IR (KBr, cm–1)  3467, 
2983, 2954, 2926, 2902, 2856, 1446, 1405, 1384, 1356, 1248, 1219, 1161, 1090, 1070, 
1050, 858, 841, 756, 715; 1H NMR (300 MHz, CDCl3)  7.70, 7.48 (d, J = 8.4 Hz, 2H), 
6.99 (d, J = 8.1 Hz, 2H), 5.03 (dd, J = 8.7, 6.8 Hz, 1H), 4.68 (s, 2H), 4.41-4.36 (m, 1H), 
4.13 (dd, J = 7.9, 5.3 Hz, 1H), 3.95 (dd, J = 7.9, 4.9 Hz, 1H), 3.67-3.60 (m, 1H), 2.94 (s, 
1H), 2.85-2.78 (m, 1H), 2.70 (s, 1H), 2.30 (s, 3H), 1.55 (s, 3H), 1.39 (s, 3H), 0.37 (s, 9H), 
0.33 (s, 9H); 13C NMR (150 MHz, CDCl3)  170.7, 152.0, 142.6, 139.7, 138.8, 137.3, 
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128.9, 127.54, 127.50, 110.2, 75.9, 75.7, 70.3, 70.0, 58.8, 53.4, 51.6, 40.0, 27.9, 27.9, 
25.2, 21.5, 1.2, 1.1; MS (+EI) m/z (%) 590 (2), 575 (13), 437 (13), 435 (100); HRMS 
(+EI) calcd for C28H42N2O6SSi
2+: 590.2302; Found: 590.2299. 
 
(3aS,3bS,6aS,6bR,12bR,12cS)-2,2,5,5-tetramethyl-7-[(4-methylphenyl)sulfonyl]-
10,11-bis(trimethylsilyl)-3a,3b,6a,6b,7,8,12b,12c-
octahydrobis[1,3]dioxolo[3,4:5,6]benzo[1,2-f]-1,7-naphthyridine (520) 
 
To a solution of diol 519 (0.040 g; 0.068 mmol) in 2,2-dimethoxypropane (1.0 mL; 8.16 
mmol) was added p-toluenesulfonic acid monohydrate (14 mg, 0.075 mmol). The 
reaction mixture was stirred until total consumption of starting material (TLC). The 
reaction mixture was quenched by addition of saturated solution of NaHCO3 (5 ml), 
extracted by EtOAc (3 × 10 ml). The combined organic phases were dried over Na2SO4, 
filtered and evaporated. The residue was purified by column chromatography 
(hexanes/EtOAc 2:1)and isolated as colourless oil (0.020 g, 47%). 
Rf 0.8 (hexanes:EtOAc 2:1); []21D − 0.4 (c = 1.0, CHCl3); IR (KBr, cm–1)  2991, 2979, 
2936, 2887, 2857, 2852, 1384, 1357, 1244, 1219, 1166, 1106, 1070, 1050, 926, 880, 841, 
815, 754; 1H NMR (300 MHz, CDCl3)  7.71, 7.45 (d, J = 8.4 Hz, 2H), 6.98 (d, J = 8.1 
Hz, 2H), 4.84 (dd, J =8.7, 6.8 Hz, 1H), 4.79-4.73 (m, 1H), 4.56-4.50 (m, 1H), 4.45-4.41 
(m, 1H), 4.38-4.33 (m, 2H), 3.53 (dd, J = 12.1, 8.7 Hz, 1H), 3.95 (dd, J = 11.7, 8.7 Hz, 
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1H), 2.30 (s, 3H), 1.60 (s, 3H), 1.50 (s, 3H), 1.42 (s, 3H), 1.39 (s, 3H), 0.36 (s, 9H), 0.33 
(s, 9H); 13C NMR (75 MHz, CDCl3)  170.8, 152.4, 142.5, 140.0, 138.5, 136.9, 128.9, 
127.6, 127.0, 110.2, 110.1, 77.6, 76.36, 76.2, 58.3, 50.3, 39.2, 27.70, 27.66, 25.19, 25.14, 
21.5, 1.15, 1.05; MS (+EI) m/z (%) 630 (1), 615 (12), 477 (15),475 (100); HRMS (+EI) 
calcd for C31H46N2O8SSi
2+: 630.2615; found: 630.2609. 
 
(3aS,3bS,6aS,6bR,12bR,12cS)-2,2,5,5-tetramethyl-7-[(4-methylphenyl)sulfonyl]-
3a,3b,6a,6b,7,8,12b,12c-octahydrobis[1,3]dioxolo[3,4:5,6]benzo[1,2-f]-1,7-
naphthyridine (521) 
 
To a solution of acetonide 520 (0.011 g; 0.017 mmol) in THF (2.0 mL) was added 
solution TBAF in THF (1 M, 0.05 mL, 0.05 mmol). The reaction mixture was stirred 
until total consumption of starting material (TLC). The reaction mixture was evaporated 
and the residue was purified by column chromatography (gradient hexanes/EtOAc 2:1 → 
1:1 ) and isolated as colourless oil (0.006 g, 70%). 
Rf 0.6 (hexanes:EtOAc 1:2); []21D + 13.0 (c = 0.3, CHCl3); IR (CHCl3, cm–1)  2998, 
2927, 1456, 1384, 1308, 1272, 1259, 1217, 1164, 1070, 924, 881, 817, 712, 696, 669; 1H 
NMR (600 MHz, CDCl3)  8.30 (d, J = 4.8 Hz, 1H), 7.74 (d, J = 7.6 Hz, 1H), 7.59 (d, J = 
7.8 Hz, 2H), 7.13 (dd, J = 7.6, 4.8 Hz, 1H), 7.11 (d, J = 8.4 Hz, 2H), 4.70 (dd, J = 9.6, 6.6 
Hz, 1H), 4.48-4.42 (m, 2H), 4.38-4.36 (m, 1H), 3.71 (dd, J = 12.0, 9.0 Hz, 1H), 2.67 (t, J 
194 
= 10.8, 1H), 2.36 (s, 3H), 1.61 (s, 3H), 1.50 (s, 3H), 1.45 (s, 3H), 1.38 (s, 3H); 13C NMR 
(150 MHz, CDCl3) 154.9, 147.1, 143.0, 137.0, 134.1, 130.2, 129.2, 129.0, 127.7, 127.5, 
122.8, 110.2, 77.6, 76.43, 76.2, 57.6, 49.3, 39.7, 31.9, 30.91, 29.7, 29.36, 27.7, 27.6, 
25.22, 25.19, 21.4;MS (+EI) m/z (%) 486 (6), 279 (10), 167 (25), 150 (11), 149 (79), 123 
(12), 43 (100); HRMS (+EI) calcd for C25H30N2O8S
+: 486.1825; found: 486.1821.  
 
tert-Butyl (3aS,4R,7R,7aS)-4-bromo-2,2-dimethyl-3a,4,7,7a-tetrahydro-4,7-
(epoxyimino)-1,3-benzodioxole-8-carboxylate (526) 
 
To a solution of diol 4 (3.8 g, 19.8 mmol) in 2,2-dimethoxypropane (10 mL) was added a 
catalytic amount of p-toluenesulfonic acid. After complete consumption of starting 
material (vide TLC), the solution was cooled to 0 °C before water (6 mL) was added. On 
a preparative scale, the intermediate acetonide 525 was not isolated. NaIO4 (3.83 g, 17.9 
mmol) was added to the reaction vessel before tert-butyl hydroxycarbamate (2.91 g, 21.8 
mmol) in 40 mL of methanol was added dropwise. To ensure complete dissolution 40 mL 
of CH2Cl2 were added. After addition, the solution was allowed to warm to room 
temperature and stirred for 16 h. Upon completion of the reaction (TLC analysis), an 
excess of saturated aqueous sodium bisulfite was added carefully until a light straw color 
was obtained. The mixture was extracted with Et2O (3 × 100 mL), the organic phase was 
washed with brine (2 × 15 mL) and dried over Na2SO4, and the solvent was removed in 
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vacuo. The oxazine 526 was isolated by flash column chromatography (hexanes/EtOAc 
4:1)  as a colourless solid affording (5.31 g, 74%). 
Rf 0.6 (hexanes/EtOAc 3:1); mp 155 °C (EtOH), []20D + 25.3 (c = 1.0, CHCl3); IR 
(CHCl3, cm
–1)  3072, 2986, 2936, 1752, 1608, 1472, 1456, 1383, 1294, 1273, 1250, 
1210, 1155, 1114, 1071, 1035, 1009, 987, 952, 895, 870, 842, 796, 773, 728, 709, 616, 
516, 456; 1H NMR (300 MHz, CDCl3)  6.45 (d, J = 8.1 Hz, 1H), 6.35 (dd, J = 8.4, 5.7 
Hz, 1H), 4.94-4.92 (m, 1H), 4.56 (s, 2H), 1.42 (s, 3H), 1.31 (s, 3H), 1.29 (s, 3H); 13C 
NMR (75 MHz, CDCl3)  156.8, 133.8, 131.3, 111.3, 87.4, 83.2, 81.4, 74.2, 53.3, 28.0, 
25.6, 25.4; MS (+EI) m/z (%) 348 (2), 173 (10), 124 (22), 100 (11), 96 (11), 94 (12), 85 
(14), 83(15) 82(17), 57 (100) ; HRMS (+EI) calcd for C14H20BrNO5
+: 361.0525; found: 
361.0528; Anal. calcd for C14H20BrNO5: C, 46.42; H, 5.57. Found C, 46.51; H, 5.55. 
 
tert-Butyl [(3aS,4R,7S,7aR)-7-hydroxy-2,2-dimethyl-3a,4,7,7a-tetrahydro-1,3-
benzodioxol-4-yl]carbamate (527) 
 
To a solution of 526 (1.02 g, 2.81 mmol) in THF:H2O (70:7 mL) was added an aluminum 
amalgam prepared by dipping aluminum foil (2.5 g, 92.9 mmol) sequentially to NaOH (1 
M), distilled water, HgCl2 (0.5% solution), distilled water, THF. After overnight stirring, 
the reaction mixture was filtered through diatomaceous earth, washed by methanol (3 × 
50 mL). Filtrate was evaporated, redissolved in toluene and evaporated again. The 
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reaction product was isolated by flash column chromatography (hexanes/EtOAc 1:1) 
affording 527 as colourless viscous oil (0.714 g, 89%). 
Rf 0.3 (hexanes/EtOAc 1:1); 
1H NMR (300 MHz, CDCl3)  5.91 (ddd, J = 9.8, 2.2, 2.2 
Hz, 1H), 5.80 (ddd, J = 9.8, 2.9, 1.0 Hz, 1H), 5.07 (b, 1H), 4.27-16 (m, 3H),4.02 (m, 1H), 
2.63(b, 1H), 1.45 (s, 12H), 1.35 (s, 3H).1H NMR matched with lit. value.235 
tert-Butyl ((3aS,4R,7S,7aS)-7-{[tert-butyl(dimethyl)silyl]oxy}-2,2-dimethyl-3a,4,7,7a-
tetrahydro-1,3-benzodioxol-4-yl)carbamate (528) 
 
To a solution of 527 (0.372 g, 1.3 mmol) in CH2Cl2 (20 mL) was added imidazole 
(0.133g, 1.96 mmol) followed by TBSCl (0.215g, 1.43 mmol). After overnight stirring, 
the reaction mixture quenched by water (10 mL), extracted by CH2Cl2 (3 × 10 mL), dried 
and evaporated. The reaction product was isolated by flash column chromatography 
(hexanes/EtOAc 8:1) affording 528 as a colourless liquid (0.425 g, 81%). 
Rf 0.9 (hexanes/EtOAc 3:1); []20D − 0.8 (c = 1.0, CHCl3), IR (CHCl3, cm–1)  3394, 
3055, 2991, 2973, 2962, 2933, 2908, 2860, 1710, 1510, 1463, 1382, 1369, 1325, 1294, 
1252, 1211, 1167, 1097, 1059, 1038, 978, 966, 937, 914;1H NMR (300 MHz, CDCl3)  
5.98-5.93 (m, , 1H), 5.35 (d, J = 8.7 Hz, 1H), 4.28-4.22 (m, 3H), 4.15-4.13 (m, 1H), 1.39 
(s, 9H), 1.33 (s, 3H), 1.27 (s, 3H), 0.88 (s, 9H) 0.10 (s, 3H), 0.08 (s, 3H); 13C NMR (75 
MHz, CDCl3)  155.2, 131.8, 131.2, 108.1, 79.2, 78.8, 67.1, 47.6, 28.3, 26.4, 25.7, 24.4, 
17.9, −4.80, −4.99; MS (+EI) m/z (%) 299 (16), 286 (37), 256 (23), 244 (13), 243 (75), 
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238 (16), 228 (54), 225 (17), 215 (24), 212 (17), 210 (38), 199 (28), 196 (11), 184 (14), 
182 (12), 168 (24), 167 (100); HRMS (+EI) calcd for C20H37NO5Si
+: 399.2441; found: 
399.2435; Anal. calcd for C20H37NO5Si: C, 60.11; H, 9.33. Found C, 60.36; H, 9.23. 
((3aS,4R,7S,7aS)-7-{[tert-Butyl(dimethyl)silyl]oxy}-2,2-dimethyl-3a,4,7,7a-
tetrahydro-1,3-benzodioxol-4-yl)amine (473) 
 
Trifluoroacetic acid (7 mL) was added dropwise to a solution of 528 (6.01 g, 15.04 
mmol) in CH2Cl2 (150 mL) at 0 °C. After 15 min reaction has been neutralised by 
addition of concentrated ammonia (50 mL). Organic layer was extracted by CH2Cl2 3 × 
50 mL, washed with brine, dried over Na2SO4 and evaporated. The free amine 473, 3.86 
g (86%), was obtained as colourless oil and of sufficient purity to use in the next step. 
Analytical sample of 473 was purified by flash column chromatography (CH2Cl2/CH3OH 
10:1). 
Rf 0.8 (CH2Cl2/ CH3OH  10:1); []20D + 15.5 (c = 1.0, CHCl3); IR (CHCl3, cm–1)  3424, 
3371, 3323, 3048, 2985, 2955, 2933, 2898, 2858, 1677, 1635, 1600, 1467, 1383, 1255, 
1212, 1163, 1117, 1060, 887, 839, 780; 1H NMR (300 MHz, CDCl3)  5.73 (dt, J = 9.8, 
2.3 Hz, 1H), 5.65 (dt, J = 9.8, 2.3 Hz, 1H), 4.19-4.16 (m, 1H), 4.11 (dd, J = 7.8, 4.8 Hz, 
1H), 3.89 (dd, J = 7.5, 6.3 Hz, 1H), 3.28 (dd, J = 5.7, 2.1 Hz, 1H), 1.66 (s, 2H), 1.44 (s, 
3H), 1.34 (s, 3H), 0.91 (s, 9H) 0.12 (s, 3H), 0.11 (s, 3H); 13C NMR (75 MHz, CDCl3)  
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132.3, 131.4, 108.7, 81.0, 80.6, 71.4, 52.0, 27.1, 25.8, 24.7, 18.3, −4.6, −4.9; MS (+EI) 
m/z (%) 242 (10), 215 (12), 212 (33), 200 (17), 199 (100); HRMS (+EI) calcd for 
C15H29NO3Si
 +: 299.1917; found: 299.1903; Anal. calcd for C15H29NO3Si: C, 60.16; H, 
9.76. Found C, 60.31; H, 9.57. 
N-((3aS,4R,7S,7aS)-7-{[tert-Butyl(dimethyl)silyl]oxy}-2,2-dimethyl-3a,4,7,7a-
tetrahydro-1,3-benzodioxol-4-yl)-3-iodopyridine-2-carboxamide (529) 
 
To a solution of lithium salt of 3-iodopicolinic acid227 (3.23 g, 12.68 mmol) in DMF (60 
mL) was added HBTU (3.93 g, 10.35 mmol), stirred for 5 min at 0 °C, followed by 
solution of 473 (3.67 g, 9.41 mmol) and diisopropylethylamine (2.46 mL, 14.12 mmol) in 
CH2Cl2 (100 ml). After 1 h stirring, the reaction mixture quenched by water (50 mL), 
extracted by CH2Cl2 (3 × 100 mL), dried over Na2SO4 and evaporated. The reaction 
product was isolated by flash column chromatography (hexanes/EtOAc 4:1) affording 
529 as a colourless oil (3.27 g, 66%). 
Rf 0.85 (hexanes/EtOAc 2:1);  []20D − 38.3 (c = 1.0, CHCl3); IR (CHCl3, cm–1)  3387, 
2986, 2953, 2930, 2901, 2856, 1678, 1507, 1462, 1456, 1383, 1254, 1212, 1164, 1120, 
1061, 1014; 1H NMR (600 MHz, CDCl3)  8.50 (dd, J = 4.5, 1.5 Hz, 1H), 8.31 (dd, J = 
8.2, 1.5 Hz, 1H), 8.21 (d, J = 9.1 Hz, 1H), 7.08 (dd, J = 7.9, 4.5 Hz, 1H), 6.06 (dd, J = 
9.8, 4.2 Hz, 1H), 5.98 (dd, J = 9.8, 4.9 Hz, 1H),4.78-4.76 (m, 1H),  4.41 (dd, J = 7.2, 3.8 
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Hz, 1H), 4.30 (dd, J = 7.2, 3.4 Hz, 1H), 4.27 (dd, J = 4.2, 3.4 Hz, 1H) 1.42 (s, 3H), 1.33 
(s, 3H), 0.9 (s, 9H), 0.14 (s, 3H), 0.13 (s, 3H); 13C NMR (150 MHz, CDCl3)  163.7, 
150.4, 148.8, 147.2, 132.9, 129.5, 126.2, 108.5, 89.6, 76.7, 68.2, 47.7, 26.7, 25.8, 25.7, 
24.6, 18.2, − 4.7, − 4.8; MS (+EI) m/z (%) 515 (6), 436 (26), 430 (31), 415 (29), 305 (14), 
298 (24), 289 (12), 282 (18) 249 (30), 232 (75), 215 (15), 205 (12), 204 (53), 185 (13), 
168 (15), 167 (83), 157 (20), 150 (10), 149 (35), 128 (10), 106 (16), 86 (20), 85 (10), 84 
(32), 79 (19), 78 (33), 77 (26), 76 (13), 75 (100);  HRMS (+EI) calcd for C20H28IN2O4Si
+: 
515.0863; found: 515.0868; Anal. calcd for C21H31IN2O4Si: C, 47.55; H, 5.89. Found C, 
47.84; H, 5.90. 
tert-Butyl ((3aS,4R,7S,7aS)-7-{[tert-butyl(dimethyl)silyl]oxy}-2,2-dimethyl-3a,4,7,7a-
tetrahydro-1,3-benzodioxol-4-yl)[(3-iodopyridin-2-yl)carbonyl]carbamate (475) 
 
To a solution of amide 529 (0.090 g, 0.17 mmol) in acetonitrile (2 mL) was added di-tert-
butyldicarbonate (0.083 g, 0.38 mmol), and DMAP (0.047 g, 0.38 mmol). After 2 h 
stirring, the reaction mixture quenched by water (5 mL), extracted by CH2Cl2 (3 × 10 
mL), dried and evaporated. The reaction product was isolated by flash column 
chromatography (hexanes/EtOAc 4:1) affording 475 as a colourless oil (0.098 g, 92%). 
Rf 0.9 (hexanes/EtOAc 2:1); []20D − 11.0 (c = 1.0, CHCl3); IR (CHCl3, cm–1)  3449, 
3050, 2983, 2955, 2934, 2901, 2858, 1743, 1684, 1473, 1461, 1430, 1387, 1353, 1343, 
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1254, 1218, 1154, 1112, 1062, 1010, 888, 839, 777; 1H NMR (300 MHz, CDCl3)  8.55 
(dd, J = 4.8, 1.2 Hz, 1H), 8.14 (dd, J = 8.1, 1.5 Hz, 1H), 7.07 (dd, J = 8.1, 4.8 Hz, 1H), 
5.71(s, 2H), 5.26(br.s, 1H), 4.67 (m, 1H), 4.24 (m, 1H), 4.16 (m, 1H), 1.51 (s, 3H), 1.37 
(s, 3H), 1.22 (s, 9H), 0.94 (s, 9H), 0.16 (s, 3H), 0.14 (s, 3H); 13C NMR (75 MHz, CDCl3) 
 169.2, 158.7, 151.6, 147.6, 146.6, 131.1, 126.4, 124.8, 108.6, 89.0, 84.4, 80.1, 75.1, 
71.2, 27.8, 27.5, 25.9, 25.7, 18.2, − 4.5, − 4.9; MS (+EI) m/z (%) 530 (10), 473 (32), 459 
(16), 430 (19), 415 (40), 305 (11), 298 (19), 282 (14) 260 (38), 249 (44), 232 (63), 204 
(37), 168 (15), 167 (68), 157 (12), 57 (100); HRMS (+EI) calcd for C26H39IN2O6Si
+: 
630.1622; found: 630.1615; Anal. calcd for C26H39IN2O6Si: C, 49.52; H, 6.23. Found C, 
49.66; H, 6.24. 
tert-Butyl (3aS,3bR,11S,11aS)-11-{[tert-butyl(dimethyl)silyl]oxy}-2,2-dimethyl-5-
oxo-3a,5,11,11a-tetrahydro[1,3]benzodioxolo[5,4-f]-1,7-naphthyridine-4(3bH)-
carboxylate (530) 
 
To a solution of 475 (1.30 g, 2.06 mmol) in toluene (45 mL) was added Pd(OAc)2 (0.093 
g, 0.41 mmol) and Ag3PO4 (0.520 g, 1.24 mmol). The reaction mixture was degassed by 
passing argon for 5 min followed by addition of 1,2-bis(diphenylphosphino)ethane (0.164 
g, 0.41 mmol). After addition of dppe the reaction mixture was refluxed for 18 h. Product 
was isolated by flash column chromatography (hexanes/EtOAc 2:1 → 1:1) affording 0.32 
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g (31%, 46% based on recovered starting material) of 530 as a colourless oil and 0.440 g 
of starting material. 
Rf 0.2 (hexanes/EtOAc 1:1); []20D + 18.1 (c = 1.0, CHCl3); IR (CHCl3, cm–1) 3450, 
3074, 2984, 2955, 2933, 2903, 2858, 1756, 1691, 1634, 1469, 1382, 1254, 1215, 1155, 
1125, 1068, 1014, 964, 920, 843, 782; 1H NMR (300 MHz, CDCl3)  8.73 (dd, J = 4.2, 
0.9 Hz, 1H), 7.99 (dd, J = 8.1, 1.2 Hz, 1H), 7.44 (dd, J = 8.4, 4.5 Hz, 1H), 6.51-6.49 (m, 
1H), 4.90 (dt, J = 7.8, 2.4 Hz 1H), 4.46-4.44 (m, 1H), 4. (dd, J = 8.1, 2.7 Hz, 1H), 1.61 (s, 
9H), 1.50 (s, 3H), 1.33 (s, 3H), 0.96 (s, 9H), 0.18 (s, 6H); 13C NMR (75 MHz, CDCl3)  
159.5, 153.2, 150.8, 141.5, 131.2, 130.3, 128.4, 126.9, 125.8, 111.7, 84.3, 79.9, 79.7, 
73.6, 57.9, 27.6, 26.9, 25.8, 25.2, 18.2, - 4.5, - 5.0; MS (+FAB) m/z (%) 503 (5), 419 
(12), 404 (77), 303 (12), 287 (10), 185 (13), 185 (13), 75 (10), 73 (100);  HRMS (+FAB) 
calcd for C26H39N2O6Si
+: 503.2577; found: 503.2538. 
 
tert-Butyl (3aS,3bR,11S,11aR)-11-hydroxy-2,2-dimethyl-5-oxo-3a,5,11,11a-
tetrahydro[1,3]benzodioxolo[5,4-f]-1,7-naphthyridine-4(3bH)-carboxylate (531) 
 
Naphthridone 530 (0.121 g, 0.024 mmol) was dissolved in THF (2.5 mL) and cooled to 0 
°C. A solution of TBAF in THF (1 M, 0.25 mL, 0.25 mmol) was added dropwise over 1 
min. The reaction mixture was stirred until total consumption of starting material was 
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observed (TLC). The reaction mixture was quenched with solution of NH4Cl (2 ml, sat. 
aq. solution) and extracted with EtOAc (6 × 15 mL). The combined organic phases were 
dried over Na2SO4, filtered and evaporated. Compound 531 was isolated by column 
chromatography (CH2Cl2/methanol 100:1) as white crystalline solid (0.072 mg, 77%).  
Rf 0.8 (CH2Cl2/methanol 10:1); mp > 200 °C (CH2Cl2); []20D − 4.1 (c = 0.2, CHCl3); IR 
(CHCl3, cm
–1)  3431, 2983, 2935, 2877, 1765, 1684, 1627, 1473, 1384, 1248, 1217, 
1153, 1115, 1070; 1H NMR (300 MHz, CDCl3)  8.69 (d, J = 3.9 Hz, 1H), 8.00 (d, J = 
8.1 Hz, 1H), 7.42 (dd, J = 8.1, 4.5 Hz, 1H), 6.72 (t, J = 2.7 Hz, 1H), 4.87-4.84 (m, 1H), 
4.53-4.52 (m, 1H), 4.38 (br s, 1H), 4.25-4.14 (m, 1H), 1.56 (s, 9H), 1.49 (s, 3H), 1.33 (s, 
3H); 13C NMR (75 MHz, CDCl3)  159.6, 152.9, 150.6, 141.1, 130.7, 128.7, 127.2, 
125.4, 111.9, 84.5, 79.7, 79.2, 72.5, 58.2, 27.4, 26.9, 25.1; MS (+FAB) m/z (%) 389 (5), 
290 (12), 289 (60), 243 (14), 242 (74), 186 (44), 185 (13), 184 (15), 142 (22), 81 (12), 77 
(10), 73 (18), 69 (24), 67(12), 57 (100);  HRMS (+FAB) calcd for 
C20H25N2O6
+:389.1713; found: 389.1694. 
 (6aR,7S,8R,9S)-7,8,9-Trihydroxy-5-oxo-5,6,6a,7,8,9-hexahydrobenzo[f]-1,7-
naphthyridin-4-ium chloride (6) 
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Compound 531 (0.072 g, 0.185 mmol) was taken up in methanol (2.5 mL) and HCl 
(conc., 0.25 mL) was added dropwise. The reaction mixture was stirred at r.t. until total 
consumption of starting material was observed (TLC). The reaction mixture was 
evaporated and dried in vacuo and off-white crystals of hydrochloride of 6 were obtained 
(53 mg, quantitative). Upon chromatography on silica gel (deactivated with 10% w/w 
water, eluent CH2Cl2/MeOH/NH3=90:10:1) free base of 6 was isolated (0.040 g, 86 %). 
Rf 0.35 (CH2Cl2/methanol/ammonia 80:35:4); mp > 200 °C (methanol); []20D − 10 (c = 
0.5, H2O); IR (CHCl3, cm
–1) 3130, 3037, 2850, 2877, 1655, 1401, 1322, 1087, 1029; 
for 6*HCl: 1H NMR (600 MHz, D2O)  8.74-8.72 (m, 2H), 8.07 (s, 1H), 6.55 (t, J = 3.0 
Hz, 1H), 4.51 (d, J = 8.4 Hz, 1H), 4.34 (t, J = 2.4 Hz, 1H), 3.98 (dd, J = 9.0, 2.4 Hz, 1H), 
3.96 (s, 1H); 13C NMR (150 MHz, D2O)  158.8, 142.8, 141.8, 136.4, 134.6, 130.1, 
129.3, 126.9, 72.2, 68.6, 68.4, 52.1; MS (+FAB) m/z (%) 389 (5), 290 (12), 289 (60), 243 
(14), 242 (74), 186 (44), 185 (13), 184 (15), 142 (22), 81 (12), 77 (10), 73 (18), 69 (24), 
67(12), 57 (100); HRMS (+FAB) calcd for C12H13N2O4
+:249.0875; found: 249.0847. 
 
(6aR,7S,8R,9S)-7,8,9-trihydroxy-6a,7,8,9-tetrahydrobenzo[f]-1,7-naphthyridin-
5(6H)-one 4-oxide (476) 
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Triol 6 (0.052 g, 0.21mmol) was dissolved in a mixture of methanol (2.5 mL) and CHCl3 
(7.5 mL) and 100% m-chloroperbenzoic acid (103 mg, 0.6 mmol) was added in one 
portion. The reaction mixture was stirred at r.t. until consumption of starting material 
(TLC). After that period the reaction mixture was evaporated and subjected to a column 
chromatography on silica gel (deactivated with 10% w/w water, eluent 
CH2Cl2/MeOH/NH3=80:35:4) to afford off-white crystals of 476 (0.014 g, 25%).  
Rf 0.05 (CH2Cl2/methanol/ammonia 80:35:4); mp > 200 °C (methanol); []20D + 733 (c = 
0.1, methanol); IR (CHCl3, cm
–1)  3483, 2982, 2930, 2877, 1740, 1670, 1627, 1473, 
1400, 1265, 1212, 1155, 1112, 1074; 1H NMR (600 MHz, CD3OD)  8.35 (d, J = 6.6 Hz, 
1H), 7.79 (d, J = 7.8 Hz, 1H), 6.52 (dd, J = 4.2, 1.8 Hz, 1H), 6.52 (d, J = 2.5 Hz, 1H), 
4.36 (d, J = 8.4 Hz, 1H), 4.30 (t, J = 3.6 Hz 1H), 3.`97 (dd, J = 8.4, 2.4 Hz, 1H), 3.94 (br 
s, 1H); 13C NMR (600 MHz, CD3OD)  158.4, 141.5, 137.8, 135.4, 129.3, 128.0, 127.5, 
123.1, 72.7, 69.3, 69.1, 52.2; MS (+FAB) m/z (%) 265 (34), 207 (10), 192 (14), 177 (16), 
176 (34), 171 (19), 165 (10), 163 (16), 151 (10), 149 (15), 136 (41), 121 (12), 113 (10), 
109(20), 107 (25), 105 (21), 55 (100); HRMS (+FAB) calcd for C12H13N2O5
+:265.0825; 
found: 265.0826. 
5-bromo pyridine-2,3-diol (534) 
 
Freshly distilled furfural (51 mL, 0.615 mol) was mixed with 700 g of ice and bromine 
(32 mL, 0.615 mol) was added dropwise to a vigorous stirred reaction mixture while 
maintaining temperature 0 °C. After 30 min of stirring HCl (conc., 30 mL) was added in 
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one portion and stirred for an additional 30 min. Bromine (32 mL, 0.615 mol) was added 
dropwise while maintaning temperature −5 °C in a period of 1 h. The reaction mixture 
was then filtered and sulfamic acid (60 g, 0.62 mol) was added to a filtrate and vigorously 
stirred for 1.5 h at 50 °C. The reaction mixture was cooled to 10 °C and filtered. 
Precipitate was dried for 18 h at 50 °C, then refluxed in glacial acetic acid with charcoal, 
and recrystallized from acetic acid. Crystals were washed with distilled water till neutral 
reaction and dried in vacuo to obtain 534 as grey crystals (76 g, 65%). 
mp 248-250 °C (AcOH), [lit.202 249 °C (AcOH)]. 
6-bromo[1,3]dioxolo[4,5-b]pyridine (533) 
 
To a solution of 5-bromo pyridine-2,3-diol 534 (0.700 g, 3.7 mmol) in 30 ml of DMF was 
added K2CO3(0.50 g, 7.4 mmol), CH2Br2 (0.75 ml, 7.4 mmol) and CuO (0.120 g, 0.74 
mmol). Mixture was heated to 95 °C for 6 h, then cooled down, filtered, diluted with H2O  
(300 mL) and extracted with EtOAc (5 × 10 ml). Organic phases were dried over Na2SO4 
and subjected to column chromatography (Hex/EtOAc 4:1). Product was isolated as 
white needles (0.135 g, 18%). 
mp 65-67°C (Hexanes-EtOAc), [Lit.202 69-71°C (EtOH)]; 1H NMR (300 MHz, CDCl3)  
7.71 (d, J = 1.9 Hz, 1 H), 7.12 (d, J = 1.9 Hz, 1 H), 6.10 (s, 2H). 
6-bromo-7-methoxy[1,3]dioxolo[4,5-b]pyridine (532) 
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To a solution of 2,2,6,6-tetramethylpiperidine (6.04 mL, 35.5 mmol) in THF (50 mL) at -
50°C nBuLi (14.30 mL, 30.8 mmol) was added dropwise. Reaction mixture was stirred 
for 15 min at −30 °C, then cooled down to −80 °C and solution of 533 (4.88 g, 23.7 
mmol) in THF (20 mL) was added dropwise, while maintaining temperature −80 °C. 
Reaction mixture was stirred for an additional 30 min, followed by addition of B(OMe)3 
(6.6 mL, 59.1 mmol) in one portion and reaction mixture was warmed up to 0 °C within 
30 min. Then reaction mixture was cooled to −50 °C and glacial acetic acid (6.76 mL, 
118 mmol) was added, followed by addition of UHP (10 g) and stirred overnight at r.t.  
Next morning excess of peroxide was quenched by NaHSO3 (sat. aq.), extracted with 
EtOAc (3×150 mL). Organic layer was dried over Na2SO4, evaporated and redissolved in 
THF:MeOH mixture (10:1, 200 mL) at 0 °C. Ethereal solution of diazomethane was 
added dropwise until disappearance of starting material was observed (TLC). Reaction 
mixture was evaporated and subjected to flash column chromatography (silica gel, 
hexane/EtOAc 4:1) to yield 532  as a white crystalline compound (2.0 g, 36%). 
Rf 0.45 (hexanes/EtOAc 4:1); mp 119-121 °C (CHCl3); IR (film, cm–1) 3092, 3003, 
2957, 2924, 2853, 1786, 1614, 1492, 1472, 1431, 1401, 1277, 1268, 1232, 1202, 1146, 
1091, 1033, 982; 1H NMR (600 MHz, CDCl3)  7.74 (s, 0.75 H), 7.62 (s, 0.2 H), 6.05 (s, 
2H), 4.21 (s, 3H); 13C NMR (150 MHz, CDCl3)  159.6, 145.7, 141.6, 139.1, 127.3, 
105.4, 100.5, 100.4, 59.8; MS (+EI) m/z (%) 233 (97), 231 (100), 203 (23), 187 (43), 175 
207 
(16), 173 (16), 160 (88), 158 (84), 132 (31), 131 (33), 130 (33), 129 (12); HRMS (+EI) 
calcd for C7H6BrNO3: 232.9512; found: 232.9507. 
 
5-bromo-7-methoxy[1,3]dioxolo[4,5-b]pyridine (538) 
 
To a solution of 2,2,6,6-tetramethylpiperidine (0.320 mL, 1.86 mmol) in THF (5 mL) at -
50°C nBuLi (0.770 mL, 1.82 mmol) was added dropwise. Reaction mixture was stirred 
for 15 min at −30 °C, then cooled down to −80 °C and added dropwise to a solution of 
532 (0.206 g, 0.89 mmol) in THF (5 mL) while maintaining temperature −80 °C. 
Reaction mixture was stirred for 20 min at this temperatute, followed by consequtive 
quenching with methanol (1 mL) and solution of NH4Cl (sat. aq., 2 mL). Reaction 
mixture was extracted with extracted with EtOAc (3 × 30 mL). Organic layer was dried 
over Na2SO4, evaporated subjected to flash column chromatography (silica gel, 
hexane/EtOAc 4:1) to yield 538 as a white crystalline compound (0.110 g, 54%). 
Rf 0.40 (hexanes/EtOAc 4:1); mp 113-115 °C (CHCl3); IR (film, cm–1) 3107, 3003, 
2950, 2924, 1789, 1632, 1591, 1504, 1476, 1453, 1428, 1417, 1334, 1281, 1191, 1129, 
1105, 1030, 958, 921, 913, 870, 830 775; 1H NMR (300 MHz, CDCl3)  6.69 (s, 1H), 
6.05 (s, 2H), 3.97 (s, 3H); 13C NMR (75 MHz, CDCl3)  158.9, 149.9, 141.6, 130.4, 
126.9, 109.2, 100.9, 57.2; MS (+EI) m/z (%) 233 (100), 231 (98), 203 (13), 201 (13), 160 
208 
(78), 158 (73), 132 (18), 130 (19), 94 (12); HRMS (+EI) calcd for C7H6BrNO3:
 232.9512; 
found: 232.9516. 
5-bromo-7-methoxy[1,3]dioxolo[4,5-b]pyridine-6-carbaldehyde (539) 
 
To a solution of 2,2,6,6-tetramethylpiperidine (0.137 mL, 0.81 mmol) in THF (5 mL) at 
−50°C nBuLi (0.324 mL, 0.77 mmol) was added dropwise. Reaction mixture was stirred 
for 15 min at −30 °C, then cooled down to -80 °C and added dropwise to a solution of 
532 (0.170 g, 0.73 mmol) in THF (5 mL) while maintaining temperature −80 °C. The 
reaction mixture was stirred for 20 min at this temperature, followed by quenching with 
dry DMF (1 mL), followed by addition of NH4Cl (sat. aq., 2 mL). The reaction mixture 
was extracted with EtOAc (3 × 20 mL). Organic layer was dried over Na2SO4, 
evaporated, and subjected to flash column chromatography (silica gel, hexane/EtOAc 4:1 
to 2:1) to yield 539 (0.015 g, 8%) as a off-white crystalline compound and 538 as white 
crystalline compound (0.062 g,36 %). 
Rf 0.2 (hexanes/EtOAc 2:1); mp 130-135 °C (CH2Cl2); IR (film, cm–1) 3110, 3000, 
2950, 2825, 2720, 1730, 1630, 1600, 1496, 1466, 1432, 1418, 1411, 1334, 1281, 1191, 
1129, 1105, 1040, 960; 1H NMR (300 MHz, CDCl3)  10.22 (s, 1H), 6.13 (s, 2H), 4.23 
(s, 3H); 13C NMR (150 MHz, CDCl3) δ 188.8, 161.1, 150.2, 137.2, 127.0, 118.0, 101.1, 
60.4; MS (+EI) m/z (%) 261 (97), 259 (100), 244 (16), 243 (12), 229 (14), 201 (10), 188 
209 
(39), 186 (40), 150 (49), 133 (13), 132 (24), 131 (13), 130 (23), 122 (12), 94 (16); HRMS 
(+EI) calcd for C8H6BrNO4:
 258.9480; found: 258.9470. 
 
5-bromo-N-((3aS,4R,7S,7aS)-7-{[tert-butyl(dimethyl)silyl]oxy}-2,2-dimethyl-
3a,4,7,7a-tetrahydro-1,3-benzodioxol-4-yl)-7-methoxy[1,3]dioxolo[4,5-b]pyridine-6-
carboxamide (541) 
 
A. Synthesis from 532: 
To a solution of 2,2,6,6-tetramethylpiperidine (0.240 mL, 1.40 mmol) in THF (30 mL) at 
−50°C nBuLi (0.640 mL, 1.37 mmol) was added dropwise.The reaction mixture was 
stirred for 15 min at −30 °C, then cooled down to −85 °C and was added dropwise to a 
solution of 532 (0.310 g, 1.336 mmol) in THF (20 mL), while maintaining temperature -
85°C. The reaction mixture was stirred for 30 min at this temperature, followed by a 
quick addition to a solid CO2 and evaporation. Solid residue was redissolved in 
acetonitrile (50 mL) and HBTU (0.455 g, 1.6 mmol) was added, followed by DIPEA 
(0.470 mL, 2.67 mmol) and solution of amine 473 (0.480 g, 1.6 mmol) in CH2Cl2 (2 mL). 
Reaction mixture was stirred for five hours, quenched with NH4Cl (sat. aq., 2 mL) 
extracted with EtOAc (3 × 10 mL). Combined organic layer was dried over Na2SO4, 
evaporated subjected to flash column chromatography (silica gel, hexane/EtOAc 3:1 to 
2:1) to yield  541 as a white crystalline compound (0.224 g, 30% based on 532). 
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B. Synthesis from 538: 
To a solution of 2,2,6,6-tetramethylpiperidine (0.070 mL, 0.41 mmol) in THF (10 mL) at 
−50°C nBuLi (0.173 mL, 0.41 mmol) was added dropwise. The reaction mixture was 
stirred for 15 min at −30 °C, then cooled down to −85 °C and solution of 538 (0.091 g, 
0.39 mmol) in THF (4 mL) was added dropwise to LTMP, while maintaining temperature 
-85 °C. The reaction  mixture was stirred for 3 min at this temperature, followed by a 
quick addition to a solid CO2 and evaporation. Solid residue was redissolved in 
acetonitrile (5 mL) and HBTU (0.178 g, 0.47 mmol) was added, followed by DIPEA 
(0.101 g, 0.784 mmol) and solution of amine 473 (0.130g, 0.43 mmol) in CH2Cl2 (2 mL). 
Reaction mixture was stirred for five hours, quenched with NH4Cl (sat. aq., 2 mL) 
extracted with EtOAc (3 × 10 mL). Combined organic layer was dried over Na2SO4, 
evaporated subjected to flash column chromatography (silica gel, hexane/EtOAc 3:1 to 
2:1) to yield  541 as a white crystalline compound (0.114 g, 52% based on 538). 
Rf 0.6 (hexanes/EtOAc 3:2); mp 153-161°C (CHCl3); []20D − 11.9 (c = 1, MeOH); IR 
(film, cm–1) 3054, 2956, 2931, 2858, 2720, 1654, 1624, 1596, 1535, 
1502, 1466, 1439, 1413, 1394, 1344, 1324, 1303, 1258, 1212, 1164, 1103, 1061, 999, 
841;1H NMR (300 MHz, CDCl3) δ 6.73 (d, J = 9.5 Hz, 1H), 6.17 (d, J = 2.5 Hz, 2H), 
6.02 (s, 2H), 4.88-4.85 (m, 1H), 4.58 – 4.49 (m, 1H), 4.36 (d, J = 6.8 Hz, 1H), 4.21 (s, 
1H), 4.09 (s, 3H), 1.36 (s, 3H), 1.31 (s, 3H), 0.72 (s, 9H), 0.06 (s, 3H), 0.01 (s, 3H); 13C 
NMR (75 MHz, CDCl3) δ 163.3, 159.2, 146.9, 132.7, 130.4, 127.9, 126.3, 122.0, 108.4, 
100.6, 78.3, 77.1, 76.4, 66.3, 59.9, 45.9, 26.3, 25.4, 24.4, 17.6, -4.9, -5.1; MS (+EI) m/z 
(%) 501(10), 499 (10), 458 (10), 284 (14), 282 (13), 260 (32), 258 (33), 246 (26), 243 
211 
(23), 242 (11), 241 (17), 226 (16), 215 (19), 212 (27), 200 (15), 199 (65), 75 (100); 
HRMS (+EI) calcd for C22H30BrN2O7Si: 541.1006; found: 541.1003.  
 tert-butyl [(5-bromo-7-methoxy[1,3]dioxolo[4,5-b]pyridin-6-
yl)carbonyl]((3aS,4R,7S,7aS)-7-{[tert-butyl(dimethyl)silyl]oxy}-2,2-dimethyl-
3a,4,7,7a-tetrahydro-1,3-benzodioxol-4-yl)carbamate (478) 
 
To a solution of amide 541 (0.568 g, 1.02 mmol) in acetonitrile (20 mL) was added di-
tert-butyldicarbonate (0.444 g, 2.04 mmol), and DMAP (0.25 g, 2.07 mmol). The 
reaction was stirred for 12 h and then quenched with water (5 mL), extracted by CH2Cl2 
(3 × 20 mL), dried and evaporated. The product was isolated by flash column 
chromatography (hexanes/EtOAc 4:1) affording 478 as a colorless oil (0.470 g, 70%). 
Rf 0.8 (hexanes/EtOAc 2:1); []17D – 19.4 (c = 1, CHCl3); IR (film, cm–1)  2959, 
2932, 2858, 1742, 1680, 1625, 1598, 1466, 1438, 1418, 1396, 1371, 1332, 1261, 1235, 
1154, 1103, 1061, 1020; 1H NMR (600 MHz, Acetone-d6) δ 6.25 (s, 1H), 6.20 (s, 1H), 
5.71 – 5.63 (m, 2H), 5.26 (s, 1H), 4.61 (dd, J = 6.6, 4.8 Hz, 1H), 4.27 – 4.23 (m, 1H), 
4.15 (d, J = 1.2 Hz, 3H), 4.09 (dd, J = 12.6, 6.0 Hz, 1H), 1.48 (d, J = 3.0 Hz, 3H), 1.35 (d, 
J = 4.2 Hz, 9H), 1.34 (d, J = 4.8 Hz, 3H), 0.96 (s, 9H), 0.19 (s, 3H), 0.18 (s, 3H); 13C 
NMR (151 MHz, Acetone) δ 165.0, 164.8, 159.2, 159.1, 151.5, 146.3, 145.9, 130.5, 
130.4, 127.1, 126.9, 125.7, 124.6, 124.0, 123.9, 108.1, 108.1, 101.3, 84.0, 84.0, 79.8, 
212 
79.8, 75.3, 71.3, 71.3, 59.7, 59.7, 27.3, 27.2, 26.9, 25.4, 24.9, 17.8, −5.1, −5.54, HRMS 
(+EI): [M−CH3−tBu−CO2]+ calcd for C22H30BrN2O7Si: 541.1000; found: 541.1004. 
 
 tert-Butyl (3aS,3bR,12S,12aS)-12-{[tert-butyl(dimethyl)silyl]oxy}-6-methoxy-2,2-
dimethyl-5-oxo-3a,5,12,12a-tetrahydro[1,3]benzodioxolo[4,5-h][1,3]dioxolo[4,5-b]-
1,6-naphthyridine-4(3bH)-carboxylate (542) 
 
To a solution of 478 (0.30 g, 0.457 mmol) in toluene (35 mL) was added Pd(OAc)2 
(0.025 g, 0.113 mmol) and Ag3PO4 (0.140 g, 0.33 mmol). The reaction mixture was 
degassed by passing argon for 5 min followed by addition of 1,2-bis 
(diphenylphosphino)ethane (0.036 g, 0.091 mmol). After addition of dppe the reaction 
mixture was stirred at 95 °C for 20 h. Product was isolated by flash column 
chromatography (hexanes/EtOAc 2:1 → 1:1) affording  542 as a white solid (0.152 g, 
58%, 69% based on recovered starting material) and 0.05 g of starting material. 
Rf 0.3 (hexanes/EtOAc 2:1); mp 86-91 °C (CH2Cl2), []17D – 29.5 (c = 1.0, CHCl3); IR 
(film, cm–1)  2981, 2952, 2929, 2856, 1759, 1681, 1624, 1610, 1579, 1475, 1434, 1399, 
1370, 1295, 1246, 1226, 1188, 1157, 1140, 1101, 1054; 1H NMR (600 MHz, CDCl3) δ 
6.98 (t, J = 3.0 Hz, 1H), 6.07 - 6.04 (m, 2H), 4.73 - 4.68 (m, 1H), 4.41 - 4.37 (m, 1H), 
4.21 (s, 3H), 4.14 (t, J = 8.1 Hz, 1H), 4.05 (dd, J = 8.4, 6.0 Hz, 1H), 1.60 (s, 9H), 1.48 (s, 
3H), 1.32 (s, 3H), 0.95 (s, 9H), 0.15 (s, 6H). 13C NMR (151 MHz, CDCl3) δ 161.7, 160.5, 
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153.9, 149.7, 145.7, 133.6, 127.3, 126.6, 111.4, 109.0, 100.0, 84.1, 79.8, 79.7, 77.0, 73.8, 
60.5, 57.7, 27.7, 27.0, 25.9, 25.1, 18.2, −4.52, −4.97; HRMS (+EI) calcd for 
C28H41N2O9Si: 577.2581; found: 577.5204.  
 
tert-Butyl (3aS,3bR,12S,12aS)-12-{[tert-butyl(dimethyl)silyl]oxy}-6-hydroxy-2,2-
dimethyl-5-oxo-3a,5,12,12a-tetrahydro[1,3]benzodioxolo[4,5-h][1,3]dioxolo[4,5-b]-
1,6-naphthyridine-4(3bH)-carboxylate (543) 
 
To a solution of 542 (0.050 g, 0.086 mmol) in dry DMF (5 mL) was added LiCl (0.010 
g), followed by three cycles of freeze-pump-thaw. The reaction mixture was heated to 90 
°C for 4.5 h. The reaction was then cooled to room temperature, diluted with distilled 
water (50 ml) and extracted with EtOAc (6 × 15 mL). The combined organic phases were 
dried over Na2SO4, filtered, and concentrated. The product was isolated by column 
chromatography (hexanes/EtOAc, 3:1) as a white crystalline solid (0.027 g, 56%). 
mp 169-175 °C (EtOAc); Rf 0.9 (hexanes:EtOAc 2:1); []20D + 36.9 (c = 1.0, CHCl3); IR 
(KBr, cm-1)  2982, 2953, 2930, 2858, 1721, 1681, 1627, 1609, 1579, 1400, 1370, 
1247, 1219, 1157, 1054, 835; 1H NMR (600 MHz, CDCl3) δ 12.70 (s, 1H), 7.02 (t, J = 
3.0 Hz, 1H), 6.12 (d, J = 3.3 Hz, 2H), 4.77 - 4.72 (m, 1H), 4.39 (dt, J = 5.3, 2.5 Hz, 1H), 
4.19 (t, J = 8.1 Hz, 1H), 4.08 (dd, J = 8.1, 5.8 Hz, 1H), 1.62 (s, 9H), 1.50 (s, 3H), 1.34 (s, 
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3H), 0.96 (s, 9H), 0.17 (s, 6H). 13C NMR (151 MHz, CDCl3) δ 166.3, 162.2, 151.8, 
149.8, 144.4, 133.6, 125.6, 111.6, 103.5, 101.1, 85.3, 79.4, 77.0, 73.6, 58.4, 27.6, 27.0, 
25.8, 25.1, 18.2, −4.54, −4.98; HRMS (+EI) calcd for C27H38N2O9Si: 562.2347; found: 
562.2317. 
 
tert-butyl (3aS,3bR,12S,12aR)-6,12-dihydroxy-2,2-dimethyl-5-oxo-3a,5,12,12a-
tetrahydro[1,3]benzodioxolo[4,5-h][1,3]dioxolo[4,5-b]-1,6-naphthyridine-4(3bH)-
carboxylate (544) 
 
Pyridine 543 (24 mg, 0.043 mmol) was dissolved in THF (2.5 mL) and cooled to 0 °C. A 
solution of TBAF in THF (1 M, 0.10 mL, 0.10 mmol) was added dropwise over 1 min. 
The reaction mixture was stirred until total consumption of starting material was 
observed (TLC). The reaction mixture was quenched with NH4Cl (sat. aq., 2 ml,) and 
extracted with EtOAc (6 × 15 mL). The combined organic phases were dried over 
Na2SO4, filtered and evaporated. Compound 544 was isolated by column chromatography 
(EtOAc) as white crystalline solid (17 mg, 89%). 
Rf 0.4 (hexanes:EtOAc 1:1); mp> 200°C (EtOAc); []20D − 32.4 (c = 0.35, MeOH); IR 
(KBr, cm-1)  2983, 2933, 1762, 1680, 1609, 1609, 1479, 1434, 1400, 1372, 1297, 
1227, 1157, 1140, 1104, 1075, 1054; 1H NMR (300 MHz, CDCl3) δ 12.59 (s, 1H), 7.02 
(t, J = 3.0 Hz, 1H), 6.12 (d, J = 4.8 Hz, 2H), 4.78 - 4.69 (m, 1H), 4.48 - 4.40 (m, 1H), 
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4.33 (t, J = 8.1 Hz, 1H), 4.21 - 4.12 (m, 1H), 1.61 (s, 9H), 1.52 (s, 3H), 1.38 (s, 3H). 13C 
NMR (75 MHz, CDCl3) δ 166.1, 162.2, 151.4, 149.6, 144.0, 131.2, 126.2, 125.8, 112.0, 
103.3, 101.2, 85.5, 79.2, 79.1, 77.0, 72.9, 58.6, 27.6, 27.0, 25.0; HRMS (+EI) calcd for 
C22H24N2O9: 448.1482; found: 448.1463. 
(2S,3R,4S,4aR)-2,3,4,7-Tetrahydroxy-3,4,4a,5-tetrahydrobenzo[h][1,3]dioxolo[4,5-
b]-1,6-naphthyridin-6(2H)-one (5c) 
 
The Boc-protected amide 544 (0.024 g, 0.054 mmol) was dissolved in CH2Cl2 (4 mL) 
and cooled to 0 ˚C. Trifluoroacetic acid (0.2 mL 5% v/v H2O) was added dropwise and 
the reaction was stirred until total consumption of starting material was observed (TLC). 
The reaction mixture was neutralized with excess of concetrated NH3, evaporated and 
finally dried under high-vac. The final product was isolated by column chromatography 
on silica gel (deactivated by 10% of water, gradient CH2Cl2 - CH2Cl2:CH3OH 50:1 - 
CH2Cl2:CH3OH 20:1) as off-white crystalline compound (15 mg, 90%). 
Rf 0.6 (CH2Cl2:MeOH 5:1); mp> 200°C (MeOH); []20D +4.1 (c =1, MeOH); IR (KBr, 
cm-1)  3054, 2958, 2924, 2857, 1664, 1628, 1593, 1541, 1509, 1458, 1432, 1398, 
1258, 1138, 1025, 802; 1H NMR (600 MHz, CD3OD) δ 6.66 (s, 1H), 6.13 (s, 2H), 4.48 
(d, J = 8.5 Hz, 1H), 4.31 – 4.25 (m, 1H), 3.95 (s, 1H), 3.93 (d, J = 9.1 Hz, 1H). 13C NMR 
(150 MHz, CD3OD) δ 169.1, 161.7, 161.6, 146.6, 130.0, 125.7, 117.8, 115.9, 101.2, 73.0, 
69.2, 69.2, 51.9. 
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6. Selected spectra.  
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